INDEX OF EXHIBITS TO THE FIRST AMENDED COMPLAINT

UNITED STATES OF AMERICA, et al. *ex rel.* DAVID BARBETTA, Plaintiffs v. DAVITA, INC. and TOTAL RENAL CARE, INC., Defendants

Case No. 09 cv 02175 WJM-KMT

DESCRIPTION OF DOCUMENT

EXHIBIT

DaVita 2010 Annual Report, pages 1-11 of 1311
HHS OIG Opinion Letter (12/22/1992)2
HHS OIG Advisory Opinion 09-09 (07/29/2009)
HHS OIG Advisory Opinion 97-5 (10/06/1997)4
Certification Examples for Medicare, Medicaid & other federal health programs5
Closed Deal Activity 06 05 09
DaVita M&A Transactions7
Rocky Mountain 2008-04-21c 39.497M (Summary worksheet)
Denver Transaction Summary9
2009-05-19 RE Acquisition Revenue Build Up Assumptions10
Wauseon Valuation Summary11
Atlanta Final Acquisition Model – 10.31.06 (Stand-alone Post DD) Rev capex plus \$100K (Summary Tab Only)
Dahhan 120407 Version 2 (Consolidated P&L worksheet)
Fayetteville RKC Model Post DD ROD Review Final \$3.79MM 080114 (Summary worksheet)
Kansas – Post DD Model 06-06-08 \$18.75M with Budgets (Summary worksheet)15
KantTucker Model 2009-06-16 (Assumptions Summary worksheet)

Email 2009-07-24 RE DeNovo Model	17
Email 2008-07-25 RE Klamath Falls MDA Question	18
Email 2009-05-05 RE RCC sensitivity	19
Email 2008-10-08 klamath falls	20
Membership Interest Purchase Agreement – Rocky Mountain 49 percent	21
Contribution Agreement – TRC Centers to Mountain West	22
Intercompany Distribution Agreement	23
Stock Purchase Agreement – Sales of TRCC shares to LLLP	24
Acute Program Purchase Agreement – Mountain West from Rocky Mountain	25
St. Cloud Transaction Summary	26
St. Cloud Model MSP 080107 final (Consolidated P&L worksheet)	27
KCI Waterfall	28
Centers of Interest	29
HHS OIG Special Fraud Alert: Joint Venture Arrangements (Issued August 1989)	

Exhibit 1

10-K 1 d10k.htm FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

For the Fiscal Year Ended

December 31, 2010

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 1-14106

DAVITA INC.

1551Wewatta Street Denver, Colorado 80202 Telephone number (303) 405-2100

Delaware (State of incorporation) 51-0354549 (I.R.S. Employer Identification No.)

Securities registered pursuant to Section 12(b) of the Act:

Class of Security: Common Stock, \$0.001 par value Common Stock Purchase Rights Registered on: New York Stock Exchange New York Stock Exchange

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ; No "

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes "No i

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes i No "

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes i No ["]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ; Accelerated filer " Non-accelerated filer " Smaller reporting company "
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes " No ;

As of June 30, 2010, the number of shares of the Registrant's common stock outstanding was approximately 102.6 million shares and the aggregate market value of the common stock outstanding held by non-affiliates based upon the closing price of these shares on the New York Stock Exchange was approximately \$6.4 billion.

As of January 31, 2011, the number of shares of the Registrant's common stock outstanding was approximately 96.0 million shares and the aggregate market value of the common stock outstanding held by non-affiliates based upon the closing price of these shares on the New York Stock Exchange was approximately \$7.1 billion.

Documents incorporated by reference

Portions of the Registrant's proxy statement for its 2011 annual meeting of stockholders are incorporated by reference in Part

III of this Form 10-K.

PART I

Item 1. Business

We were incorporated as a Delaware corporation in 1994. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are made available free of charge through our website, located at <u>http://www.davita.com</u>, as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission, or SEC. The SEC also maintains a website at <u>http://www.sec.gov</u> where these reports and other information about us can be obtained. The contents of our website are not incorporated by reference into this report.

Overview

DaVita is a leading provider of kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease, or ESRD. As of December 31, 2010, we operated or provided administrative services to 1,612 outpatient dialysis centers located in 42 states and the District of Columbia, serving approximately 125,000 patients. We also provide acute inpatient dialysis services in approximately 750 hospitals and related laboratory services. Our dialysis and related lab services business accounts for approximately 94% of our consolidated net operating revenues. Our other ancillary services and strategic initiatives currently account for approximately 6% of our consolidated net operating revenues and relate primarily to our core business of providing kidney dialysis services.

The dialysis industry

The loss of kidney function is normally irreversible. Kidney failure is typically caused by Type I and Type II diabetes, high blood pressure, polycystic kidney disease, long-term autoimmune attack on the kidney and prolonged urinary tract obstruction. ESRD is the stage of advanced kidney impairment that requires continued dialysis treatments or a kidney transplant to sustain life. Dialysis is the removal of toxins, fluids and salt from the blood of ESRD patients by artificial means. Patients suffering from ESRD generally require dialysis at least three times a week for the rest of their lives.

According to United States Renal Data System, there were 382,000 ESRD dialysis patients in the United States in 2008 and the underlying ESRD dialysis patient population has grown at an approximate compound rate of 3.8% from 2000 to 2008, the latest period for which such data is available. The growth rate is attributable to the aging of the population, increased incidence rates for diseases that cause kidney failure such as diabetes and hypertension, lower mortality rates for dialysis patients and growth rates of minority populations with higher than average incidence rates of ESRD.

Since 1972, the federal government has provided health care coverage for ESRD patients under the Medicare ESRD program regardless of age or financial circumstances. ESRD is the first and only disease state eligible for Medicare coverage both for dialysis and dialysis-related services and for all benefits available under the Medicare program. Under this system, Congress established Medicare rates for dialysis treatments, related supplies, lab tests and medications. Although Medicare reimbursement limits the allowable charge per treatment, it provides industry participants with a relatively predictable and recurring revenue stream for dialysis services provided to patients without commercial insurance. Approximately 89% of our total patients are under government-based programs, with approximately 80% of our patients under Medicare and Medicare-assigned plans.

Prior to January 2011, dialysis providers operating under the Medicare ESRD program received a composite payment rate to cover routine dialysis treatments and certain supplies. There was a separate payment for laboratory testing and pharmaceuticals such as erythropoietin, or EPO, vitamin D analogs and iron supplements

that were not included in the composite payment rate. However, beginning in January 2011, Medicare implemented a new payment system in which all ESRD payments are now made under a single bundled payment rate that provides for an annual inflation adjustment based upon a market basket index, less a productivity improvement factor. The bundled payment rate provides a fixed rate to encompass all goods and services provided during the dialysis treatment, including pharmaceuticals that were historically separately reimbursed to the dialysis providers, such as EPO, vitamin D analogs and iron supplements, irrespective of the level of pharmaceuticals administered or additional services performed. Most lab services that used to be paid directly to laboratories are also included in the new payment bundle.

Treatment options for ESRD

Treatment options for ESRD are dialysis and kidney transplantation.

Dialysis Options

Hemodialysis

Hemodialysis, the most common form of ESRD treatment, is usually performed at a freestanding outpatient dialysis center, a hospital-based outpatient center, or at the patient's home. The hemodialysis machine uses an artificial kidney, called a dialyzer, to remove toxins, fluids and salt from the patient's blood. The dialysis process occurs across a semi-permeable membrane that divides the dialyzer into two distinct chambers. While blood is circulated through one chamber, a pre-mixed fluid is circulated through the other chamber. The toxins, salt and excess fluids from the blood cross the membrane into the fluid, allowing cleansed blood to return into the patient's body. Each hemodialysis treatment that occurs in the outpatient dialysis centers typically lasts approximately three and one-half hours and is usually performed three times per week.

Some ESRD patients who are healthier and more independent may perform home-based hemodialysis in their home or residence through the use of a hemodialysis machine designed for home therapy that is portable, smaller and easier to use. Patients receive training, support and monitoring from registered nurses, in some cases in our outpatient dialysis centers, in connection with treatments. Home-based hemodialysis is typically performed with greater frequency than dialysis treatments performed in outpatient dialysis centers and on varying schedules.

Hospital inpatient hemodialysis services are required for patients with acute kidney failure resulting from trauma, patients in early stages of ESRD, and ESRD patients who require hospitalization for other reasons. Hospital inpatient hemodialysis is generally performed at the patient's bedside or in a dedicated treatment room in the hospital, as needed.

• Peritoneal dialysis

Peritoneal dialysis uses the patient's peritoneal or abdominal cavity to eliminate fluid and toxins and is typically performed at home. The most common methods of peritoneal dialysis are continuous ambulatory peritoneal dialysis, or CAPD, and continuous cycling peritoneal dialysis, or CCPD. Because it does not involve going to an outpatient dialysis center three times a week for treatment, peritoneal dialysis is an alternative to hemodialysis for patients who are healthier, more independent and desire more flexibility in their lifestyle. However, peritoneal dialysis is not a suitable method of treatment for many patients, including patients who are unable to perform the necessary procedures and those at greater risk of peritoneal infection.

CAPD introduces dialysis solution into the patient's peritoneal cavity through a surgically placed catheter. Toxins in the blood continuously cross the peritoneal membrane into the dialysis solution. After several hours, the patient drains the used dialysis solution and replaces it with fresh solution. This procedure is usually repeated four times per day.



CCPD is performed in a manner similar to CAPD, but uses a mechanical device to cycle dialysis solution through the patient's peritoneal cavity while the patient is sleeping or at rest.

• Kidney transplantation

Although kidney transplantation, when successful, is generally the most desirable form of therapeutic intervention, the shortage of suitable donors, side effects of immunosuppressive pharmaceuticals given to transplant recipients and dangers associated with transplant surgery for some patient populations limit the use of this treatment option.

Services we provide

Dialysis and Related Lab Services

Outpatient dialysis services

As of December 31, 2010, we operated or provided administrative services to 1,612 outpatient dialysis centers in the United States that are designed specifically for outpatient hemodialysis. In 2010, we added a net total of 82 outpatient dialysis centers primarily as a result of acquisitions and the opening of new centers, net of center closures and divestitures. This represented a total increase of approximately 5% to our overall network of outpatient dialysis centers.

As a condition of our enrollment in Medicare, we contract with a nephrologist or a group of affiliated nephrologists to provide medical director services at each of our centers. In addition, other nephrologists may apply for practice privileges to treat their patients at our centers. Each center has an administrator, typically a registered nurse, who supervises the day-to-day operations of the center and its staff. The staff of each center typically consists of registered nurses, licensed practical or vocational nurses, patient care technicians, a social worker, a registered dietician, biomedical technician support and other administrative and support personnel.

Many of our outpatient dialysis centers offer services for dialysis patients who prefer and are able to perform either homebased hemodialysis in their homes or peritoneal dialysis. Home-based hemodialysis services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance. Registered nurses train patients and their families or other caregivers to perform either home-based hemodialysis or peritoneal dialysis.

Under Medicare regulations, we cannot promote, develop or maintain any kind of contractual relationship with our patients which would directly or indirectly obligate a patient to use or continue to use our dialysis services, or which would give us any preferential rights other than those related to collecting payments for our services. Our total patient turnover averaged approximately 30% per year for the last two years. However, in 2010 the overall number of patients to whom we furnished services increased by approximately 6%, primarily from continued growth within the industry, lower mortality rates and the opening of new centers and acquisitions.

Hospital inpatient hemodialysis services

We provide hospital inpatient hemodialysis services, excluding physician services, to patients in approximately 750 hospitals. We render these services for a contracted per-treatment fee that is individually negotiated with each hospital. When a hospital requests our services, we typically administer the dialysis treatment at the patient's bedside or in a dedicated treatment room in the hospital, as needed. Hospital inpatient hemodialysis services are required for patients as discussed above. In 2010, hospital inpatient hemodialysis services accounted for approximately 4% of our total dialysis treatments.

ESRD laboratory services

We own two separately incorporated, licensed, clinical laboratories specializing in ESRD patient testing. These specialized laboratories provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients. Our laboratories provide these tests predominantly for our network of ESRD patients throughout the United States. These tests are performed to monitor a patient's ESRD condition, including the adequacy of dialysis, as well as other medical conditions. Our laboratories utilize information systems which provide information to our dialysis centers regarding critical outcome indicators.

Management services

We currently operate or provide management and administrative services to 32 outpatient dialysis centers in which we either own a minority equity investment or are wholly-owned by third parties. These services are provided pursuant to management and administrative services agreements. Management fees are established by contract and are recognized as earned typically based on a percentage of revenues or cash collections generated by the centers.

Ancillary services and strategic initiatives

Ancillary services and strategic initiatives, which currently account for approximately 6% of our total consolidated net operating revenues, consist of the following:

- *Pharmacy services*. DaVita Rx is a pharmacy that provides oral medications to DaVita's patients with ESRD. The main objectives of the pharmacy are to improve clinical outcomes by facilitating increased patient compliance and to provide our patients a convenient way to fill their prescription needs by delivering the prescriptions to the center where they are treated. Revenues are recognized as prescriptions are filled and shipped to patients.
- Infusion therapy services. HomeChoice Partners provides personalized infusion therapy services to patients typically in their own homes as a cost-effective alternative to inpatient hospitalization. Intravenous and nutritional support therapies are typically managed by registered and/or board-certified professionals including pharmacists, nurses and dieticians in collaboration with the patient's physician in support of the patient's ongoing health care needs. Revenues are recognized in the period when infusion therapy services are provided.
- *Disease management services*. VillageHealth provides advanced care management services to health plans and government agencies for employees/members diagnosed with Chronic Kidney Disease (CKD) or ESRD. Through a combination of clinical coordination, medical claims analysis and information technology, we endeavor to assist our customers and patients in obtaining superior renal health care and improved clinical outcomes, as well as helping to reduce overall medical costs. Revenues are typically based upon an established contract fee and are recognized as earned over the contract period and can include additional fees for cost savings recognized by certain customers.
- Vascular access services. Lifeline provides management and administrative services to physician-owned vascular
 access clinics that provide surgical and interventional radiology services for dialysis patients. Lifeline also is the
 majority-owner of one vascular access clinic. Management fees generated from providing management and
 administrative services are recognized as earned typically based on a percentage of revenues or cash collections
 generated by the clinics. Revenues associated with the vascular access clinic that is majority-owned are recognized in the
 period when physician services are provided.
- *ESRD clinical research programs.* DaVita Clinical Research conducts research trials principally with dialysis patients and provides administrative support for research conducted by DaVita-affiliated nephrology practices. Revenues are based upon an established fee per study, as determined by contract with drug companies and other sponsors and are recognized as earned according to the contract terms.

Physician services. DaVita Nephrology Partners offers practice management and administrative services to physicians
who specialize in nephrology under management and administrative services agreements. Practice management and
administrative services typically include operations management, IT support, billing and collections, credentialing and
coding, and other support functions. Management fees generated from providing practice management and administrative
services to physician practices are recognized as earned typically based upon cash collections generated by the practices.

Quality care

We employ 180 clinical service specialists. The primary focus of this group is assuring and facilitating processes that aim to achieve superior clinical outcomes at our centers.

Our physician leadership in the Office of the Chief Medical Officer (OCMO) includes eight senior nephrologists, led by our Chief Medical Officer, with a variety of academic, clinical practice, and clinical research backgrounds. Our Physician Council is an advisory body to senior management, composed of nine physicians with extensive experience in clinical practice in addition to the members of OCMO and five Group Medical Directors.

Sources of revenue—concentrations and risks

Our dialysis and related lab services business revenues represent approximately 94% of our consolidated net operating revenues for the year ended December 31, 2010, with the balance of our revenues from ancillary services and strategic initiatives. Dialysis and related lab services revenues are derived primarily from our core business of providing kidney dialysis services, the administration of pharmaceuticals, related laboratory services and to a lesser extent management fees generated from providing management and administrative services to certain outpatient dialysis centers.

The sources of our dialysis and related lab services revenues are principally from government-based programs, including Medicare and Medicare-assigned plans, Medicaid and Medicaid-assigned plans and commercial insurance plans.

The following table summarizes our dialysis and related lab services revenues by source for the year ended December 31, 2010:

	Revenue
	percentages
Medicare and Medicare-assigned plans	57%
Medicaid and Medicaid-assigned plans	6%
Other government-based programs	<u> </u>
Total government-based programs	66%
Commercial (including hospital inpatient dialysis services)	34%
Total dialysis and related lab services revenues	100%

The following table summarizes our dialysis and related lab services revenues by modality for the year ended December 31, 2010:

	Revenue
	percentages
Outpatient hemodialysis centers	83%
Peritoneal dialysis and home-based hemodialysis	12%
Hospital inpatient hemodialysis	5%
Total dialysis and related lab services revenues	100%

Medicare revenue

Under the Medicare ESRD program, payment rates for dialysis are established by the U.S. Congress. Prior to January 2011, the Medicare composite rate set by the Centers for Medicare and Medicaid Services, or CMS, paid dialysis providers for services furnished to Medicare beneficiaries in two parts: (1) the composite payment which included a base payment, adjusted for case-mix which linked payments more closely with illness severity and regional geography differences, and a drug add-on payment, which was updated annually to account for changes in drug prices and utilization and (2) separately billable reimbursement for certain drugs. Thus, dialysis providers received a composite payment rate per treatment to cover routine dialysis services, certain pharmaceuticals, routine lab work, and other supplies, as well as a separate payment for pharmaceuticals, which include EPO (a pharmaceutical used to treat anemia, a common complication associated with ESRD), vitamin D analogs and iron supplements that are not included in the composite payment rate. Pharmaceuticals were generally paid at average sale price, or ASP, plus 6% based upon prices set by Medicare. The Medicare payment rates that were paid to us, including payments for separately billable drugs, were not sufficient to cover our average cost of providing a dialysis treatment.

ESRD patients receiving dialysis services become eligible for primary Medicare coverage at various times, depending on their age or disability status, as well as whether they are covered by an employer group health plan. Generally, for a patient not covered by an employer group health plan, Medicare becomes the primary payor either immediately or after a three-month waiting period. For a patient covered by an employer group health plan, Medicare generally becomes the primary payor after 33 months, which includes a three month waiting period, or earlier if the patient's employer group health plan coverage terminates. When Medicare becomes the primary payor, the payment rate we receive for that patient shifts from the commercial insurance plan rate to the Medicare payment rate.

Medicare pays 80% of the amount set by the Medicare system for each covered treatment. The patient is responsible for the remaining 20%. In most cases, a secondary payor, such as Medicare supplemental insurance, a state Medicaid program or a commercial health plan, covers all or part of these balances. Some patients, who do not qualify for Medicaid but otherwise cannot afford secondary insurance, can apply for premium payment assistance from charitable organizations through a program offered by the American Kidney Fund. We and other dialysis providers support the American Kidney Fund and similar programs through voluntary contributions. If a patient does not have secondary insurance coverage, we are generally unsuccessful in our efforts to collect from the patient the 20% portion of the ESRD composite rate that Medicare does not pay. However, we are able to recover some portion of this unpaid patient balance from Medicare through an established cost reporting process by identifying these Medicare bad debts on each center's Medicare cost report.

The Medicare composite payment rates set by Congress for dialysis treatments that were in effect for 2010 were between \$151 and \$169 per treatment, with an average rate of \$161 per treatment. Historically, Medicare payment rates for dialysis services have not been routinely increased to compensate for the impact of inflation, which negatively impacted our margins as patient care costs continued to rise. The Medicare Improvements for Patients and Providers Act for 2008, or MIPPA, provided dialysis providers with an increase in the composite rate of 1% that went into effect on January 1, 2009 and an additional 1% that went into effect on January 1, 2010. This legislation also changed the way Medicare pays for dialysis services beginning in January 2011, as further described below. The new payment system also provides for an annual inflation adjustment based upon a market basket index, less a productivity adjustment, beginning in 2012. Also beginning in 2012, the rule provides for up to a 2% annual payment withhold that can be earned back by facilities that meet certain defined clinical performance standards.

The new payment system reimburses providers based on a single bundled or average payment for each Medicare treatment provided. The new bundled payment amount is designed to cover all dialysis services that were historically included in the composite rate and all separately billable ESRD services such as pharmaceuticals and laboratory tests. This new bundled payment rate is adjusted for certain patient characteristics, a geographic wage

index and certain other factors. The initial 2011 bundled payment rate includes reductions of 2% and 3.1%, respectively, to conform to the provisions of MIPPA and to establish budget neutrality. Further, there is a 5.94% reduction tied to an expanded list of case mix adjustors which can be earned back based upon the presence of these certain patient characteristics and co-morbidities at the time of treatment. There are also other provisions which may impact payment including an outlier pool and a low volume facility adjustment. Historically, services that were separately billable accounted for approximately 30% of our total dialysis and related lab revenues. Now the dialysis providers are at risk for variations in pharmaceutical utilization since reimbursement set at a fixed average reimbursement rate. With regard to the expanded list of case-mix adjustors, these are difficult or, in some cases, have been impossible for our dialysis clinics to document and track, which could result in a reduction in the reimbursement amounts that we would otherwise be entitled to receive.

We are attempting to reduce our operating costs to minimize the overall negative financial impact from the reductions in reimbursement for services we provide to Medicare patients. However, certain operating expenditures, such as labor and supply costs, are subject to inflation, and without a compensating inflation-based increase in the new bundled payment rate system, could significantly impact our operating results.

We participated in two Medicare demonstration programs through a contract with CMS in 2010. One program was an ESRD demonstration program that started in January 2006 and terminated in December 2010. This program was converted into a full service health care plan for ESRD patients in 2011, which is referred to as a Medicare Advantage ESRD Special Needs Plan that works with CMS to provide ESRD patients full service health care. The revenue in 2010 was capitated for all medical services required by enrollees in the program. We are still at risk for all medical costs of the program in excess of the capitation payments. The other program is a CKD/ESRD demonstration program which started in November 2008 and will continue for three years. We are paid a management fee for program enrollees relating to CKD and ESRD disease states. Management fee revenues are subject to retraction if medical cost savings targets are not met.

Medicaid revenue

Medicaid programs are state-administered programs partially funded by the federal government. These programs are intended to provide health coverage for patients whose income and assets fall below state-defined levels and who are otherwise uninsured. These programs also serve as supplemental insurance programs for co-insurance payments due from Medicaid-eligible patients with primary coverage under Medicare. Some Medicaid programs also pay for additional services, including some oral medications that are not covered by Medicare. We are enrolled in the Medicaid programs in the states in which we conduct our business.

Commercial revenues

Before a patient becomes eligible to have Medicare as their primary payor for dialysis services, a patient's commercial insurance plan, if any, is responsible for payment of such dialysis services. Although commercial payment rates vary significantly, average commercial payment rates are generally significantly higher than Medicare rates. The payments we receive from commercial payors generate nearly all of our profits. Payment methods from commercial payors include a single lump-sum per treatment, referred to as bundled rates, and in some cases separate payments for treatments and pharmaceuticals, if used as part of the treatment, referred to as fee for service rates. Commercial payment rates are typically the result of negotiations between us and insurers or third-party administrators. Our out-of-network payment rates are on average higher than in-network payment rates. In 2010, we entered into several new commercial contracts with certain commercial payors that will primarily pay us a single bundled payment rate for all dialysis services provided to patients covered by the commercial insurance plan. However, some of the contracts will pay us for certain other services and pharmaceuticals in addition to the bundled payment. These contracts contain annual escalators and effectively eliminate all payments for out-of-network patients. We are continuously in the process of negotiating agreements with our commercial payors and if our negotiations result in overall commercial rate reductions in excess of our commercial rate increases, our revenues and operating results could be negatively impacted. In addition, if there

are sustained or increased job losses in the United States as a result of current economic conditions, or depending upon changes to the healthcare regulatory system, we could experience a decrease in the number of patients covered under commercial plans.

Approximately 34% of our dialysis and related lab services revenues and approximately 11% of our patients were associated with commercial payors for the year ended December 31, 2010. Less than 1% of our dialysis and related lab services revenues are due directly from patients. No single commercial payor accounted for more than 5% of total dialysis and related lab services revenues for the year ended December 31, 2010.

Revenue from EPO and other pharmaceuticals

Approximately 26% of our total dialysis and related lab services revenues for the year ended December 31, 2010 are associated with the administration of physician-prescribed pharmaceuticals that improve clinical outcomes when included with the dialysis treatment. These pharmaceuticals include EPO, vitamin D analogs and iron supplements. However, as described above, the majority of these pharmaceuticals will no longer be separately billable as a result of the new Medicare single bundled payment rate system effective in January 2011 as well as some of our new commercial contracts that implemented a single bundled payment rate.

EPO is an erythropoiesis stimulating agent, or ESA, genetically-engineered form of a naturally occurring protein that stimulates the production of red blood cells. EPO is used in connection with all forms of dialysis to treat anemia, a medical complication most ESRD patients experience. The administration of EPO, which was separately billable under the Medicare payment program through 2010, accounted for approximately 18% of our dialysis and related lab services revenues for the year ended December 31, 2010.

Furthermore, EPO is produced by a single manufacturer, Amgen, who can unilaterally increase its price for EPO at any time during the term of our agreement with them. Any interruption of supply or product cost increases could adversely affect our operations. In 2010, we experienced an increase in the cost of EPO of approximately 2%. In December 2010, we entered into a new Dialysis Organization Agreement (the "Agreement") with Amgen USA Inc., a wholly owned subsidiary of Amgen Inc. The Agreement sets forth the terms under which we and certain of our affiliates will purchase EPO. The Agreement, among other things, provides for discount pricing and rebates for EPO. Some of the rebates are subject to various qualification requirements based on a variety of factors including process improvement targets, patient outcome targets and data submission. The term of the Agreement commenced January 1, 2011 and ends June 30, 2011.

There continues to be significant media discussion and government scrutiny regarding anemia management practices in the United States. In late 2006, the U.S. House of Representatives Ways and Means Committee held a hearing on the issue of the utilization of ESAs, which include EPO, and in 2007, the FDA required changes to the labeling of EPO and darbepoetin alfa, or Aranesp[®] to include a black box warning, the FDA's strongest form of warning label. An FDA advisory panel on ESA use met in October 2010, which meeting was similar to the prior meeting held in 2007 in that there was significant discussion and concern about the safety of ESAs. The panel concluded it would not recommend a change in ESA labeling. However, the FDA is not bound by the panel's recommendation. In addition, in June 2010, CMS opened a National Coverage Analysis (NCA) for ESAs. Further, in January 2011, CMS convened a meeting of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) to evaluate evidence for the pending NCA. CMS expects to complete its decision memo in March 2011 and issue final guidance in June 2011. The foregoing congressional and agency activities and related actions could result in further restrictions on the utilization and reimbursement for ESAs. Commercial payors have also increasingly examined their administration policies for EPO and, in some cases, have modified those policies. Inclusion of EPO in the Medicare bundled payment rate, as well as in a bundled payment rate for several of our commercial payors, is expected to mitigate the effect of lower utilization of EPO. However, further changes in labeling of EPO and other pharmaceuticals in a manner that alters physician practice patterns or accepted clinical practices, changes in private and governmental payment criteria, including the introduction of EPO administration policies or the conversion to alternate types of administration of EPO or other pharmaceuticals that result in further decreases in utilization or reimbursement for EPO and other pharmaceuticals, could have a material adverse effect on our operating results.

Physician relationships

An ESRD patient generally seeks treatment at an outpatient dialysis center near his or her home where his or her treating nephrologist has practice privileges. Our relationships with local nephrologists and our ability to meet their needs and the needs of their patients are key factors in the success of our dialysis operations. Over 3,900 nephrologists currently refer patients to our outpatient dialysis centers. As is typical in the dialysis industry, one or a few physicians, including the outpatient dialysis center's medical director, usually account for all or a significant portion of an outpatient dialysis center's patient base. If a significant number of physicians, including an outpatient dialysis center's medical directors, were to cease referring patients to our outpatient dialysis centers, our business could be adversely affected.

Participation in the Medicare ESRD program requires that dialysis services at an outpatient dialysis center be under the general supervision of a medical director who is a licensed physician. We have engaged physicians or groups of physicians to serve as medical directors for each of our outpatient dialysis centers. At some outpatient dialysis centers, we also separately contract with one or more physicians to serve as assistant or associate medical directors or to direct specific programs, such as home dialysis training programs. We have contracts with approximately 1,400 individual physicians and physician groups to provide medical director services.

Medical directors enter into written contracts with us that specify their duties and fix their compensation generally for periods of ten years. The compensation of our medical directors is the result of arm's length negotiations and generally depends upon an analysis of various factors such as the physician's duties, responsibilities, professional qualifications and experience, among others.

Our medical director contracts generally include covenants not to compete. Also, when we acquire an outpatient dialysis center from one or more physicians or where one or more physicians own minority interests in our outpatient dialysis centers, these physicians have agreed to refrain from owning interests in other competing outpatient dialysis centers within a defined geographic area for various time periods. These agreements not to compete restrict the physicians from owning or providing medical director services to other outpatient dialysis centers, but do not prohibit the physicians from referring patients to any outpatient dialysis center, including competing centers. Many of these agreements not to compete continue for a period of time beyond expiration of the corresponding medical director agreements, although some expire at the same time as the medical director agreement. Occasionally, we experience competition from a new outpatient dialysis center established by a former medical director following the termination of his or her relationship with us.

Government regulation

Our dialysis operations are subject to extensive federal, state and local governmental regulations. These regulations require us to meet various standards relating to, among other things, government payment programs, dialysis facilities and equipment, management of centers, personnel qualifications, maintenance of proper records and quality assurance programs and patient care.

Because we are subject to a number of governmental regulations, our business could be adversely impacted by:

- Loss or suspension of federal certifications;
- Loss or suspension of licenses under the laws of any state or governmental authority from which we generate substantial revenues;
- Exclusion from government healthcare programs including Medicare and Medicaid;
- Significant reductions or lack of inflation-adjusted increases in payment rates or reduction of coverage for dialysis and ancillary services and related pharmaceuticals;
- Fines, damages and monetary penalties for anti-kickback law violations, Stark Law violations, submission of false claims, civil or criminal liability based on violations of law or other failures to meet regulatory requirements;

- Claims for monetary damages from patients who believe their protected health information has been used or disclosed in violation of federal and state patient privacy laws;
- · Mandated changes to our practices or procedures that significantly increase operating expenses; or
- Refunds of payments received from government payors and government health care program beneficiaries because of any failures to meet applicable requirements.

We expect that our industry will continue to be subject to substantial regulation, the scope and effect of which are difficult to predict. Our activities could be reviewed or challenged by regulatory authorities at any time in the future. This regulation and scrutiny could have a material adverse impact on us.

Licensure and Certification

Our dialysis centers are certified by CMS, as is required for the receipt of Medicare payments. In some states, our dialysis centers also are required to secure additional state licenses and permits. Governmental authorities, primarily state departments of health, periodically inspect our centers to determine if we satisfy applicable federal and state standards and requirements, including the conditions of participation in the Medicare ESRD program.

To date, we have not experienced significant difficulty in maintaining our licenses or our Medicare and Medicaid authorizations. However, we have experienced delays in obtaining certifications from CMS.

CMS continues to study the regulations applicable to Medicare certification to provide dialysis services. On April 15, 2008, CMS issued new regulations for Medicare-certified ESRD facilities to provide dialysis services, referred to as Conditions for Coverage. The Conditions for Coverage were effective October 14, 2008, with some provisions having a phased in implementation date of February 1, 2009. The new regulations are patient, quality and outcomes focused. Among other things, they establish performance expectations for facilities and staff, eliminate certain procedural requirements, and promote continuous quality improvement and patient safety measures. We have established an interdisciplinary work group to facilitate implementation of the Conditions of Coverage and have developed comprehensive auditing processes to monitor ongoing compliance. We continue to assess the impact these changes will have on our operating results.

Federal anti-kickback statute

The "anti-kickback" statute contained in the Social Security Act imposes criminal and civil sanctions on persons who receive, make, offer or solicit payments in return for:

- The referral of a Medicare or Medicaid patient for treatment;
- The ordering or purchasing of items or services that are paid for in whole or in part by Medicare, Medicaid or similar federal and state programs; or
- Arranging for or recommending the ordering or purchasing of such items.

Federal criminal penalties for the violation of the anti-kickback statute include imprisonment, fines and exclusion of the provider from future participation in the Medicare and Medicaid programs. Violations of the anti-kickback statute are punishable by imprisonment for up to five years and fines of up to \$250,000 or both. Larger fines can be imposed upon corporations under the provisions of the U.S. Sentencing Guidelines and the Alternate Fines Statute. Individuals and entities convicted of violating the anti-kickback statute are subject to mandatory exclusion from participation in Medicare, Medicaid and other federal healthcare programs for a minimum of five years. Civil penalties for violation of this law include up to \$50,000 in monetary penalties per violation, repayments of up to three times the total payments between the parties and suspension from future participation in Medicare and Medicaid. Court decisions have also held that the statute is violated whenever one of the purposes of remuneration is to induce referrals.

Exhibit 2

Web Link: http://oig.hhs.gov/fraud/docs/safeharborregulations/acquisition122292.htm

December 22, 1992

Mr. T. J. Sullivan

Technical Assistant (Health Care Industries)

Office of the Associate Chief Counsel

(Employee Benefits and Exempt Organizations)

Internal Revenue Service

Washington, D.C. 20224

Dear Mr. Sullivan:

You have informally inquired about our views concerning the application of the Medicare and Medicaid anti-kickback statute, 42 U.S.C. 1320a-7b(b), to certain types of situations involving the acquisition of physician practices. In the situations in question, the physician practices would be acquired either by a hospital or by another entity which would also acquire one or more hospitals (and potentially other health care providers as well). The physicians from these practices would continue to treat patients and be affiliated (through an employment relationship or otherwise) with the hospital or other entity which acquired their practices. The acquisition of the physician practices could arise through a number of different methods or arrangements and the resulting or ensuing relationships or affiliations could vary. However, the end result in each case would be the common ownership or control of both hospitals and physician practices by a single entity. We are responding to your inquiry in general terms and not in reference to any specific fact pattern(s).

Typically, in the case of the acquisition of a physician practice by a hospital or other entity, there is a large, up front payment to the physician, often of many hundreds of thousands of dollars or more. This sum is asserted to be payment for the purchase of the assets of the practice. There are also payments made to the physician subsequent to the sale of the practice where the physician becomes employed by the hospital or entity or otherwise enters into a contract to provide services to patients. These payments are asserted to be compensation for services rendered to patients by the physician.

As you know, the anti-kickback statute provides for penalties against anyone who knowingly and willfully solicits, receives, offers or pays remuneration, in cash or in kind, to induce or in return for:

A. referring an individual to a person for the furnishing or arranging for the furnishing of any

item or service payable under the Medicare or Medicaid programs, or

B. purchasing, leasing or ordering or arranging for or recommending purchasing, leasing, or ordering any good, facility, service or item payable under the Medicare or Medicaid programs.

Persons who violate the anti-kickback statute are subject to criminal penalties and/or exclusion from participation in the Medicare and Medicaid programs. The anti-kickback statute sets forth certain specific exceptions to the general prohibition against remuneration, and specifically authorizes this Department to promulgate, by regulation, additional payment practices (known as "safe harbors") which will be immune from prosecution. The Department published final "safe harbor" regulations on July 29, 1991 (42 C.F.R. 1001.952, 56 Fed. Reg. 35,952) setting forth eleven regulatory exceptions to the anti-kickback statute. Among the safe harbors included in the regulations were provisions relating to employees and sale of practitioner practices. Additional safe harbor provisions relating to "managed care" entities were published as final regulations (with comment period) on November 5, 1992 (57 Fed. Reg. 52,723).

We have significant concerns under the anti-kickback statute about the type of physician practice acquisitions described in your inquiry to us. Frequently, hospitals seek to purchase physician practices as a means to retain existing referrals or to attract new referrals of patients to the hospital. Such purchases implicate the anti-kickback statute because the remuneration paid for the practice can constitute illegal remuneration to induce the referral of business reimbursed by the Medicare or Medicaid programs.(1)

We believe the same concerns raised by hospital purchases of physician practices could also arise where another entity (such as a foundation) purchases a physician practice, when such foundation also owns or operates a hospital which benefits from referrals from those physicians.

In particular, we are concerned that the remuneration paid in connection with or as a result of the acquisition of a physician's practice could serve to interfere with the physician's subsequent judgment of what is the most appropriate care for a patient. The remuneration could result in the delivery of inappropriate care to Medicare or Medicaid beneficiaries by inducing the physician to utilize the affiliated hospital rather than another hospital or less costly facility which may provide better or more appropriate care. It could also have the effect of inflating costs to the Medicare or Medicaid programs by causing physicians to overuse inappropriately the services of a particular hospital (or other affiliated provider). This higher cost could occur directly because of the higher rates of that hospital or the ordering of unnecessary serviced or indirectly as a result of lessened competition in the marketplace. Finally, these arrangements could significantly interfere with a beneficiary's freedom of choice of providers. All these considerations are the very abuses that the antikickback statute was designed to prevent. We recently addressed these same types of possible abuses in an Office of Inspector General Special Fraud Alert entitled "Hospital Incentives to Physicians". A copy of that Fraud Alert is enclosed for your information.

The following are specific aspects of physician practice acquisition or subsequent activities that may implicate or result in violations of the anti-kickback statute. Our comments focus primarily on two broad issue categories: (1) the total amount paid for the physician practice and the nature

and type of items for which the physician receives payment; and (2) the amount and manner in which the physician is subsequently compensated for providing services to patients.(2)

Under the anti-kickback statute, either of the above categories of payment could constitute illegal remuneration. This is because under the anti-kickback statute, the statute is violated if "one purpose" of the payment is to induce the referral of future Medicare or Medicaid program business. United States v. Greber, 760 F.2d 68, 69 (3rd Cir. 1985) cert. denied, 474 U.S. 988 (1985); United States v. Kats, 871 F.2d 105, 108 (9th Cir. 1989). Thus, it is necessary to scrutinize the payments (including the surrounding facts and circumstances) to determine the purpose for which they have been made. As part of this undertaking, it is necessary to consider the amounts paid for the practice or as compensation to determine whether they reasonably reflect the fair market value of the practice or the services rendered, in order to determine whether such items in reality constitute remuneration for referrals. Moreover, to the extent that a payment exceeds the fair market value of the practice or the value of the services rendered, it can be inferred that the excess amount paid over fair market value is intended as payment for the referral of program-related business. United States v. Lipkis, 770 F.2d 1447 (9th Cir. 1985).

When considering the question of fair market value, we would note that the traditional or common methods of economic valuation do not comport with the prescriptions of the anti-kickback statute. Items ordinarily considered in determining the fair market value may be expressly barred by the anti-kickback statute's prohibition against payments for referrals. Merely because another buyer may be willing to pay a particular price is not sufficient to render the price paid to be fair market value. The fact that a buyer in a position to benefit from referrals is willing to pay a particular price may only be a reflection of the value of the referral stream that is likely to result from the purchase.(3)

Accordingly, when attempting to assess the fair market value (as that term is used in an anti-kickback analysis) attributable to a physician's practice, it may be necessary to exclude from consideration any amounts which reflect, facilitate or otherwise relate to the continuing treatment of the former practice's patients. This would be because any such items only have value with respect to the on-going flow of business to the practice. It is doubtful whether this value may be paid by a party who could expect to benefit from referrals from that ongoing practice.(4) Such amounts could be considered as payments for referrals. Thus, any amount paid in excess of the fair market value of the hard assets of a physician practice would be open to question. Similarly, in determining the fair market value of services rendered by employee or contract physicians, it may be necessary to exclude from consideration any amounts which reflect or relate to past or future referrals or any amounts which reflect or are affected by the expectation or guarantee of a certain volume of business (by either the physician or the hospital). Specific items that we believe would raise a question as to whether payment was being made for the value of a referral stream would include, among other things:

-- payment for goodwill,

-- payment for value of ongoing business unit,

- -- payment for covenants not to compete,
- -- payment for exclusive dealing agreements,
- -- payment for patient lists, or
- -- payment for patient records.

Payments for the above types of assets or items are questionable where, as is the case here, there is a continuing relationship between the buyer and the seller and the buyer relies (at least in part) on referrals from the seller.

We believe a very revealing inquiry would be to compare the financial welfare of the physicians involved before and after the acquisition. (One can expect to find projections on this subject among materials given to prospective physician participants in these arrangements.) If the economic position of these physicians is expected to significantly improve as a result of the acquisition, it is likely that a purpose of the acquisition is to offer remuneration for the referrals which these physicians can make to the buyer. Another revealing inquiry would be to compare referral patterns before and after the acquisition, specifically, whether the sellers become increasingly "loyal" to the buyer. (Obviously, this inquiry would only occur if the acquisition took place, but it is a potential topic to study in the future to the extent acquisitions occur and are subject to audit or investigation by the Internal Revenue Service.)

In sum, these arrangements raise grave questions of compliance with the anti-kickback statute. We believe that many of these arrangements are merely sophisticated disguises to share the profits of business at a hospital with referring physicians, in order to induce the physicians to steer referrals to the hospital.

We hope this letter has provided helpful information in response to your informal inquiry.

Sincerely,

/s/

D. McCarty Thornton

Associate General Counsel

Inspector General Division

Enclosure

FOOTNOTES:

1. Since tax exempt hospitals are generally required to participate in the Medicare and-Medicaid

programs as a condition of obtaining or maintaining their tax exempt status, the antikickback statute is necessarily a significant issue to be addressed by them.

2. We would also note that while the anti-kickback statute contains a statutory exemption for payments made to employees by an employer, the exemption does not cover any and all such payments. Specifically, the statute exempts only payments to employees which are for "the provision of covered items or services". Accordingly, since referrals do not represent covered items or services, payments to employees which are for the purpose of compensating such employees for the referral of patients would likely not be covered by the employee exemption.

3. This deviation from the normal "economic" model was made expressly clear in the safe harbor provisions. For purposes of determining the value of space or equipment rentals, "fair market value" is specifically defined to exclude the "additional value one party . . . would attribute to the property [equipment] as a result of its proximity or convenience to sources of referrals or business otherwise generated". 42 C.F.R. 1001.952(b) and (c), 56 Fed. Reg. 35971-35973, 35985.

4. We note that these physician practice acquisitions do not fall within the parameters of the existing safe harbor provisions on the sale of practitioner practices. In the final safe harbor regulations, we expressly declined to expand the scope of the safe harbor to cover purchases of physician practices by hospitals or other types of entities or to situations where the seller remains in a continuing position to make referrals or influence referrals to the buyer because of our concerns that many of such purchases were in fact merely attempts to provide remuneration in return for a future stream of referrals. See Preamble to the final safe harbor regulations, 56 Fed. Reg. at 35975. We also attempted to deal with arrangements which have the potential to lock in a referral stream in the safe harbor provisions dealing with joint ventures. See 42 C.F.R. 1001.952(a), 56 Fed. Reg. 35,984-85.

Exhibit 3



DEPARTMENT OF HEALTH & HUMAN SERVICES

Office of Inspector General

Washington, D.C. 20201

[We redact certain identifying information and certain potentially privileged, confidential, or proprietary information associated with the individual or entity, unless otherwise approved by the requestor.]

Issued: July 22, 2009

Posted: July 29, 2009

To: ATTACHED DISTRIBUTION LIST

Re: OIG Advisory Opinion No. 09-09

Ladies and Gentlemen:

We are writing in response to your request for an advisory opinion regarding a proposed joint venture involving ownership of an ambulatory surgery center by a hospital and physicians (the "Proposed Arrangement"). Specifically, you have inquired whether the Proposed Arrangement would constitute grounds for the imposition of sanctions under the exclusion authority at section 1128(b)(7) of the Social Security Act (the "Act"), or the civil monetary penalty provision at section 1128A(a)(7) of the Act, as those sections relate to the commission of acts described in section 1128B(b) of the Act, the Federal anti-kickback statute.

You have certified that all of the information provided in your request, including all supplemental submissions, is true and correct and constitutes a complete description of the relevant facts and agreements among the parties.

In issuing this opinion, we have relied solely on the facts and information presented to us. We have not undertaken an independent investigation of such information. This opinion is limited to the facts presented. If material facts have not been disclosed or have been misrepresented, this opinion is without force and effect.

Based on the facts certified in your request for an advisory opinion and supplemental submissions, we conclude that while the Proposed Arrangement could potentially generate prohibited remuneration under the anti-kickback statute, if the requisite intent to induce or reward referrals of Federal health care program business were present, the Office of

Inspector General ("OIG") would not impose administrative sanctions on [names redacted] (the "Requestors") under sections 1128(b)(7) or 1128A(a)(7) of the Act (as those sections relate to the commission of acts described in section 1128B(b) of the Act) in connection with the Proposed Arrangement. This opinion is limited to the Proposed Arrangement and, therefore, we express no opinion about any ancillary agreements or arrangements disclosed or referenced in your request letter or supplemental submissions.

This opinion may not be relied on by any persons other than the Requestors of this opinion, and is further qualified as set out in Part IV below and in 42 C.F.R. Part 1008.

I. FACTUAL BACKGROUND

[Name redacted] owns and operates a general acute care hospital, [name redacted], in [city redacted] [state redacted]. (For purposes of this opinion, both of these entities will be designated as the "Hospital.")

[Name redacted] (the "Surgeon LLC") is a limited liability company organized under the laws of the State of [state redacted], owned by seven orthopedic surgeons (the "Surgeon Investors") who are members of a single physician group practice. The Requestors have certified that each Surgeon Investor's ownership in the Surgeon LLC is proportional to his or her capital investment and that each Surgeon Investor received at least one-third of his or her medical practice income for the previous fiscal year or previous 12-month period from the performance of procedures payable by Medicare when performed in an ambulatory surgery center ("ASC").

The Surgeon Investors (through the Surgeon LLC) and the Hospital desire to enter into a joint venture to own and operate an ASC with two operating rooms in a medical office building (the "Building") owned by the Hospital and located on its campus.

The Requestors have certified that, under state law, the development of an ASC requires obtaining a certificate of need ("CON"), except in certain circumstances. They have devised the Proposed Arrangement, by which they plan to develop a single two-operating room ASC by first developing two separate and adjacent ASCs, each consisting of one operating room and neither requiring a CON, and subsequently merging the two into a single ASC.¹

In furtherance of this goal, the Surgeon LLC has developed an outpatient operating room in the Building and is operating it as a Medicare-certified ASC (the "Surgeon ASC"). The

¹ We express no opinion with respect to whether the Proposed Arrangement complies with state law.

Requestors have certified that the Surgeon ASC occupies space in the Building pursuant to a lease agreement that complies with the requirements of the space rental safe harbor at 42 C.F.R. § 1001.952(b).

Under the Proposed Arrangement, the Hospital will develop a single hospital operating room (the "OR") in space within the Building adjacent to the Surgeon ASC. Upon receipt of necessary regulatory approvals, it will then contribute the assets used to operate the OR to [name redacted] (the "Company"), after which the OR will be operated as a Medicare-certified ASC (the "Hospital ASC"). The Hospital currently is the sole member of the Company, which at the present time has no tangible assets.

The Requestors have certified that, upon receipt of necessary regulatory approvals, the Surgeon LLC will purchase 50 percent of the membership units in the Company. The purchase price will consist, at least in part, of the Surgeon ASC, which the Surgeon LLC will contribute to the Company. Prior to this contribution, appraisals will be conducted to determine the fair market value of the Company (whose sole asset at that time will be the Hospital ASC) and the fair market value of the Surgeon ASC. The Requestors have certified that the appraisals will not take into account the volume or value of referrals made or business otherwise generated among the parties to the transaction, including past or anticipated referrals to the ASCs, but will be based solely on the fair market value of the tangible assets of the Company and the Surgeon ASC, which will consist for the most part of equipment, furnishings, and supplies. If the fair market value of the tangible assets of the Surgeon ASC is determined to be less than the fair market value of the tangible assets of the Company, the Surgeon LLC will make a cash contribution to the Company in the amount of the difference. If the fair market value of the tangible assets of the Surgeon ASC is determined to be more than the fair market value of the tangible assets of the Company, the Hospital will make a cash contribution to the Company in the amount of the difference. At the time of this transaction, the lease for the space occupied by the Surgeon ASC will be terminated, and the Hospital (as lessor) and the Company (as lessee) will execute a lease for the combined space. The Requestors have certified that this lease will comply with the requirements of the safe harbor for space rental at 42 C.F.R. § 1001.952(b).

At the conclusion of this transaction, the Hospital and the Surgeon LLC will jointly own the Company, which in turn will own and operate a two-operating room ASC (the "Hospital-Surgeon ASC"). The Requestors have certified that this ASC will comply with all the requirements of the safe harbor for hospital/physicians-owned ASCs at 42 C.F.R. § 1001.952(r)(4), except for the requirements that (1) the hospital not be in a position to make or influence referrals directly or indirectly to any investor or the ASC (see 42 C.F.R. § 1001.952(r)(4)(viii)); (2) physician investors in the ASC invest directly or through a group practice composed of physicians who meet the requirements of paragraphs (r)(1), (r)(2) or (r)(3) of 42 C.F.R. § 1001.952(r)(4); and (3) the amount of

payment to an investor in return for the investment be directly proportional to the amount of the capital investment (including the fair market value of any pre-operational services rendered) of that investor (see 42 C.F.R. 1001.952(r)(4)(iii)).

The Requestors have certified that any physicians employed by the Hospital or its affiliates will not make referrals to the Hospital-Surgeon ASC; the Hospital will not take any actions to require or encourage its medical staff to refer patients to the Hospital-Surgeon ASC or the Surgeon Investors; neither the Hospital nor the Company will track referrals to the Hospital-Surgeon ASC or the Surgeon Investors by the Hospital or members of its medical staff; any compensation the Hospital pays its medical staff may make to the Hospital-Surgeon ASC or to its Surgeon Investors; and the Hospital will inform its medical staff annually of these measures. In addition, the Hospital will continue to operate its own facilities for outpatient surgery.

II. LEGAL ANALYSIS

A. Law

The anti-kickback statute makes it a criminal offense knowingly and willfully to offer, pay, solicit, or receive any remuneration to induce or reward referrals of items or services reimbursable by a Federal health care program. <u>See section 1128B(b) of the Act</u>. Where remuneration is paid purposefully to induce or reward referrals of items or services payable by a Federal health care program, the anti-kickback statute is violated. By its terms, the statute ascribes criminal liability to parties on both sides of an impermissible "kickback" transaction. For purposes of the anti-kickback statute, "remuneration" includes the transfer of anything of value, directly or indirectly, overtly or covertly, in cash or in kind.

The statute has been interpreted to cover any arrangement where <u>one</u> purpose of the remuneration was to obtain money for the referral of services or to induce further referrals. <u>United States v. Kats</u>, 871 F.2d 105 (9th Cir. 1989); <u>United States v. Greber</u>, 760 F.2d 68 (3d Cir.), <u>cert. denied</u>, 474 U.S. 988 (1985). Violation of the statute constitutes a felony punishable by a maximum fine of \$25,000, imprisonment up to five years, or both. Conviction will also lead to automatic exclusion from Federal health care programs, including Medicare and Medicaid. Where a party commits an act described in section 1128B(b) of the Act, the OIG may initiate administrative proceedings to impose civil monetary penalties on such party under section 1128A(a)(7) of the Act. The OIG may also initiate administrative proceedings to exclude such party from the Federal health care programs under section 1128(b)(7) of the Act.

The Department of Health and Human Services has promulgated safe harbor regulations that define practices that are not subject to the anti-kickback statute because such practices would be unlikely to result in fraud or abuse. See 42 C.F.R. § 1001.952. The safe harbors set forth specific conditions that, if met, assure entities involved of not being prosecuted or sanctioned for the arrangement qualifying for the safe harbor. However, safe harbor protection is afforded only to those arrangements that precisely meet all of the conditions set forth in the safe harbor.

The safe harbor for investment income from physician/hospital-owned ASCs, 42 C.F.R. § 1001.952(r)(4), is potentially applicable to the Proposed Arrangement.

B. Analysis

Although joint ventures by physicians and hospitals are susceptible to fraud and abuse, the OIG recognizes that hospitals may be at a competitive disadvantage when they compete with ASCs owned by physicians, who principally control referrals. Thus, the OIG promulgated a safe harbor for investment income from ASCs jointly-owned by physicians and hospitals that meet certain conditions, 42 C.F.R. § 1001.952(r)(4). Among the ownership arrangements potentially protected by this safe harbor are ASCs jointly owned by hospitals and general surgeons or surgeons engaged in the same surgical specialty. Because all the Surgeon Investors in the ASC are engaged in the same surgical specialty (orthopedics), the safe harbor is potentially applicable to the Proposed Arrangement.

The Requestors acknowledge that the Proposed Arrangement does not qualify for protection by this safe harbor, however, for the reasons noted below. Because no safe harbor would protect the investment income from the Hospital-Surgeon ASC, we must determine whether, given all the relevant facts, the Proposed Arrangement poses a minimal risk under the anti-kickback statute.

<u>First</u>, safe harbor protection requires that the Hospital not be in a position to make or influence referrals directly or indirectly to any investor or the ASC. 42 C.F.R. § 1001.952(r)(4)(viii). Here, the Hospital is in a position to make or influence referrals to the ASC and to the Surgeon Investors. However, the Proposed Arrangement includes certain commitments limiting the ability of the Hospital to direct or influence such referrals. The Requestors have certified that employees of the Hospital will not refer patients to the Hospital-Surgeon ASC, and the Hospital will refrain from any actions to require or encourage any members of its medical staff to refer patients to the ASC or to its Surgeon Investors. The Hospital will not track referrals, if any, by its medical staff to the Hospital-Surgeon ASC or to its Surgeon Investors; any compensation the Hospital pays its medical staff will be at fair market value and will not take into account any referrals to the Hospital-Surgeon ASC or to its Surgeon Investors; and the Hospital will inform its medical staff

annually of these measures. Also, the Hospital will continue to operate its own facilities for outpatient surgery. In light of these safeguards, the ability of the Hospital to direct or influence referrals to the Hospital-Surgeon ASC or to its Surgeon Investors is significantly constrained.

<u>Second</u>, safe harbor protection requires physician investors to hold their investment interests in an ASC either directly or through a group practice composed entirely of physicians who are qualified to invest directly. <u>See</u> 42 C.F.R. § 1001.952(r)(4). Each of the Surgeon Investors is qualified to invest in the ASC directly without destroying its eligibility for safe harbor protection.² In the Proposed Arrangement, they would invest in the Hospital-Surgeon ASC indirectly, through the Surgeon LLC, which would own 50 percent of the Company. The Company, in turn, would own and operate the Hospital-Surgeon ASC. We have previously expressed concern that intermediate investment entities could be used to redirect revenues to reward referrals or otherwise vitiate the safeguards provided by direct investment, including distributions of profits in proportion to capital investment. However, in this case, the use of a "pass-through" entity does not substantially increase the risk of fraud or abuse. Each Surgeon Investor's ownership in the Surgeon LLC is proportional to his or her capital investment, and the individual Surgeon Investors will receive a return on their investments that is the same as if they had invested in the Hospital-Surgeon ASC directly.

<u>Third</u>, safe harbor protection requires that the amount of payment to an investor in return for the investment be directly proportional to the amount of capital invested by that investor. 42 C.F.R. § 1001.952(r)(4)(iii). This requirement helps ensure that referral sources are not rewarded for their referrals through investment returns that are disproportionate to the capital they invested. In this case, the Surgeon Investors, through the Surgeon LLC, have developed the Surgeon ASC, and the Hospital is to develop the Hospital ASC. The Requestors propose to value the respective contributions to the jointly-owned Hospital-Surgeon ASC by obtaining appraisals of the tangible assets of the ASCs at the time of their merger, with either party (the Surgeon LLC or the Hospital) contributing cash, if necessary, to equalize the value of their respective contributions. The Requesters have certified that the appraisals will not take into account the volume or value of referrals made or business otherwise generated among the parties to the transaction, including past or anticipated referrals to the ASCs, but will be based solely on the fair market value of tangible assets.³

² The Surgeon Investors are qualified to invest in the ASC directly because each of them practices a single surgical specialty (orthopedic surgery) and receives at least one-third of his or her medical practice income from performing procedures that are payable by Medicare when performed in an ASC. See 42 C.F.R. § 1001.952(r)(1).

³ We are not authorized to opine on whether fair market value shall be, or was, paid or received for any goods, services, or property. See section 1128D(b)(3) of the Act.

Depending upon the amounts originally invested in the separate ASCs and the value of the tangible assets at the time of the planned merger, it is possible that the Hospital and the Surgeon LLC (and through the Surgeon LLC, the Surgeon Investors) will receive different returns on their investments.⁴

Given the facts presented here, however, we conclude that the risk of abuse resulting from any differences in return on capital is low. There are a number of factors that might influence the degree of such differences, including amounts paid for, and depreciation of, tangible assets. Nothing in the facts presented to us, however, suggests that any differences in return on capital might be related to the investors' past or anticipated referrals.⁵

For these reasons, taken together, we conclude that, while the Proposed Arrangement would result in income to investors that would not be protected by any safe harbor, it involves minimal risk of fraud or abuse.

Therefore, we rely on the certification of the Requestors with regard to whether the valuations described will represent fair market value, without taking into account the volume and value of referrals.

⁴ In the particular circumstances of the Proposed Arrangement, where the Hospital and the Surgeon Investors developed two separate ASCs as part of a plan to form a single, jointly-owned Hospital-Surgeon ASC, we consider each investor's investment to be the amount that the investor contributes to develop a separate ASC, plus any additional cash that the investor contributes at the time the two ASCs are merged. We would measure each investor's return on investment accordingly.

⁵Our conclusion might be different if the valuation of the respective contributions of the investors included intangible assets. For example, given the circumstances of the Proposed Arrangement, we might be concerned if the valuation were based on a cash flow analysis of the Surgeon ASC as a going concern. Because the Surgeon Investors are referral sources for the Surgeon ASC, a cash flow-based valuation of that business potentially would include the value of the Surgeon Investors' referrals over the time that their ASC was in existence prior to the merger with the Hospital ASC. The result might be that the Surgeon Investors would receive a greater return on their capital investment than the Hospital, which could reflect the value of their referrals to the Surgeon ASC. (In these circumstances, the Hospital ASC, being newly developed at the time of the proposed merger, may have little or no cash flow record, but we might be similarly concerned with a valuation based on a cash flow analysis of a hospital-owned ASC for which the hospital could influence referrals.) We do not assert that a cash flow-based valuation or other valuation involving intangible assets would necessarily result in a violation of the anti-kickback statute; the existence of a violation depends upon all the facts and circumstances of a particular case.

III. CONCLUSION

Based on the facts certified in your request for an advisory opinion and supplemental submissions, we conclude that while the Proposed Arrangement could potentially generate prohibited remuneration under the anti-kickback statute, if the requisite intent to induce or reward referrals of Federal health care program business were present, the OIG would not impose administrative sanctions on the Requestors under sections 1128(b)(7) or 1128A(a)(7) of the Act (as those sections relate to the commission of acts described in section 1128B(b) of the Act) in connection with the Proposed Arrangement. This opinion is limited to the Proposed Arrangement and, therefore, we express no opinion about any ancillary agreements or arrangements disclosed or referenced in your request letter or supplemental submissions.

IV. LIMITATIONS

The limitations applicable to this opinion include the following:

- This advisory opinion is issued only to the Requestors of this opinion. This advisory opinion has no application to, and cannot be relied upon by, any other individual or entity.
- This advisory opinion may not be introduced into evidence in any matter involving an entity or individual that is not a requestor of this opinion.
- This advisory opinion is applicable only to the statutory provisions specifically noted above. No opinion is expressed or implied herein with respect to the application of any other Federal, state, or local statute, rule, regulation, ordinance, or other law that may be applicable to the Proposed Arrangement, including, without limitation, the physician self-referral law, section 1877 of the Act.
- This advisory opinion will not bind or obligate any agency other than the U.S. Department of Health and Human Services.
- This advisory opinion is limited in scope to the specific arrangement described in this letter and has no applicability to other arrangements, even those which appear similar in nature or scope.
- No opinion is expressed herein regarding the liability of any party under the False Claims Act or other legal authorities for any improper billing, claims submission, cost reporting, or related conduct.

This opinion is also subject to any additional limitations set forth at 42 C.F.R. Part 1008.

The OIG will not proceed against the Requestors with respect to any action that is part of the Proposed Arrangement taken in good faith reliance upon this advisory opinion, as long as all of the material facts have been fully, completely, and accurately presented, and the Proposed Arrangement in practice comports with the information provided. The OIG reserves the right to reconsider the questions and issues raised in this advisory opinion and, where the public interest requires, to rescind, modify, or terminate this opinion. In the event that this advisory opinion is modified or terminated, the OIG will not proceed against the Requestors with respect to any action taken in good faith reliance upon this advisory opinion, where all of the relevant facts were fully, completely, and accurately presented and where such action was promptly discontinued upon notification of the modification or termination of this advisory opinion. An advisory opinion may be rescinded only if the relevant and material facts have not been fully, completely, and accurately disclosed to the OIG.

Sincerely,

/Lewis Morris/

Lewis Morris Chief Counsel to the Inspector General

Exhibit 4

October 6, 1997

[Names and addresses of Requestors have been redacted]

Re: Advisory Opinion No. 97-5

Dear Sirs:

We are writing in response to your request for an advisory opinion on behalf of Radiology Group X and Hospital System A. The request asks whether an outpatient radiology imaging center joint venture owned by a medical group specializing in radiology and a hospital care provider (i) generates prohibited remuneration within the meaning of the anti-kickback statute, Section 1128B of the Social Security Act ("Act"); (ii) constitutes grounds for the imposition of an exclusion under Section 1128(b)(7) of the Act (as it applies to kickbacks); (iii) constitutes grounds for criminal sanctions under Section 1128B(b) of the Act; and/or (iv) satisfies the criteria set out in Section 1128B(b)(3) of the Act or associated regulations, 42 C.F.R. § 1001.952.

Radiology Group X and Hospital System A have certified that all of the information provided in the request, including all supplementary letters, is true and correct, and constitutes a complete description of the relevant facts and agreements among the parties regarding the joint venture ("Proposed Arrangement"). Radiology Group X and Hospital System A have also certified that upon our approval, they will undertake to effectuate the Proposed Arrangement.

In issuing this opinion, we have relied solely on the facts and information presented to us. We have not undertaken an independent investigation of such information. This opinion is limited to the facts presented. If material facts have not been disclosed, this opinion is without force and effect.

Based on the information provided and subject to certain conditions described below, we have determined that the Proposed Arrangement does not meet any of the statutory or regulatory safe harbors set out in Section 1128B(b)(3) of the Act or 42 C.F.R. § 1001.952. However, we also conclude that the Proposed Arrangement would not generate prohibited remuneration within the meaning of the anti-kickback statute, Section

Page 2

1128B of the Act, and therefore, does not constitute grounds for the imposition of either an exclusion under Section 1128(b)(7) of the Act (as it applies to kickbacks) or criminal sanctions under Section 1128B(b) of the Act.

This opinion may not be relied on by any person or entity other than the addressees and is further qualified as set out in Part III below and in 42 C.F.R. Part 1008.

I. FACTUAL BACKGROUND

Radiology Group X and Hospital System A have made the following representations with respect to the Proposed Arrangement. Radiology Group X and Hospital System A are collectively the "Requestors".

A. Parties to the Proposed Arrangement.

Hospital System A. Hospital System A operates three hospitals in State C: Hospital 1, Hospital 2, and Hospital 3. Hospital 1, located in State C, is licensed for 351 beds and is the largest hospital in the several counties surrounding City D. Hospital 1 has a full range of radiological equipment at its facility, including a CT scanner, ultrasound equipment, fluoroscopic radiographic equipment, nuclear radiographic equipment, and magnetic resonance imaging ("MRI") equipment. Hospital 1 will continue to operate its radiology department after the Proposed Arrangement is implemented.

Hospital System A employs three physicians directly or through its subsidiary organizations. These physicians will not make referrals to the Proposed Arrangement's joint venture imaging center, nor will any such referrals be accepted if made.

Radiology Group X. Radiology Group X is a medical group specializing in radiology. It is a State C professional corporation owned and controlled by five radiologists. Dr. Y, serves as the President of Radiology Group X.

The shareholders of Radiology Group X are also the members of Radiology Group X's affiliate, Company Z. Ownership and control interests in Radiology Group X and Company Z are identical. Company Z is a newly-formed State C limited liability company and one of the members of the Proposed Arrangement's joint venture company, Imaging Center [defined below].

Current Relationship Between Radiology Group X and Hospital 1. Radiology Group X and Hospital 1 have represented that they have an informal, unwritten arrangement whereby Radiology Group X provides professional radiology services to the hospital, while hospital employees provide the technical services. The hospital owns all of the radiological equipment and is responsible for employing qualified technicians. As part of

Page 3

1

this arrangement, Radiology Group X's president, Dr. Y, serves as Hospital 1's Director of the Department of Radiology. His duties are set forth in the hospital's Medical and Dental Staff By-Laws. In addition, Hospital 1 provides Radiology Group X with space in its facility to perform radiologic interpretations.¹

While there is no written agreement, the hospital has certified that the fair market value of the space used by Radiology Group X is substantially equal to the fair market value for compensation of Dr. Y's duties as the Director of the Department of Radiology. Further, the arrangements whereby Radiology Group X and Dr. Y provide services to Hospital 1 and Hospital 1 provides Radiology Group X with space in its facility are separate from, and not dependent on, the terms and conditions of the Proposed Arrangement.

B. Proposed Arrangement.

Radiology Group X, through its affiliate Company Z, and Hospital System A have proposed to enter into a joint venture to establish an outpatient radiology imaging center ("Imaging Center"). The Imaging Center will be located in the Village of E, at the western edge of City D. The Imaging Center will offer a full range of state-of-the-art imaging techniques, including X-ray equipment, fluoroscope equipment, a superconducting open MRI system, a computerized tomography scanner, and an ultrasound system.

The Imaging Center will be owned and operated by a State C limited liability company, Company B. The members of Company B will be Company Z and Hospital System A. Company Z and Hospital System A will make capital contributions of \$204,000 and \$196,000, respectively. In return, each member will receive voting and distribution rights proportional to its investment. Additional capital contributions will be apportioned to Company Z and Hospital System A based upon their respective ownership interests.²

² If either member of Company B is unable or unwilling to make any part of an additional capital contribution, the other member has a right to make up the difference, treat such amount as either an additional capital contribution or as a loan, and adjust the

Radiology Group X does not have any non-hospital based office space.

Page 4

The Imaging Center will be staffed by employees hired by Company B. Radiology Group X radiologists will be the exclusive providers of professional services to the Imaging Center. The president of Radiology Group X, or his designee, will be in charge of supervising and administering all aspects of the clinical services rendered at the Imaging Center, including quality assurance. The Radiology Group X radiologists will not be employees of the Imaging Center, but will enter into a service provider agreement with Company B. Under the service agreement, Radiology Group X will not receive any compensation from the Imaging Center. Radiology Group X will bill patients and thirdparty payers, including Medicare and Medicaid, for the professional component of radiological services directly. The Imaging Center will bill separately its technical component to patients and third-party payers.

II. LEGAL ANALYSIS

The anti-kickback statute makes it a criminal offense knowingly and willfully to offer, pay, solicit or receive any remuneration to induce referrals of items or services reimbursed by Federal health care programs. 42 U.S.C. § 1320a-7b(b). Where remuneration is paid purposefully in exchange for referrals of items or services paid for by a Federal health care program, the kickback statute is violated. By its terms, the statute ascribes criminal liability to parties on both sides of an impermissible "kickback" transaction.

The statute has been interpreted to cover any arrangement where <u>one</u> purpose of the remuneration is to obtain money for the referral of services or to induce further referrals. <u>United States v. Kats</u>, 871 F.2d 105 (9th Cir. 1989); <u>United States v. Greber</u>, 760 F.2d 68 (3d Cir.), <u>cert</u>. <u>denied</u>, 476 U.S. 988 (1985). Violations of the statute constitute a felony punishable by a maximum fine of \$25,000, imprisonment up to five years or both. Conviction will also lead to automatic exclusion from Federal health care programs including Medicare and Medicaid.

The Office of Inspector General may also initiate an administrative proceeding to exclude an individual from Federal health care programs for fraud, kickbacks and other prohibited activities. Section 1128(b)(7) of the Act. Because both the criminal and administrative

proportional percentages of ownership accordingly. For purposes of this opinion, we have assumed that any loan would be at fair market value.

sanctions related to the Proposed Arrangement are based on the anti-kickback statute, the analysis is the same under either provision.

Health care joint ventures in which investors are also sources of referrals or suppliers of items or services to the joint venture raise many questions under the anti-kickback statute. In 1989, the Office of Inspector General issued a "Special Fraud Alert" specifically discussing joint venture arrangements that may violate the anti-kickback statute.³ In general, joint ventures between radiologists and health care providers in a position to order imaging services may be suspect, because distributions from the joint ventures may be disguised remuneration paid in return for referrals. Like any kickback scheme, these arrangements can lead to overutilization of such services, increased costs for Federal health care programs, corruption of professional judgment, and unfair competition.

A. The Proposed Joint Venture Does Not Meet the Safe Harbor For Investment Interests in Small Entities.

In 1991, the Department of Health and Human Services ("Department") published safe harbor regulations which define practices that are not subject to the anti-kickback statute because such arrangements would be unlikely to result in fraud or abuse. Failure to comply with a safe harbor provision does not make an arrangement <u>per se</u> illegal. Rather, the safe harbors set forth specific conditions that, if fully met, would assure the entities involved of not being prosecuted or sanctioned for the arrangement qualifying for the safe harbor. The only safe harbor regulation potentially available to the Proposed Arrangement addresses investment interests in small entities. <u>See</u> 42 C.F.R. § 1001.952(a)(2).⁴

The safe harbor for investments in small entities has eight elements, each of which must be satisfied in order for the arrangement to qualify for the exception. The eight elements address three areas of concern in abusive joint ventures: (i) how investors are selected and retained; (ii) the nature of the business structure; and (iii) the financing and profit distributions. The eight elements are:

³ <u>See</u> Special Fraud Alert, "Joint Venture Arrangements" (OIG-89-4), <u>reprinted</u> <u>in</u> 59 Fed. Reg. 65373 (December 19, 1994).

⁴ The Requestors had suggested that the "shared risk" statutory exception to the anti-kickback statute added by Section 216 of the Health Insurance Portability and Accountability Act, Pub. Law No. 104-191 (Aug. 21, 1996), potentially applied. That provision, however, applies only to contractual arrangements where a person supplying items or services is at risk for the cost or utilization of such items or services and is obligated to provide them, as in some managed care contracts.

- no more than forty percent of the investment interests may be held by investors who are in a position to make or influence referrals, furnish items or services, or generate business ("Interested Investors");
- interests offered to passive investors who are Interested Investors cannot be made on terms different from those offered to other investors;
- the terms on which an investment is offered to Interested Investors cannot take into account any previous or expected volume of referrals, services furnished, or amount of business generated from such investors;
- there is no requirement that a passive investor make referrals to, or otherwise generate business for, the entity as a condition of remaining an investor;
- the entity cannot market or furnish the items or services differently to passive investors and non-investors;
- no more than forty percent of the gross revenue of the entity may come from Interested Investors;
- the entity cannot loan or guarantee funds to an Interested Investor if the loan or guarantee is used to obtain the investment interest; and
- an investor's return on investment must be directly proportional to the amount of capital investment of that investor.

Strict compliance with all elements is required. See 56 Fed. Reg. 35952, 35954 (July 29, 1991).

The Proposed Arrangement fails to meet at least one of the eight elements. More than 40% of the investment interest is owned by persons who furnish items or services to the new venture; Radiology Group X owns 51% of the entity and will provide the professional services to the venture. Accordingly, the Proposed Arrangement does not meet the only relevant safe harbor.

B. The Proposed Arrangement Will Not Result in Prohibited Remuneration.

Even though the Proposed Arrangement does not fall within a safe harbor, it does not necessarily violate the anti-kickback statute. With respect to joint ventures, the major concern is that the profit distributions to investors in the joint venture, who are also referral sources to the joint venture, may potentially represent remuneration for those referrals. A related concern is that, where the investing parties have a referral relationship wholly apart from the joint venture, distributions from the joint venture could potentially represent remuneration to one party for referrals to the other party based on those independent relationships. Accordingly, all aspects of all relationships between the parties must be examined.

1. There Is No Prohibited Remuneration For Referrals To The Imaging Center.

Our initial inquiry is whether the distributions from the joint venture may be "disguised" remuneration for referrals by the investors to the joint venture. Based upon the information and representations provided, we find that neither Radiology Group X nor Hospital System A will be able to generate referrals to the joint venture.

A threshold issue is the proper characterization of Hospital System A's role in relationship to the joint venture. In many instances, hospitals are capable of influencing, and do influence, referrals to other health care providers, such as through discharge planning with respect to post-discharge care. In addition, hospitals are in a position to influence the flow of radiology work performed at the hospital, because the hospital controls to whom radiologic interpretations are referred. See Financial Arrangements Between Hospitals and Hospital-Based Physicians, OEI-09-89-00330, 1991. In this instance, however, and subject to the conditions set out below, we do not believe that the Hospital System A hospitals will be able to generate referrals to the Imaging Center.

<u>First</u>, Hospital System A has represented that its employed physicians will make no referrals to the Imaging Center, and the Imaging Center will not accept any referrals from those physicians. <u>Second</u>, Hospital System A has agreed that it will take no actions, either overt or covert, financial or otherwise, to induce its medical staff (<u>i.e.</u>, any physician with admitting or staff privileges) to use the Imaging Center. <u>Third</u>, Hospital System A has agreed that it will inform the medical staff of the preceding agreement. <u>Fourth</u>, physician referrals to the Imaging Center will not be tracked by Hospital System A, its hospitals, Company Z, or Radiology Group X. <u>Fifth</u>, Hospital System A hospitals will continue to operate and use their own radiology units. In these circumstances, referrals from physicians with admitting or staff privileges at the Hospital System A hospitals would not be attributable to Hospital System A.

Moreover, the Radiology Group X radiologists are also unlikely to be able to generate an appreciable number of referrals to the Imaging Center. In general, radiologists do not order the radiological tests they perform; such tests are ordered by a patient's attending

physician. Although there may be situations in which a radiologist can recommend additional testing to the attending physician during the course of a consultation and, as a practical matter, indirectly generate some additional business, those tests must be approved by the patient's attending physician.⁵ In these limited circumstances -- the recommendation of additional testing by a radiologist to an attending physician with whom the radiologist has no financial arrangements and pursuant to a <u>bona fide</u> medical consultation -- we conclude that a Radiology Group X radiologist's recommendation is not prohibited under the anti-kickback statute.⁶

In sum, since neither Radiology Group X nor Hospital System A will be in a position to generate or influence an appreciable number of referrals to the Imaging Center, the

⁵ <u>See</u> 61 Fed. Reg. 59490, 59497 (November 22, 1996) (with respect to when Medicare will cover diagnostic tests, the Health Care Financing Administration has stated, "we believe that the physician interpreting the diagnostic tests has an obligation to discuss any changes in or additions to the original order with the patient's physician.").

⁶ Radiology Group X radiologists receive no remuneration from patients' \Box attending physicians, and none of the attending physicians which refer to Radiology Group X have any financial relationships with Radiology Group X.

distributions of any profits would not constitute illegal remuneration in exchange for referrals.

2. There Is No Prohibited Remuneration For Referrals Outside Of The Joint Venture.

Radiology Group X derives a substantial amount of its revenues from its position as the exclusive provider of professional radiology services for Hospital 1.⁷ This raises the possibility that the joint venture may be a vehicle by which Radiology Group X may indirectly reward Hospital System A for revenues Radiology Group X receives as a result of its arrangement with Hospital 1.⁸

In determining whether the joint venture may be a vehicle for illegally remunerating one investor for referrals to another investor, we examine initially whether the party making the referrals receives a disproportionate return on its investment compared to the return on the investment of the party receiving the referrals. Any excess or disproportionate return on the investment may be remuneration for referrals. Based on the facts and circumstances as represented by Radiology Group X and Hospital System A, both parties have made substantial financial investments in the venture, and control of the venture and

⁸ Specific problems with financial arrangements between hospital-based physicians, such as radiologists, and hospitals were discussed in a 1991 Management Advisory Report entitled <u>Financial Arrangements Between Hospitals and Hospital-Based Physicians</u>, OEI-09-89-00330 (1991).

⁷ Radiology Group X radiologists are not in a position to make referrals to the Hospital System A hospitals for the same reasons that they cannot make appreciable referrals to the Imaging Center. Accordingly, the potential profit distributions from the Imaging Center to the Radiology Group X radiologists would not represent disguised remuneration for any possible referrals to Hospital System A hospitals.

distribution of profits will be in direct proportion to such investments. Thus, both parties' return on investment is commensurate with their undertakings and would not appear to include any "unearned" remuneration to Hospital 1 attributable to its arrangements with Radiology Group X. Accordingly, any profit distributions from the Proposed Arrangement would not appear to represent compensation to Hospital System A or Hospital 1 for their referrals to Radiology Group X.

Moreover, based on the representations by Radiology Group X and Hospital System A that the value of the premises and equipment provided to Radiology Group X are substantially equal to the value of Dr. Y's services to Hospital 1, we conclude that any profit distribution from the Imaging Center will not represent illegal remuneration for the use of space and equipment at Hospital 1.⁹

However, even in situations where each party's return is proportionate with its investment, the mere opportunity to invest (and consequently receive profit distributions) may in certain circumstances constitute illegal remuneration if offered in exchange for past or future referrals. Such situations may include arrangements where one or several investors in a joint venture control a sufficiently large stream of referrals to make the venture's financial success highly likely, or where one investor has an established track record with similar ventures or the financial investment required is so small that the investors have little or no real risk. By contrast, there are no such indicia that the Proposed Arrangement will generate any profits for its investors, since neither party is in a position to influence appreciable referrals to the joint venture nor has successfully operated a freestanding imaging center before. In light of the substantial financial investment being made by Hospital System A, we find no evidence that the mere opportunity to participate as an investor in the Imaging Center constitutes illegal remuneration to Hospital System A.

III. CONCLUSION

For the above reasons, we have determined that the Proposed Arrangement does not contain any prohibited remuneration within the meaning of the anti-kickback statute,

⁹ We are not, however, making any independent finding as to the legality of the current arrangement between Radiology Group X and Hospital 1.

1128B of the Social Security Act ("Act"), and consequently does not constitute grounds for the imposition of either an exclusion under section 1128(b)(7) of the Act (as it applies to kickbacks) or criminal sanction under 1128B(b) of the Act.

IV. LIMITATIONS

The limitations applicable to this opinion include the following:

- This advisory opinion is issued only to the Radiology Group X and Hospital System A, which are the Requestors of this opinion. This advisory opinion has no application, and cannot be relied upon, by any other individual or entity.
- This advisory opinion may not be introduced into evidence in any matter involving an entity or individual that is not a Requestor to this opinion.
- This advisory opinion is applicable only to the statutory provisions specifically noted above. No opinion is herein expressed or implied with respect to the application of any other Federal, state, or local statute, rule, regulation, ordinance, or other law that may be applicable to the Proposed Arrangement, including any laws relating to insurance or insurance contracts.
- This advisory opinion will not bind or obligate any agency other than the U.S. Department of Health and Human Services.
- This advisory opinion is prospective only. It has no application to conduct which precedes the date of this opinion.
- This advisory opinion does not make any determination as to whether any amounts paid by one party to another are representative of fair market value.
- This advisory opinion is limited in scope to the specific arrangement described in this letter and has no applicability to other arrangements, even those which appear similar in nature or scope.

This opinion is also subject to any additional limitations set forth at 42 C.F.R. Part 1008.

The OIG will not proceed against the Requestors with respect to any action taken in good faith reliance upon this advisory opinion as long as all of the material facts have been fully, completely, and accurately presented, and the arrangement in practice comports with the information provided. The OIG reserves the right to reconsider the questions


and issues raised in this advisory opinion and, where the public interest requires, modify or terminate this opinion. In the event that this advisory opinion is modified or terminated, the OIG will not proceed against the Requestors with respect to any action taken in good faith reliance upon this advisory opinion, where all of the relevant facts were fully, completely, and accurately presented and where such action was promptly discontinued upon notification of the modification or termination of this advisory opinion.

Sincerely,

/S/

D. McCarty Thornton Chief Counsel to the Inspector General

Exhibit 5



SECTION 15: CERTIFICATION STATEMENT

An **AUTHORIZED OFFICIAL** means an appointed official (for example, chief executive officer, chief financial officer, general partner, chairman of the board, or direct owner) to whom the organization has granted the legal authority to enroll it in the Medicare program, to make changes or updates to the organization's status in the Medicare program, and to commit the organization to fully abide by the statutes, regulations, and program instructions of the Medicare program.

A **DELEGATED OFFICIAL** means an individual who is delegated by an authorized official the authority to report changes and updates to the supplier's enrollment record. A delegated official must be an individual with an "ownership or control interest" in (as that term is defined in Section 1124(a)(3) of the Social Security Act), or be a W-2 managing employee of, the supplier.

Delegated officials may not delegate their authority to any other individual. Only an authorized official may delegate the authority to make changes and/or updates to the supplier's Medicare status. Even when delegated officials are reported in this application, an authorized official retains the authority to make any such changes and/or updates by providing his or her printed name, signature, and date of signature as required in Section 15B.

NOTE: Authorized officials and delegated officials must be reported in Section 6, either on this application or on a previous application to this same Medicare fee-for-service contractor. If this is the first time an authorized and/or delegated official has been reported on the CMS-855B, you must complete Section 6 for that individual.

By his/her signature(s), an authorized official binds the supplier to all of the requirements listed in the Certification Statement and acknowledges that the supplier may be denied entry to or revoked from the Medicare program if any requirements are not met. All signatures must be original and in ink. Faxed, photocopied, or stamped signatures will not be accepted.

Only an authorized official has the authority to sign (1) the initial enrollment application on behalf of the supplier or (2) the enrollment application that must be submitted as part of the periodic revalidation process. A delegated official does not have this authority.

By signing this application, an authorized official agrees to immediately notify the Medicare fee-for-service contractor if any information furnished on the application is not true, correct, or complete. In addition, an authorized official, by his/her signature, agrees to notify the Medicare fee-for-service contractor of any future changes to the information contained in this form, after the supplier is enrolled in Medicare, in accordance with the timeframes established in 42 C.F.R. 424.520(b). (IDTF changes of information must be reported in accordance with 42 C.F.R. 410.33.)

The supplier can have as many authorized officials as it wants. If the supplier has more than two authorized officials, it should copy and complete this section as needed.

EACH AUTHORIZED AND DELEGATED OFFICIAL MUST HAVE AND DISCLOSE HIS/HER SOCIAL SECURITY NUMBER.

SECTION 15: CERTIFICATION STATEMENT (Continued)

A. ADDITIONAL REQUIREMENTS FOR MEDICARE ENROLLMENT

These are additional requirements that the supplier must meet and maintain in order to bill the Medicare program. Read these requirements carefully. By signing, the supplier is attesting to having read the requirements and understanding them.

By his/her signature(s), the authorized official(s) named below and the delegated official(s) named in Section 16 agree to adhere to the following requirements stated in this Certification Statement:

- 1. I authorize the Medicare contractor to verify the information contained herein. I agree to notify the Medicare contractor of any future changes to the information contained in this application in accordance with the timeframes established in 42 C.F.R. § 424.516. I understand that any change in the business structure of this supplier may require the submission of a new application.
- 2. I have read and understand the Penalties for Falsifying Information, as printed in this application. I understand that any deliberate omission, misrepresentation, or falsification of any information contained in this application or contained in any communication supplying information to Medicare, or any deliberate alteration of any text on this application form, may be punished by criminal, civil, or administrative penalties including, but not limited to, the denial or revocation of Medicare billing privileges, and/or the imposition of fines, civil damages, and/or imprisonment.
- 3. I agree to abide by the Medicare laws, regulations and program instructions that apply to this supplier. The Medicare laws, regulations, and program instructions are available through the Medicare contractor. I understand that payment of a claim by Medicare is conditioned upon the claim and the underlying transaction complying with such laws, regulations, and program instructions (including, but not limited to, the Federal anti-kickback statute and the Stark law), and on the supplier's compliance with all applicable conditions of participation in Medicare.
- 4. Neither this supplier, nor any five percent or greater owner, partner, officer, director, managing employee, authorized official, or delegated official thereof is currently sanctioned, suspended, debarred, or excluded by the Medicare or State Health Care Program, e.g., Medicaid program, or any other Federal program, or is otherwise prohibited from supplying services to Medicare or other Federal program beneficiaries.
- 5. I agree that any existing or future overpayment made to the supplier by the Medicare program may be recouped by Medicare through the withholding of future payments.
- 6. I will not knowingly present or cause to be presented a false or fraudulent claim for payment by Medicare, and I will not submit claims with deliberate ignorance or reckless disregard of their truth or falsity.
- 7. I authorize any national accrediting body whose standards are recognized by the Secretary as meeting the Medicare program participation requirements, to release to any authorized representative, employee, or agent of the Centers for Medicare & Medicaid Services (CMS) a copy of my most recent accreditation survey, together with any information related to the survey that CMS may require (including corrective action plans).

SECTION 15: CERTIFICATION STATEMENT (Continued)

B. 1st AUTHORIZED OFFICIAL SIGNATURE

I have read the contents of this application. My signature legally and financially binds this supplier to the laws, regulations, and program instructions of the Medicare program. By my signature, I certify that the information contained herein is true, correct, and complete and I authorize the Medicare fee-for-service contractor to verify this information. If I become aware that any information in this application is not true, correct, or complete, I agree to notify the Medicare fee-for-service contractor of this fact immediately.

If you are changing, adding, or deleting information, check the applicable box, furnish the effective date, and complete the appropriate fields in this section.

CHECK ONE	🗆 ADD	🗆 delete
DATE (mm/dd/yyyy)		

Authorized Official's Information and Signature

First Name	Middle Initial	Last Name	Suffix (e.g., Jr., Sr.)
Telephone Number		I	Title/Position
Authorized Official Signature (First, Middle, L	ast Name, Jr., Sr., M.D., D.O.,	etc.)	Date Signed (mm/dd/yyyy)

(blue ink preferred)

C. 2ND AUTHORIZED OFFICIAL SIGNATURE

I have read the contents of this application. My signature legally and financially binds this supplier to the laws, regulations, and program instructions of the Medicare program. By my signature, I certify that the information contained herein is true, correct, and complete and I authorize the Medicare fee-for-service contractor to verify this information. If I become aware that any information in this application is not true, correct, or complete, I agree to notify the Medicare fee-for-service contractor of this fact immediately.

If you are changing, adding, or deleting information, check the applicable box, furnish the effective date, and complete the appropriate fields in this section.


CHECK ONE	CHANGE	ADD	DELETE
DATE (mm/dd/yyyy)			

Authorized Official's Information and Signature

First Name	Middle Initial	Last Name	Suffix (e.g., Jr., Sr.)
Telephone Number		I	Title/Position
Authorized Official Signature (F	irst, Middle, Last Name, Jr., Sr., M.D.,	D.O., etc.)	Date Signed (mm/dd/yyyy)

All signatures must be original and signed in ink (blue ink preferred). Applications with signatures deemed not original will not be processed. Stamped, faxed or copied signatures will not be accepted.

Case 1:09-cv-02175-WJM Document 35-1 Filed 12/23/11 USDC Colorado Page 51 of 97



NUBC

UB-04 NOTICE: THE SUBMITTER OF THIS FORM UNDERSTANDS THAT MISREPRESENTATION OR FALSIFICATION OF ESSENTIAL INFORMATION AS REQUESTED BY THIS FORM, MAY SERVE AS THE BASIS FOR CIVIL MONETARY PENALTIES AND ASSESSMENTS AND MAY UPON CONVICTION INCLUDE FINES AND/OR IMPRISONMENT UNDER FEDERAL AND/OR STATE LAW(S).

Submission of this claim constitutes certification that the billing information as shown on the face hereof is true, accurate and complete. That the submitter did not knowingly or recklessly disregard or misrepresent or conceal material facts. The following certifications or verifications apply where pertinent to this Bill:

- If third party benefits are indicated, the appropriate assignments by the insured /beneficiary and signature of the patient or parent or a legal guardian covering authorization to release information are on file. Determinations as to the release of medical and financial information should be guided by the patient or the patient's legal representative.
- If patient occupied a private room or required private nursing for medical necessity, any required certifications are on file.
- 3. Physician's certifications and re-certifications, if required by contract or Federal regulations, are on file.
- For Religious Non-Medical facilities, verifications and if necessary re-certifications of the patient's need for services are on file.
- Signature of patient or his representative on certifications, authorization to release information, and payment request, as required by Federal Law and Regulations (42 USC 1935f, 42 CFR 424.36, 10 USC 1071 through 1086, 32 CFR 199) and any other applicable contract regulations, is on file.
- 6. The provider of care submitter acknowledges that the bill is in conformance with the Civil Rights Act of 1964 as amended. Records adequately describing services will be maintained and necessary information will be furnished to such governmental agencies as required by applicable law.
- 7. For Medicare Purposes: If the patient has indicated that other health insurance or a state medical assistance agency will pay part of his/her medical expenses and he/she wants information about his/her claim released to them upon request, necessary authorization is on file. The patient's signature on the provider's request to bill Medicare medical and non-medical information, including employment status, and whether the person has employer group health insurance which is responsible to pay for the services for which this Medicare claim is made.
- 8. For Medicaid purposes: The submitter understands that because payment and satisfaction of this claim will be from Federal and State funds, any false statements, documents, or concealment of a material fact are subject to prosecution under applicable Federal or State Laws.

9. For TRICARE Purposes:

- (a) The information on the face of this claim is true, accurate and complete to the best of the submitter's knowledge and belief, and services were medically and appropriate for the health of the patient;
- (b) The patient has represented that by a reported residential address outside a military medical treatment facility catchment area he or she does not live within the catchment area of a U.S. Public Health Service medical facility, or if the patient resides within a catchment area of such a facility, a copy of Non-Availability Statement (DD Form 1251) is on file, or the physician has certified to a medical emergency in any instance where a copy of a Non-Availability Statement is not on file;
- (c) The patient or the patient's parent or guardian has responded directly to the provider's request to identify all health insurance coverage, and that all such coverage is identified on the face of the claim except that coverage which is exclusively supplemental payments to TRICARE-determined benefits;
- (d) The amount billed to TRICARE has been billed after all such coverage have been billed and paid excluding Medicaid, and the amount billed to TRICARE is that remaining claimed against TRICARE benefits;
- (e) The beneficiary's cost share has not been waived by consent or failure to exercise generally accepted billing and collection efforts; and,
- (f) Any hospital-based physician under contract, the cost of whose services are allocated in the charges included in this bill, is not an employee or member of the Uniformed Services. For purposes of this certification, an employee of the Uniformed Services is an employee, appointed in civil service (refer to 5 USC 2105), including part-time or intermittent employees, but excluding contract surgeons or other personal service contracts. Similarly, member of the Uniformed Services does not apply to reserve members of the Uniformed Services not on active duty.
- (g) Based on 42 United States Code 1395cc(a)(1)(j) all providers participating in Medicare must also participate in TRICARE for inpatient hospital services provided pursuant to admissions to hospitals occurring on or after January 1, 1987; and
- (h) If TRICARE benefits are to be paid in a participating status, the submitter of this claim agrees to submit this claim to the appropriate TRICARE claims processor. The provider of care submitter also agrees to accept the TRICARE determined reasonable charge as the total charge for the medical services or supplies listed on the claim form. The provider of care will accept the TRICARE-determined reasonable charge even if it is less than the billed amount, and also agrees to accept the amount paid by TRICARE combined with the costshare amount and deductible amount, if any, paid by or on behalf of the patient as full payment for the listed medical services or supplies. The provider of care submitter will not attempt to collect from the patient (or his or her parent or guardian) amounts over the TRICARE determined reasonable charge. TRICARE will make any benefits payable directly to the provider of care, if the provider of care a participating provider.

PAL PADDC4MP PROCKUP PROCKUP PROVINCE PR		FORM CLAIM COMMITTEE 08/05			
MEDICARE MEDICARE TOCARE CHARMAN CODE In Allowed St 10 Audeen Provinging in the accurate of junction PATIENT'S MARE (Las Name, Frai Name, Marte Indo) 3 Provinging in the accurate of junction 3 Provinging in the accurate of junction 4 REURED S NAME (Las Name, Frai Name, Marte Indo) 3 Provinging in the accurate of junction 4 REURED S NAME (Las Name, Frai Name, Marte Indo) 7 NEURED S NAME (Las Name, Frai Name, Marte Indo) 7 NEURED S NAME (Las Name, Frai Name, Marte Indo) 7 NEURED S NAME (Las Name, Frai Name, Marte Indo) 7 NEURED S NAME (Las Name, Frai Name, Marte Indo) 9 Provinging in the accurate of put in the set of put in the put indo, i	PICA				
Jakebard Di	MEDICARE MEDICA		AMPVA GROUP FECA OTHE	R 1a. INSURED'S I.D. NUMBER	
MM DS V Column ATTENT'S ADDRESS (Ms. Struct) 5. PATION' RELATIONOMIN' TO INSURED 7. HOLINED'S ADDRESS (Ms. Struct) V STATE 8. PATION' RELATIONOMIN' TO INSURED 7. HOLINED'S ADDRESS (Ms. Struct) V STATE 8. PATION' RELATIONOMIN' TO INSURED 20 CORE TELEPHONE Insude Area Code CODE TELEPHONE Insude Area Code Environitie Statem 11. INSURED'S POLICY GROUP OF FECA NUMBER 2011EGT INSURED'S POLICY ON SHOUP MARKER PATIENT' Current of Previous) a. EXPLOYING TY Current of Previous) a. EXPLOYING TY Current of Previous) b. AUTO ACCIDENT 2011EGT INSURED'S POLICY ON SHOUP MARKER D. AUTO ACCIDENT PLOCE (State) b. AUTO ACCIDENT 2011EGT INSURED'S POLICY ON SHOUP MARKER D. AUTO ACCIDENT PLOCE (State) b. MOLICY PREVIDENCE POLICY GROUP OF BORNA NAME 2011EGT INSURED'S POLICY ON SHOUP MARKER TO ALTO ACCIDENT PLOCE (State) b. MOLICY PREVIDENCE POLICY RELETION ADME 2011EGT INSURED'S POLICY ON SHOUP MARKER TO ALTO ACCIDENT PLOCE (State) c. INSURED'S POLICY ON SHOUP MARKER 2011EGT INSURED'S POLICY ON SHOUP MARKER D. AUTO ACCIDENT PLOCE (State) c. INSURED'S POLICY (State) <	(Medicare #) (Medicaid	(Me) CHAMPUS (Sponsor's SSN) (Me)	mber ID#) HEALTH PLAN BUK LUNG (ID)		(For Frogram in them Ty
PATERTS ADDRESS (Mo. Street) c. PATERTS ADDRESS (Mo. Street) 7. INSURED'S ADDRESS (Mo. Street) Y STATE & PATERTS ADDRESS (Mo. Street) CITY STATE Y STATE & PATERTS ADDRESS (Mo. Street) CITY STATE Y STATE & PATERTS ADDRESS (Mo. Street) CITY STATE Y STATE & PATERTS ADDRESS (Mo. Street) CITY STATE Y STATE & PATERTS CONSTITUES Differ Moure (To State CT) TIL INSURED'S POLICY OR OPPOLY MUMER EVENUE State (To State CT) TIL INSURED'S POLICY OR OPPOLY MUMER EVENUE State (To State CT) TIL INSURED'S POLICY OR OPPOLY MUMER EVENUE State (To State CT) INSURED'S POLICY OR OPPOLY MUMER EVENUE State (To State CT) INSURED'S CITY EVENUE CITY State (To State CT) INSURED'S CITY EVENUE CITY EVENUE	PATIENT'S NAME (Last Nam	e, First Name, Middle Initial)		4. INSURED'S NAME (Last Name, First	Name, Middle Initial)
PY ISTATE Is Patient Status Corr Corr Status Status 2006 TELEPHONE (Include Anel Code) Include Phone Status Statu	PATIENT'S ADDRESS (No., S	Street)		7. INSURED'S ADDRESS (No., Street)	
CODE TELEPHONE (Include Area Code) Since The Provide Include Area Code) Code TelePHONE (Include Area Code) Since TelePHONE (Include Area Code) Code TelePHONE (Include Area Code)			Self Spouse Child Other		
CODE TELEPHONE (Include Ana Cx89) Fell Time ZIP CODE TELEPHONE (Include Ana Cx89) DTHER INSURED'S NAME (Last Name, Finit Name Middle Initia) ID. IS PATIENT CONDITION RELATED TO. 11. INSURED'S POLICY OR GROUP OR FECA NUMBER DTHER INSURED'S POLICY OR GROUP NUMBER a. EMPLOYMENT? (Curron or Phonos) a. INSURED'S POLICY OR GROUP OR FECA NUMBER DTHER INSURED'S FOLICY OR GROUP NUMBER a. EMPLOYMENT? (Curron or Phonos) a. INSURANCE PLAN NAME OR SCHOOL NAME DTHER INSURED'S SATE OF BIRTH SEX b. AUTO ACCIDENT? PLACE (Statu) DTHER INSURED'S SATE OF BIRTH SEX b. AUTO ACCIDENT? PLACE (Statu) DATE C. OTHER ACCIDENT? C. INSURANCE PLAN NAME OR PROGRAM NAME ID. INSURANCE PLAN NAME OR PROGRAM NAME NAME OR PEROVES SCIENCILLE Lambridge and any model a bord in formation necessary ID. INSURED'S ON AUTO-RECEPTORULE LINES IS THERE ANOTHER HEALTH BENEFIT PLAN? NAME OF PEROVES SCIENCILLE Lambridge and any model a bord in formation necessary ID. INSURED'S ON AUTO-RECEPTORULE LINES SCIAED DATE SCIAAE DATE IS INFERE ANOTHER HEALTH BENEFIT PLAN? SCIAED DATE SCIAAE DATE SCIAAE DATE SCIALING SCIAE OR INDUTOR IN SUPLICES INSURIDE'S ON AUTO-RECEPTORULE	Ŷ	S		CITY	STATE
Content HSURED'S NAME (Last Name, First Name, Mode inflay) THER HSURED'S DATE OF BITH SEX Subart Sub	CODE	TELEPHONE (Include Area Code			PHONE (Include Area Code)
DTHER INSURED'S NAME List Name, Mode InNui) 10. IS PATERYS CONCINCT RELATED TO 11. INSURED'S POLICY OR GROUP OR FECA NUMBER a. EMPLOYMENT? (Current or Previous) a. EMPLOYMENT? (Current or Previous) a. INSURED'S DOLICY GROUP OR FECA NUMBER a. INSURED'S OLICY OR GROUP NUMBER a. EMPLOYMENT? (Current or Previous) a. INSURED'S DATE OF BITTH SEX MM DD YES NO		()			
THE FILLING FOR A DATE OF GIRTH SEX D A UTO ACCIDENT? PLACE (GRap D A UTO ACCIDENT? PLACE (GRap D A UTO ACCIDENT? PLACE (GRap C D A UTO ACCIDENT? PLACE (GRap C D A D A UTO ACCIDENT? PLACE (GRap C D A D A D A UTO ACCIDENT? PLACE (GRap C D A D A D A D A D A D A D A D A D A D	THER INSURED'S NAME (I	Last Name, First Name, Middle Initial		11. INSURED'S POLICY GROUP OR FE	J ECA NUMBER
		· · · · · · · · · · · · · · · · · · ·			
STHER INSURED'S OATE OF BIRTH SEX AUT OACCIDENT? PLACE (Stain) EMPLOYER'S NAME OR SCHOOL NAME C OTHER ACCIDENT? PLACE (Stain) EMPLOYER'S NAME OR SCHOOL NAME C OTHER ACCIDENT? E CONSUMATION CONTROL FOR BROAD NAME C OTHER ACCIDENT? EAD BACK OF FORM BEFORE COMPLETING & SIGNING THIS FORM PATEOTIS OR AUTHORIZE PLANNAME OR PROGRAM NAME I DIA RESERVED FOR LOCAL USE C OTHER ACCIDENT? READ BACK OF FORM BEFORE COMPLETING & SIGNING THIS FORM PATEOTIS OR AUTHORIZE PLANNAME OR SUBALTIONE: Lauboras the data of any medical or other information necessary I DIA NOVER'S SIGNATURE Lauboras the data of any medical or other information necessary DATE OF CURRENT I DIA SIGNED DATE OF CURRENT I DIA SIGNED I DIA SIGNED	THER INSURED'S POLICY	OR GROUP NUMBER	a. EMPLOYMENT? (Current or Previous)	a. INSURED'S DATE OF BIRTH	SEX
M DD YY International construction of the party with a complex structure in the maximum of participant of the party with a complex structure in the maximum of participant of the party with a complex structure in the maximum of participant of the party with a complex structure in the maximum of participant of the party with a complex structure in the maximum of participant in the maximum of participant in the maximum of participant of the party with a complex structure in the maximum of participant in the maximum of partemark in the maximum of participant in the maximum of partemark i		FRIBTH		I	
MPLOYERS NAME OR SCHOOL NAME			PLACE (Slate)	b. EMPLOYER'S NAME OR SCHOOL N	AME
	MPLOYER'S NAME OR SCI			NOUDANCE DI ANNUE DE DE	24449445
SURANCE PLAN NAME OR PROGRAM NAME 104. RESERVED FOR LOCAL USE d. IS THERE ANOTHER HEALTH BENEFIT PLAN7 IMPROVEMENT OR AUTHORIZED PERSON'S SIGNATURE 1 authors the values of any medical or other infermation necessary reduces the induced of the infermation necessary reduces the infermation of induced of the infermation necessary reduces the infermation of induced of the infermation necessary reduces the infermation of induced of the infermation necessary reduces the infermation of induced of the infermation necessary reduces the infermation of induced of the infermation necessary reduces the infermation of induced of the infermation of induced of the infermation necessary reduces the infermation of induced of the infermation necessary reduces the infermation necessary reduces the infermation of induced of the infermation necessary reduces the infermation necessary reduces the infermation of induced of the infermation necessary reduces t				C INSUMANUE PLAN NAME OF PROG	
PEAD BACK OF FORM BEFORE COMPLETING & SIGNING THIS FORM. Image: Complete complete item 9 ATIENTS OR AUTHORIZED FERSONS SIGNATURE I authoraze the release of any medical or other information necessary Image: Complete item 9 ATIENTS OR AUTHORIZED FERSONS SIGNATURE I authoraze the release of any medical or other information necessary Image: Complete item 9 ATIENTS OR AUTHORIZED FERSONS SIGNATURE I authoraze the release of any medical or other party who accepts assignment Image: Complete item 9 SIGNED DATE Signed Image: Complete item 9 MITE OF CURRENT ILLINESS (First symptom) OR Is IP PATIENT DATE Image: Complete item 9 MITE OF CURRENT ILLINESS (First symptom) OR Is IP PATIENT DATE Image: Complete item 9 MITE OF CURRENT ILLINESS (First symptom) OR Is IP PATIENT DATE Image: Complete item 9 MITE OF CURRENT Image: Complete item 9 To Image: Complete item 9 Image: Complete item 9 MITE OF CURRENT Image: Complete item 9 MITE OF ILLINESS OR INJURY (Reliate item 9: 1, 2; 3 or 4 to item 24E by Line) Image: Complete item 9 Image: Complete item 9 Image: Complete item 9 Image: Complete item 9	ISURANCE PLAN NAME OF	R PROGRAM NAME		d. IS THERE ANOTHER HEALTH BENE	FIT PLAN?
PREAD BACK OF FORM BEFORE COMPLETING & SIGNATURE 1 auditor The Unit Point					
A LEXIS OF SERVICE REFERENCES OF INJURY (Relate Items 1. 2. 3 or 4 to liten 24E by Line) A DATE(S) OF SERVICE ROUND FOR LOCAL USE A DATE(S) OF SERVICE ROUND A CONTRACTOR SERVICES OF SUPPLIES DIAGNOSIS OF NATURE OF ILLNESS OF INJURY (Relate Items 1. 2. 3 or 4 to liten 24E by Line) A DATE(S) OF SERVICE ROUND A CONTRACTOR ROUND A CONTRACTOR SERVICES OF SUPPLIES DIAGNOSIS OF SERVICE ROUND A CONTRACTOR ROUND A		BACK OF FORM BEFORE COMPL	ETING & SIGNING THIS FORM.	13. INSURED'S OR AUTHORIZED PER	SON'S SIGNATURE I authorize
SIGNED	o process this claim. I also re-	quest payment of government benefits	er the release of any medical or other information necessary either to myself or to the party who accepts assignment		idersigned physician or supplier for
DATE OC CURRENT MAIL DD ILLINESS (Final symptom) OR (BUE FIRST DATE Is IP AFILENT HAS HAD SAME OB SIMILAR ILLINESS (BUE FIRST DATE Is OATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATI FROM NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a 16. DATES PATIENT UNABLE TO WORK IN CURRENT SERVICES FROM 16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATI FROM NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a 18. HOSPTALZTICH DATES RELATED TO CURRENT SERVICES TABLE AT THE OF ILLINESS OF INJURY (Reliate Items 1, 2, 3 or 4 to item 24E by Line) 20. OUTSIDE LAB? \$ CHARGES DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Reliate Items 1, 2, 3 or 4 to item 24E by Line) 3 22. MEDICAD RESUBMISSION 23. PRIOR AUTHORIZATION NUMBER A DATE(S) OF SERVICE DIAGNOSIS OF SERVICE B. OP CEDURES, SERVICES, OR SUPPLIES (Explain Unusual Groutinstances) (DO YY MM DD YY SERVE EMG CONTROL OF ILLINESS EMG CONTROL OF ILLINESS (EMG CONTROL OF ILLINESS) 23. PRIOR AUTHORIZATION NUMBER A DATE(S) OF SERVICE DIAGNOSIS OF SERVICE B. OP CEDURES, SERVICES, OR SUPPLIES (Explain Unusual Groutinstances) (DO YY MM DD YY SERVE EMG CONTROL OF ILLINESS (EMG TO DO YY MM DD YY SERVE EMG CONTROL OF ILLINESS (EMG TO DO YY MM DD YY SERVE EMG CONTROL OF ILLINESS (EMG TO DIAGNOSIS OR NATURE OF ILLIN			DATE	SIGNED	
IPHELMARCY(LMP) INAME OF REFERRING PROVIDER OR OTHER SOURCE IT2 INP IF HOM IF HOF IF HOM		ILLNESS (First symptom) OR			K IN CURRENT OCCUPATION
AESERVED FOR LOCAL USE IVD		PREGNANCY(LMP)		FROM	TO
RESERVED FOR LOCAL USE 1/D IVP I	NAME OF REFERRING PRO	OVIDER OR OTHER SOURCE		18. HOSPITALIZATION DATES RELATE	D TO CURRENT SERVICES
DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate items 1, 2, 3 or 4 to item 24E by Line) DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate items 1, 2, 3 or 4 to item 24E by Line) A DATE(S) OF SERVICE A DATE(S) OF SERVICE A DATE(S) OF SERVICE B C D PROCEDURES, SERVICES, OR SUPPLIES DIAGNOSIS From To RACE OF C D PROCEDURES, SERVICES, OR SUPPLIES DIAGNOSIS S CHARGES C D RACE OF C D PROVIDER C D PROCEDURES, SERVICES, OR SUPPLIES DIAGNOSIS S CHARGES C D RACE OF C D PROVIDER C D PROVIDER C D PROCEDURES, SERVICES, OR SUPPLIES DIAGNOSIS S CHARGES C D PROVIDER C PROVIDER C PROVIDE	RESERVED FOR LOCAL US	3E	17b. NPI	FHOM	TO 1 1
DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate items 1. 2. 3 or 4 to item 24E by Line)		~			\$ CHARGES
CODE	DIAGNOSIS OR NATURE O	F ILLNESS OR INJURY (Relate item	s 1, 2, 3 or 4 to item 24E by Line)		
A DATE(S) OF SERVICE B. C. D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) DIAGNOSIS S CHARGES UNITS Provide II. RENDERIN POINTER S CHARGES UNITS Provide II. RENDERIN PROVIDER II. NPI UNITS Provide II. RENDERIN PROVIDER II. NPI UNITS Provide II. RENDERIN PROVIDER II. NPI UNITS Provide II. NPI UNITS PROVID				CODE	NAL REF. NO.
A. DATE(S) OF SERVICE B. C. D. PROCEDURES, SERVICES, OR SUPPLIES E. DIAGNOSIS DAGNOSIS DO YY MM DD YY SERVICE EMG CPT/HCPCS MODIFIER DIAGNOSIS S CHARGES UNS FOR UNS FOR OUAL PROVIDER IS CHARGES UNS S CHARGES UN	·		J. L	23. PRIOR AUTHORIZATION NUMBER	
From To PLACE OF EXPLANE OF EMG CPUTHOPCS MODIFIER DIAGNOSIS S. CHARGES DATE DATE <td></td> <td></td> <td>4.</td> <td></td> <td></td>			4.		
DD YY MM DD YY SERVICE EMG CPT/HCPCS MODIFIER POINTER S CHARGES UNTS PROVIDER IN PROVIDERI					
EDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? POr gord, claims, see backy 28. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE YES NO \$ \$ \$ \$ \$ \$				OR Family	
EDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? FOT 901. dams, see backo 28. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE YES NO \$ \$ \$ \$ \$ \$					
EDERAL TAX 1.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? IFOr gout, claims, see backo 28. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE YES NO \$ \$ \$ \$ \$ \$	i				NPI
EDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE					NPI
EDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE YES NO \$ \$ \$		t ,		<u></u>	
EDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE YES NO \$ \$ \$					NPI
EDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE YES NO \$ \$ \$	T T I I	1 5 6 5			
EDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE					NPI
EDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE					
EDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE POT gout, claims, see backy YES NO S S S					NP1
EDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE POT gout, claims, see backy YES NO S S S					
YES NO S S	EDERAL TAX I.D. NUMBER	SSN EIN 26. PATIER	IT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT?		
IGNATURE OF PHYSICIAN OR SUPPLIER 32 SERVICE FACILITY LOCATION INFORMATION 33 BILLING PROVIDER INFO 1 DH 4					
vCLUDING DEGREES OR CREDENTIALS certify that the statements on the reverse pply to this bill and are made a part thereof.)	CLUDING DEGREES OR C certify that the statements o	CREDENTIALS on the reverse	E FACILITY LOCATION INFORMATION	33. BILLING PROVIDER INFO & PH #	()

BECAUSE THIS FORM IS USED BY VARIOUS GOVERNMENT AND PRIVATE HEALTH PROGRAMS. SEE SEPARATE INSTRUCTIONS ISSUED BY APPLICABLE PROGRAMS

NOTICE. Any person who knowingly Blasis adaptment of cloum containing any misrepresentation or any table incomplete or mistrading information may be gor'ty of a criminal set punishable under law and may be subject to crist penalties.

REFERS TO GOVERNMENT PROGRAMS ONLY

REFERS TO GOVERNMENT PROGRAMS ONLY. THE FEAST AND PARE 1.110 ANTITLE proves a statute explosition of the feast of the fea

BLACK LUNG AND FECA CLAIMS

, contration of additional devices and examples and the pression of the EBLA parameters in Model addition for the due of

SIGNATURE OF PHYSICIAN OR SUPPLIER IMEDICARE, CHAMPUS, FECA AND BLACK LUNG)

ние, претекторите, чести на состание на состаните состаните на состание на состание и полноние. Ние, претекторите, на состание состание и при состание состание и состание на состание при состание на состани С. 1946 г. состание состание состание и на состание при состание состание и общение при постание быти и на сост

ት እና የሰነት የትርጉሙ ሥላላዊ ትርጉሙ ለማስሻዋና በርግሥና የትርጉሙ የትርጉሙ የግርግ የመሆኑ የሰነት በዚህ እና በትርጉሙ በሆኑ አንካት ችግር የሰነት ለማስሻዋና ትርጉሙ አ ከተና እና አንስ መሆኑ በማስፋር ትርጉሙ በትርጉሙ የአንስት የመሆኑ የትርጉሙ የትርጉሙ የሚገሩ የተሰረጉሙ በዚህ የተሰረጉሙ ችግር መሆኑ ለመስጥ የሚያስት የተቀናለው በርግጥ በመ እና እና ከተጠረጉሙ የአንስት በተሰረጉ በመሆኑ የመሆኑ የትርጉሙ በሆኑ በትርጉሙ የሰረጉሙ

NOTICE TO PATIENT ABOUT THE COLLECTION AND USE OF MEDICARE, CHAMPUS, FECA, AND BLACK LUNG INFORMATION

(1) The second secon

FOR OWOP CLARASY TO RETURN TO THE STATE TO A SUBJECT OF A DESCRIPTION OF A

And Andrews, and a solid description of a strain strain strain strain strain.
 And Andrews, and a solid description of a strain str

ни на продата и продата и продата со продата и продата со состата со состата и продата со состата и и и и прод 1999 г. С. 1997 г. С. 1999 г. С. 1999 г. С. 1997 г. С. 1997 г. С. 19 1997 г. С. 1999 г. С. 1999 г. С. 1997 г. С. 1999 г. С. 1997 г. С. 1999 г. С. 1997 г. С. 1999 г. С. 1997 г. С. 1 1997 г. С. 1997 г. 1997 г. 1997 г. 1997 г. 1997 г. 2000 г. 1997 г.

(1) Construction of the second state to the construction of the construction of the second state of the

e e l'estre d'un company de la company de company de la presente d'un que l'estre de la company de la company a MEDICAID PAYMENTS (PROVIDER CERTIFICATION)

مارچ کار در میرد سال میں رود درمینی میں میری میں میری میں میں میں میں میں میں در در میں میں میں میں میں در میں سالچ کار در میرد سال میں رود درمین اردی در میں میں میں میں میں در در در در در در میں میں میں میں میں میں دور می سی میر والے مرد والو اور میں الامین در میں کہ در میں میں میں میں در در در در در میں میں میں میں میں میں اور می a service in period of a service of the service of

(2) State of the second sec

Exhibit 6

| 202 Accountions 202 Accoun | 915
915
915
913
913
913
915
915
915
915
915
915
915
915
915
915
 | 915
915
915
915
915
915
 | 315
882
815
843
843
843
 | 915
821
915
916
916
916
916
 | 915
821
915
916
916
916
916 | 315
882
815
843
843
843
 | 9 9 5 5 9 9 1 5 9 9 1 5 9 9 1 5 9 9 1 5 9 9 1 5 9 9 9 1 5 9 9 9 9 | 9 9 5 5 9 9 1 5 9 9 1 5 9 9 1 5 9 9 1 5 9 9 1 5 9 9 1 5 9 9 9 9
 | 315
821
815
840
843
843 |
--
--
--
--
--
--
--
--	---
XXX Acquisitions March2 billing Lin March2 billing Lin March2 billing Lin March2 billing Lin Lin <thlin< th=""> Lin <thlin< th=""></thlin<></thlin<>	9 15 5 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
event Mark CA K (3 UN) CA C (3 UN) CA CA C (3 UN) CA CA CA CA CA <thca< th=""> CA CA <thca< t<="" th=""><td>9 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0</td><td>9 1 5 2 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0</td><td>33 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3</td><td>9 1 5 2 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0</td><td>9 1 5 2 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0</td><td>33 33 33 34 3 3 3 3 3 3 3 3 3 3</td><td>83 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3</td><td>915 8215 940 941 941 941 941 941 941 941 941 941 941</td><td>883 43 88 44 9 88 44 88 44 9 88 44 88 48 48 48 48 48 48 48 48 48 48</td></thca<></thca<>	9 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 | 9 1 5
2 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 | 33 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
 | 9 1 5
2 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 | 9 1 5
2 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 | 33
33
33
34
3
3
3
3
3
3
3
3
3
3 | 83 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 | 915
8215
940
941
941
941
941
941
941
941
941
941
941
 | 88 3 43 88 44 9 88 44 88 44 9 88 44 88 48 48 48 48 48 48 48 48 48 48 |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | 8 1 0 0 3 8 1 0 0 3 8 1 0 0 3 8 1 0 0 3 8 1 0 0 0 3 8 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 | 8410
8410
8410
 | 8 80 93 84 10 98
 | 8410
8410
8410
 | 8410
8410
8410
 | 8 80 308 - 10
8 80 208 - 10
8 80 1000000000000000000000000000000000 | 8 8 3 3 8 4 9 9 8 8 4 9 9 8 9 9 8 9 9 9 9 9 9 9 | 8 1 0 0 3 0 1 0 0 3 0 1 0 0 0 3 0 1 0 0 0 0 | 8 80 93 87 9
8 80 93
87 9
8 80 90 90 90 90 90 90 90 90 90 90 90 90 90 |
| The formation of the second s | 822 - 202 -
 | 8 2 2 9 2 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2
 | 8
3519
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
19
19
19
19
19
19
19
19
19
19
19
19
1
 | 8 2 2 9 2 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2
 | 8 2 2 9 2 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 | 8
83519
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
10
10
10
10
10
10
10
10
10
10
10
10
10
 | 8
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
83519
835519
835519
835519
835519
835519
835519
835519
835519
8355510
8355555555 | 8 2 2 4 0 0 2 2 | 8
3519
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
835-19
19
19
19
19
19
19
19
19
19
19
19
19
1
 |
| $ \begin{array}{c} \label{eq:constraint} \end{tabular} & \begin{tabular}{c} \begin{tabular}{c} \end{tabular} \\ \end{tabular} & \begin{tabular}{c} \begin{tabular}{c} \end{tabular} \\ \end{tabular} & \begin{tabular}{c} \begin{tabular}{c$ | 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 | 81 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 | 8 10 00 00 00 00 00 00 00 00 00 00 00 00
 | 81 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 | 81 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 8 97 99 99 99 99 99 99 99 99 99 99 99 99
 | 8 97 92 92 92 92 92 92 92 92 92 92 92 92 92 | 9 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 8 10 00 00 00 00 00 00 00 00 00 00 00 00
 |
| AdministDec/2MAL (190% (5773)) $4.92(3)$ $1.92(3)$ | 8 40 0
 | 8 7 9 0 0
 | 8 8 9 9
 | 8 7 9 0 0
 | 8 7 9 0 0
 | 8 8 9 9 | 8 8 9 9 | 8 6 7 0 0
 | 8 8 9 0 |
| and
and
totalDecude
totalMA <td>240</td> <td>240</td> <td>240
843</td> <td>240</td> <td>240</td> <td>240
843</td> <td>240
843</td> <td>240</td> <td>240</td> | 240
 | 240
 | 240
843
 | 240
 | 240
 | 240
843 | 240
843 | 240
 | 240 |
| 002 Use 003 Use |
 |
 |
 |
 |
 | | |
 | |
| 002.V/S 002.V/V 0.V/V 002.V/V 0.V/V 002.V/V 0.V/V | 2.V/s 2.V/s <th< td=""><td>002.1Vs 002.1Vs 002.1Vs</td><td>002.1Vs 002.1Vs 002.1Vs</td><td>002.VS 002.VS 002.VS 0.01.02 CA H (2.4%) NA 5 inver Nephrology (HS / JV DeNovo)(c) Und22 CA H (2.4%) NA 53 1 or dead (JV DeNovo)(f) Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2" Colspan="2" South Construction (HS / JV DeNovo)(f) Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan= 2 Colspan= 2 Colspan= 2 Colspan= 2 Colspan= 2 Colspan= 2 Colspan= 2 Colspan= 2 <th< td=""><td>20.2 Vs 20.2 Vs mer Mephrology (HS / JV DeNovo) (r) UHd2 CA H (2.4%) NA 53 1 mer Mephrology (HS / JV DeNovo) (r) Glased
(1502 CA H (2.4%) NA 50 5 polge 8 South Creat Hospital (HS / JV DeNovo) (r) Glased
(1502 CA B (6.1%) NuA 60 2 paded (JV DeNovo) Oct-02 CA B (6.1%) NuA 60 2 paded (JV DeNovo) Oct-02 CA B (6.1%) NuA 60 2 padeta UV DeNovo) Oct-02 CA B (6.1%) NuA 60 2 padeta UV DeNovo) Oct-02 CA H (2.4%) S 60.000 60 1 not Indudes acute equivalent patents. Aar-02 CA H (2.4%) S 60.000 60 1 Not ontoos Const Aar-02 CA H (2.4%) S 60.000 60 1 Not ontoos Const Aar-02 CA H (2.4%) S 60.000 60 1 Not ontoos For ontoos For ontoos For ontoos For ontoos 1 1 Not ontoos For ontoos For ontos For ontoos<</td><td>Distribution Und2 CA H(2.4%) NA 53 1 no V DeNovo) Closed CO E(4.5%) NA 50 1 nover Nepriciogy (HS / JV DeNovo) (c) Closed CO E(4.5%) NA 50 5 pulse & South Creat Hospital (HS / JV DeNovo) (t) Cickog CK B (6.1%) NA 60 2 eadd (JV DeNovo) (t) Cickog CK B (6.1%) NA 60 2 eadd (JV DeNovo) (t) Cickog CK B (6.1%) NA 60 2 action (the field of the field of t</td><td>Motion Motion Motion<td>002.1Vs 002.1Vs 002.1Vs</td><td>Mod 2.Ves Mod 2.Ves</td></td></th<></td></th<> | 002.1Vs | 002.1Vs | 002.VS 002.VS 002.VS 0.01.02 CA H (2.4%) NA 5 inver Nephrology (HS / JV DeNovo)(c) Und22 CA H (2.4%) NA 53 1 or dead (JV DeNovo)(f) Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2" Colspan="2" South Construction (HS / JV DeNovo)(f) Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan="2" Colspan= 2 Colspan= 2 Colspan= 2 Colspan= 2 Colspan= 2 Colspan= 2 Colspan= 2 Colspan= 2 <th< td=""><td>20.2 Vs 20.2 Vs mer Mephrology (HS / JV DeNovo) (r) UHd2 CA H (2.4%) NA 53 1 mer Mephrology (HS / JV DeNovo) (r) Glased
(1502 CA H (2.4%) NA 50 5 polge 8 South Creat Hospital (HS / JV DeNovo) (r) Glased
(1502 CA B (6.1%) NuA 60 2 paded (JV DeNovo) Oct-02 CA B (6.1%) NuA 60 2 paded (JV DeNovo) Oct-02 CA B (6.1%) NuA 60 2 padeta UV DeNovo) Oct-02 CA B (6.1%) NuA 60 2 padeta UV DeNovo) Oct-02 CA H (2.4%) S 60.000 60 1 not Indudes acute equivalent patents. Aar-02 CA H (2.4%) S 60.000 60 1 Not ontoos Const Aar-02 CA H (2.4%) S 60.000 60 1 Not ontoos Const Aar-02 CA H (2.4%) S 60.000 60 1 Not ontoos For ontoos For ontoos For ontoos For ontoos 1 1 Not ontoos For ontoos For ontos For ontoos<</td><td>Distribution Und2 CA H(2.4%) NA 53 1 no V DeNovo) Closed CO E(4.5%) NA 50 1 nover Nepriciogy (HS / JV DeNovo) (c) Closed CO E(4.5%) NA 50 5 pulse & South Creat Hospital (HS / JV DeNovo) (t) Cickog CK B (6.1%) NA 60 2 eadd (JV DeNovo) (t) Cickog CK B (6.1%) NA 60 2 eadd (JV DeNovo) (t) Cickog CK B (6.1%) NA 60 2 action (the field of the field of t</td><td>Motion Motion Motion<td>002.1Vs 002.1Vs 002.1Vs</td><td>Mod 2.Ves Mod 2.Ves</td></td></th<> | 20.2 Vs 20.2 Vs mer Mephrology (HS / JV DeNovo) (r) UHd2 CA H (2.4%) NA 53 1 mer Mephrology (HS / JV DeNovo) (r) Glased
(1502 CA H (2.4%) NA 50 5 polge 8 South Creat Hospital (HS / JV DeNovo) (r) Glased
(1502 CA B (6.1%) NuA 60 2 paded (JV DeNovo) Oct-02 CA B (6.1%) NuA 60 2 paded (JV DeNovo) Oct-02 CA B (6.1%) NuA 60 2 padeta UV DeNovo) Oct-02 CA B (6.1%) NuA 60 2 padeta UV DeNovo) Oct-02 CA H (2.4%) S 60.000 60 1 not Indudes acute equivalent patents. Aar-02 CA H (2.4%) S 60.000 60 1 Not ontoos Const Aar-02 CA H (2.4%) S 60.000 60 1 Not ontoos Const Aar-02 CA H (2.4%) S 60.000 60 1 Not ontoos For ontoos For ontoos For ontoos For ontoos 1 1 Not ontoos For ontoos For ontos For ontoos< | Distribution Und2 CA H(2.4%) NA 53 1 no V DeNovo) Closed CO E(4.5%) NA 50 1 nover Nepriciogy (HS / JV DeNovo) (c) Closed CO E(4.5%) NA 50 5 pulse & South Creat Hospital (HS / JV DeNovo) (t) Cickog CK B (6.1%) NA 60 2 eadd (JV DeNovo) (t) Cickog CK B (6.1%) NA 60 2 eadd (JV DeNovo) (t) Cickog CK B (6.1%) NA 60 2 action (the field of the field of t | Motion Motion <td>002.1Vs 002.1Vs 002.1Vs</td> <td>Mod 2.Ves Mod 2.Ves</td> | 002.1Vs | Mod 2.Ves |
| vire (JV DeNovo) Jurodo Cosed CO E (45%) NVA 53 1
enver Nephrology (HS / JV DeNovo) (r) Cosed CO E (45%) NVA 50 5
923/002 Effective Effective Effective E (45%) NVA 50 2
orded of (JV DeNovo) (r) Coct-02 CK B (6.1%) NVA 60 2
orded of (JV DeNovo) (r) Coct-02 CK B (6.1%) NVA 60 2
orded of (JV DeNovo) 0
orded of VD DeNovo) (r) Coct-02 CK B (6.1%) NVA 60 00 0 1
rould searche equivalent patients. JV census represents 100% contestin.
I) Includes acute equivalent patients. JV census represents 100% contestin.
I) Nicludes acute equivalent patients. JV census represents 100% contestin.
I) Nicludes acute equivalent patients. JV census represents 100% contestin.
I) Nicludes acute equivalent patients. JV census represents 100% contestin.
I) Nicludes acute equivalent patients. JV census represents 100% contestin.
I) Nicludes acute equivalent patients. JV census represents 100% contestin.
I) Nicludes acute equivalent patients. JV census represents 100% contestin.
I) Nicludes acute equivalent patients. JV census represents 100% contest in the deal.
I) Nicludes acute equivalent patients are depresented approximately 700 patients (saved pre G&A EBITDA of 5.6 mV. JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
I) Nicludes acute equivalent patients (saved pre G&A EBITDA of 50.5 mV. JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
I) Resolved hot sport hundes Price. | e (JV DeNovo) UH-02 CA H(2.4%) N/A 53 1
ver Nephrology (HS / JV DeNovo) (c) UH-02 CA H(2.4%) N/A 150 5
effective effective e
 | vine (V/ DeNovo) Jui-02 CA H(2.4%) NA 53 1 enver Nephrology (HS / JV DeNovo) (t) Cloce E (4.5%) NA 53 1 atolipa 8 South Crest Hospital (HS / JV DeNovo) (t) 01-02 CA H (2.4%) NA 53 1 atolipa 8 South Crest Hospital (HS / JV DeNovo) (t) 01-02 CA B (6.1%) NA 60 2 atolipa 8 South Crest Hospital (HS / JV DeNovo) (t) 01-02 CA B (6.1%) NA 60 2 atolipa 8 South Crest Hospital (HS / JV DeNovo) (t) 01-02 CA B (6.1%) NA 60 1 atolita Denovo) 01-02 CA H (2.4%) S 60.000 60 1 atolita Durduse scale equivalent patient: An -02 C H (2.4%) S 60.000 60 1 1) Furchase Route Regeneration Restoremants 100% ownersition An -02 C H (2.4%) S 60.000 60 1 1) Furchase Route Regeneration Restoremants 100% ownersition S 60.000 60 1 1
 | vire (VD eNovo) (Jun C C A H(2.4%) NVA 53 1
enver Nephrology (HS / JV DeNovo) (e) C C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (150.2 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (150.2 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (12.0 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (12.0 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (12.0 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (12.0 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (12.0 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (12.0 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (12.0 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (12.0 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (12.0 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (12.0 C (H (2.4%) NVA 150 5
enver Nephrology (HS / JV DeNovo) (f) C (12.0 C (H (2.4%) NVA 15 5
enver Nephrology (HS / JV DeNovo) (f) (HS / JV DENOVO
 | vine (V/ DeNovo) (J. 1002 CA H(2.4%) N/A 150 5 1 1 2.302 (J. 14.4%) N/A 150 5 1 1 2.302 (J. 14.4%) N/A 150 5 1 2 2 1 15.302 (J. 15.02 OK E(4.5%) N/A 150 5 1 15.02 (J. 15.02 OK E(4.5%) N/A 150 5 1 15.02 (J. 15.02 OK E(4.5%) N/A 150 5 1 15.02 (J. 15.02 OK E(4.5%) N/A 150 5 1 15.02 (J. 15.02 OK E(4.5%) N/A 150 5 1 15.02 (J. 15.02 OK E(4.5%) N/A 150 5 1 15.02 (J. 15.02 OK E(4.5%) N/A 150 5 1 15.02 (J. 15.02 OK E(4.5%) N/A 150 5 1 15.02 (J. 15.02 OK E(4.5%) N/A 150 5 1 15.02 (J. 15.02 OK E(4.5%) N/A 150 5 1 15.02 (J. 15.02 OK E(4.5%) N/A 15.0 (J. 15.02 OK E(4.5%) J. 15.02 (J. 15.02 (J. 15.02 OK E(4.5%) J. 15.02 (J. 15.02 (J | Image (X) OeNovo) Jund2 CA H (2.4%) NA 53 1 enver Nephrology (HS / X) DeNovo) (c) Diseded CO E (4.5%) NA 150 5 prover Nephrology (HS / X) DeNovo) (f) Effective
Effective
Effective
Effective CO E (4.5%) NA 150 5 prover Nephrology (HS / X) DeNovo) (f) CO:02 OK B (6.1%) NA 60 2 prover Nephrology (HS / X) DeNovo) (f) CO:02 OK B
(6.1%) NA 60 2 prover Nephrology (HS / J) DeNovo) (f) CO:02 CK H (2.4%) NA 60 7 2 prove Nephrology (HS / I) Oc:02 CK H (2.4%) NA 60 0 1 Total Oc:02 CA H (2.4%) Y 60.000 60 1 Stadema Purchase Rights (HS) (e) Apr-02 CA H (2.4%) Y denovo for 5 new centers. Total aprovementation 1 Stadema Purchase Rights (HS) (e) Apr-02 CA H (2.4%) Y denovo for 5 new centers. Total patients saved plus new JV patients was 850. Interase Action and eptorineneand EBITDA | me (V Derkkovo) UH02 C A H (2.4%) N/A 53 1
rer Nephrology (HS / JV DeNovo) (r) UH02 C C E (4.5%) N/A 150 5
9/2302 C B (6.1%) N/A 150 5
6/Filective
elected (V DeNovo) (r) Coto2 C A (1.5%) N/A 60 2
0/202 C A (1.5%) N/A 60 0
elected (V DeNovo) (r) Coto2 C A (1.5%) N/A 60 0
0/202 C A (1.5%) N/A 60 0
1 0
2 0 0
2 0 0
1 0
2 0 0
2 0
1 0
2 0 0
1 0
2 0 0
2 0
0 0
0 0
0 0
1 1
2 0 0
1 0
2 0
0 0
0 0
0 0
1 1
2 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0 | ine (V/ DerNovo) UH-02 CA H(2.4%) N/A 53 1
sine r Mephrology (H5 / JV DeNovo) (c) UH-02 CA
H(2.4%) N/A 55 5
sine r Mephrology (H5 / JV DeNovo) (f) Catalogo CA E (4.5%) N/A 50 5
sine r Mephrology (H5 / JV DeNovo) (f) Catalogo CA E (4.5%) N/A 50 5
sine r Mephrology (H5 / JV DeNovo) (f) Catalogo CA E (4.5%) N/A 50 5
r MA 50 7
r Catalogo CA 7 | vire (JV DeNovo) UH-02 CA H(2.4%) NIA 53 1 enver Nephrology (HS / JV DeNovo) (c) $0_{22}30$,
$0_{23}0$,
$0_{23}0$,
$0_{23}0$,
$0_{15}02$ CA H(2.4%) NIA 53 1 apula 8 South Crest Hospital (HS / JV DeNovo) (f) $0_{12}02$ CK B (6.1%) NIA 60 2 apula 8 South Crest Hospital (HS / JV DeNovo) (f) $0_{12}02$ CK B (6.1%) NIA 60 2 apula 8 South Crest Hospital (HS / JV DeNovo) (f) 0_{CLO2} CK B (6.1%) NIA 60 2 apola 0 0_{12} CA H (2.4%) N A 50 1 asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) S (60.000 60 1 asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) Y denovo for 5 new centers. Total patients saved puter mainto the saved provements in the watcher and EBITDA referent David's pron rate propriotione constraint interest. 1 1 (N equide an equival patients. JV centers in alto popolition interest in the dat strain saved propriotion econstraint interest in the dat strain saved propriotion econstraint interest. Total patients saved plus new JV patients was 850. 1 < | vine (V/ DeNovo) (Jun-10, Jun-2, CA, H(2,4%) N/A, 53, 1
enver Nephrology (HS / JV DeNovo) (t) Classed CO, E (4,5%) N/A, 150, 5
aprile (JV DeNovo) (t) Classed CO, E (4,5%) N/A, 150, 5
aprile (JV DeNovo) (t) Classed C, CA, B (6, 1%) N/A, 150, 2
aprile (JV DeNovo) (t) Classed C, CA, B (6, 1%) N/A, 150, 2
aprile (JV DeNovo) (t) Classed C, CA, B (6, 1%) N/A, 150, 2
aprile (JV DeNovo) (t) Classed C, CA, B (6, 1%) N/A, 150, 2
aprile (JV DeNovo) (t) Classed C, CA, B (6, 1%) N/A, 150, 2
aprile (JV DeNovo) (t) Classed C, CA, B (6, 1%) N/A, 150, 2
aprile (JV DeNovo) (t) Classed C, CA, B (6, 1%) N/A, 150, 2
aprile (JV DeNovo) (t) Classed C, CA, B (6, 1%) N/A, 150, 2
aprile (JV DeNovo) (t) Classed C, CA, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12 |
| enver Naphrology (HS / JV DeNovo) (c) Closed CO E (4.5%) NA T50 5 apula 8 South Crest Hospital (HS / JV DeNovo) (f) 0ct-02 0K B (6.1%) NA 150 2 apula 8 South Crest Hospital (HS / JV DeNovo) (f) 0ct-02 0K B (6.1%) NA 50 2 oledad (JV DeNovo) 0ct-02 0K B (6.1%) NA 308 2 oledad (JV DeNovo) 0ct-02 0K B (6.1%) NA 50 2 oledad (JV DeNovo) 0ct-02 0K B (6.1%) NA 50 1 oledad (JV DeNovo) 0ct-02 0K B (6.1%) NA 50 2 oledad (JV DeNovo) 0ct-02 0K B (6.1%) NA 50 1 oledad (JV DeNovo) 0ct-02 CA H (2.4%) \$ 60 0 1 oledad (JV DeNovo) 0ct-02 CA H (2.4%) \$ \$ 60.000 1 1 OUTOR 0ct-02 CA H (2.4%) \$ \$ 60.0000 1 1 | ver Nephrology (HS / JV DeNovo) (c) Closed CO E (4.5%) N/A 150 5 Effective Fifective Fifetive Fifective Fifetive Fi
 | Increase Reprotocy (HS / JV DeNovo) (c) Closed
Closed
(Firsting
(HS / JV DeNovo) (f) Closed
(firsting
(firsting) CO CO E (a 1%)
(firsting) NA Fib 5 actual a cutor
dided (JV DeNovo) 00:02 0X B (a 1%)
(firsting) NIA 60 2 actual
actual
Data 00:000 0X MA 45 2 00:000 0X 0X MA 45 2 00:000 0X 0X 0X 1 1 00:000 0X 0X 0X 1 1 00:000 0X 0X 0X 1 1 1 00:000 0X 0X 0X 0X 1 1 1 00:000 0X 0X 0X 0X 0X 1
 | ienver Nephrology (HS / JV DeNovo) (c) Closed C0 E (4.5%) NA 150 5 apuloa & South Creat Hospital (HS / JV DeNovo) (t) Cicr.02 CK B (6.1%) NIA 60 2 apuloa & South Creat Hospital (HS / JV DeNovo) (t) Cicr.02 CK B (6.1%) NIA 60 2 adedad (JV DeNovo) Oct.02 CK B (6.1%) NIA 60 2 adedad (JV DeNovo) Oct.02 CA B (6.1%) NIA 60 2 adena Purchase Rights (HS) (e) Apr.02 CA H (2.4%) \$ 60.000 60 1 002 Citien asadena Purchase Rights (HS) (e) Apr.02 CA H (2.4%) \$ 60.000 60 1 012 Citien asadena Purchase Rights (HS) (e) Apr.02 CA H (2.4%) \$ 60.000 60 1 012 Citien Apr.02 CA H (2.4%) \$ 60.000 60 1 012 Citien Apr.02 CA H (2.4%) \$ 60.000 60 1 012 Citien Apr.02 CA H (2.4%) \$ 60.000 60 1 012 Citien Apr.02 CA H (2.4%)
 | Interference Closed CO E (45%) NA 150 5 renorus & South Creat Hospital (HS / JV DeNovo) (c) 9/23/02
(6/15/02 CK B (6 1%) N/A 60 2 adulad (JV DeNovo) 0ct-02 CK B (6 1%) N/A 60 2 adedad (JV DeNovo) 0ct-02 CK B (6 1%) N/A 50 2 adedad (JV DeNovo) 0ct-02 CK B (6 1%) N/A 50 1 adedad (JV DeNovo) 0ct-02 CK B (6 1%) N/A 50 2 adedad (JV DeNovo) 0ct-02 CK B (6 1%) N/A 50 1 adedad (JV DeNovo) 0ct-02 CA H (2 4%) \$ 60 1 asadena Purchase Rights (HS) (e) Apr-02 C Apr-02 C 1 1 asadena Purchase Rights (HS) (e) Apr-02 C H (2 4%) \$ 60.000 60 1 asadena Purchase Rights (HS) (e) Apr-02 C H (2 4%) \$ 60.000 60 1 asadena Purchase Rights (HS) (e) Apr-02 C H (2 4%) \$ 60.000 60 1 incudes acute equivalent parents prove renets and aproxima
 | erver Nephrology (HS / JV DeNovo) (c) Closed CO E (4.5%) NA 150 5
Packad (JV DeNovo) (c) Closed CO E (4.5%) NA 150 5
Packad (JV DeNovo) (f) Cot-02 OK B (6.1%) NA 45 0
Packad (JV DeNovo) (f) Cot-02 OK B (6.1%) NA 45 0
Total
202 Other
302 Other
302 Other
302 Other
302 Other
304 Devices Rights (HS) (e) Apr-02 C A H (2.4%) \$ 60,000 60 1
(FIS) (e) Apr-02 C A H (2.4%) V envolved for the termination of termination of the termination of the termination of termination of termination of the termination of termination of termination of termination of the termination of terminatin of terminatin of | river Nephrology (HS / JV DeNovo) (c) Closed CO E (4.5%) N/A 150 5
Effective
Effective
Effective
Effective
Effective
Effective
Cd B (6.1%) N/A 000 (c) 2
edad (JV DeNovo) (f) Cd-02 CK B (6.1%) N/A 000 2
Total
Total
Total
addenta Purchase Rights (HS) (e) An-02 CA H (2.4%) \$ 60,000 60 1
20 Cthor
addenta Purchase Rights (HS) (e) An-02 CA H (2.4%) \$ 60,000 60 1
Purchase Price and EBITDA reflect DaVials providential proportionale ownership.
The An-02 CA H (2.4%) \$ 60,000 60 1
Purchase Price and EBITDA reflect DaVials providential proportionale ownership.
The An-02 CA H (2.4%) Y denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcreat units. Partners have identified 3 additional potential JV locations.
 | arver Nephrology (HS / JV DeNovo) (c) Closed CO E (4.5%) NA 150 5
Effective
Effective
Effective
Filter (MS / JV DeNovo) (f) Cr(5)02 OK B (6.1%) N/A 60 2
Total
Total
Total
2
2
2
2
2
2
2
2
2
2
2
2
2 | Interver Nephrology (HS / JV DeNovo) (c) Closed
20200
(Fiscine
Effective
(Fiscine
(Fiscine
(Fiscine) CO E (4.5%) N/A 150 5 a puip a 8 south Creat Hospital (HS / JV DeNovo) (f) Coc.02
(Fiscine) CK B (6.1%) N/A 60 2 a poid ad (JV DeNovo) Coc.02
(or coc.02
(Joel) CK B (6.1%) N/A 50 2 a poid
Joel Coc.02
(Joel CK B (6.1%) N/A 50 2 a poid Coc.02
(Joel CK B (6.1%) N/A 50 2 a point Cor.02
(Joel CK B (6.1%) N/A 50 1 a point Cor.02
(Joel CK B (6.1%) N/A 50 1 1 a point Cor.02
(Joel CA H (2.4%) S 60.000 60 1 1 a point Effective Apr-02 CA H (2.4%) Y denove for seconter equivalent point with Y point seconter point and proportionate ownership interest in the deal. 1 1 Includes Price and EBIDA (FIS) (e) Apr-02 CA H (2.4%) Y denove for 5 new centers. Total patients saved plus was 850.< | New rephrology (HS / JV DeNovo) (c) Closed
(c) CO E (4.5%) NA 150 5 a poilog & South Creat Hospital (HS / JV DeNovo) (f) 00:020
6(1502 CK B (6.1%) N/A 60 2 a dead (JV DeNovo) 01:020 CK B (6.1%) N/A 500 2 a dead (JV DeNovo) 00:02 CK B (6.1%) N/A 50 2 a dead (JV DeNovo) 00:02 CK B (6.1%) N/A 50 1 a dead (JV DeNovo) 00:02 CK B (6.1%) N/A 50 1 a dead (JV DeNovo) 00:02 CK B (6.1%) N/A 50 1 a dead (JV DeNovo) 00:02 CA B (6.1%) N/A 50 1 a dead (JV DeNovo) 00:02 CA B (6.1%) N/A 50 1 a dead (JV DeNovo) 00:02 CA B (6.1%) N 1 1 a dead (JV DeNovo) 00:02 CA H (2.4%) S (60:00) 60 1 a dead (JV DeNovo) An-02 CA H (2.4%) S (60:00) 60 1 a deader and EBITDA reflect DeaVira's portanter (M on the deal Execute equivalent patents. J centers and approximatel
 |
| PULZANZ,
Fifteritive Fifteritive VIX A 00 2 ediad (JV DeNovo) (f) 0ct-02 0K B (6,1%) N/A 60 2 oledad (JV DeNovo) 0ct-02 0K B (6,1%) N/A 60 2 oledad (JV DeNovo) 0ct-02 CK B (6,1%) N/A 60 2 oledad (JV DeNovo) 0ct-02 CA H (2,4%) \$ 60.000 60 1 olog China Apr-02 CA H (2,4%) \$ 60.000 60 1 olog China Apr-02 CA H (2,4%) \$ 60.000 60 1 olog China Apr-02 CA H (2,4%) \$ \$ 60.000 60 1 I) Includes acute equivalent patients. JV census represents 100% ownership. \$ 60.000 60 1 1 I) Purchase Rights (HS) (e) Apr-02 CA H (2,4%) \$ \$ 60.000 60 1 I) Purchase Rice and Eprovimately 700 patients (staved pre G&A EBITDA of \$5.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. | 91/2.302.
Endows
Endows
Endows
Endows
Endows
Endows
Total
Total
Total
Endows
Total
Endows
Total
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endows
Endow
 | Pricator,
Effective
615002 Effective
615002 N/A 60 2 period ad (V/ DeNovo) (f) Oct-02 CK B (6.1%) N/A 60 2 oledad (V/ DeNovo) Oct-02 CK B (6.1%) N/A 60 2 total Oct-02 CK B (6.1%) N/A 60 7 9 002 Othor Apr-02 CA H (2.4%) \$ 60,000 60 1 002 Othor Apr-02 CA H (2.4%) \$ 60,000 60 1 010 Othor Apr-02 CA H (2.4%) \$ 60,000 60 1 011 Includes cube equivalent paterix. <i>J</i> census represents 10% connership. Norwership 1 1 1 1) Includes cube equivalent paterix. <i>J</i> census represents 10% connership. 1 1 1 1 1) Includes cube equivalent paterix. <i>J</i> census represents 10% connership. 1 1 1 1 1) Meignice accube equivalent paterix. <i>J</i> census represents 10% connership. 1 1 1 1 1) Meignice accube equivalent paterix. <i>J</i> census represents 10% conters 6
 | Provided Filebrow Partal (HS / JV DeNovo) (1) Cit-02 CK B (6 1%) N/A 60 2 oledad (LV DeNovo) Cit-02 CK B (6 1%) N/A 60 2 oledad (LV DeNovo) Cit-02 CK B (6 1%) N/A 60 2 oledad (LV DeNovo) Cit-02 CK B (6 1%) N/A 60 1 OC OC CA H (2 4%) S 60.000 60 1 O2 Other Apr-02 CA H (2 4%) S 60.000 60 1 O2 Other Secoved hot specific paviral proportionate ownership Apr-02 CA H (2 4%) S 5 <td< td=""><td>Price Vice 91.2 NC Price Vice 61150/2 CK B (6.1%) N/A 60 2 oledad (V/ DeNovo) 00.0002 CK B (6.1%) N/A 60 2 oledad (V/ DeNovo) 00.0002 CK B (6.1%) N/A 60 2 0.02 Othor 0.02 Othor Apr.02 CA H (2.4%) \$ 60.000 60 1 0.02 Othor Apr.02 CA H (2.4%) \$ 60.000 60 1 0.02 Othor Apr.02 CA H (2.4%) \$ 60.000 60 1 0.1 runsae Frice and EBITDA reflect DaViras provainately 700 patients (saved pre G&A EBITDA of \$5.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. 1 1 Neighted accute equivalent patents. JV centers and approximately 700 patients (saved pre G&A EBITDA of \$5.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. 1 1 Neighted accute equivalent patents. At centers, and \$3.5MM in pre G&A EBITDA. For centers. Total patients saved plus new JV patients was 850. 1 1 Neighted accute equivalent patents. A centers, and \$3.5MM in pre G&A EBITDA. For centers. Total patients tot with Tulsa Nephrology saving 275 patients, and \$3.5MM in pre G&A EBITDA. For c</td><td>Produce and a south Creat Hospital (HS / JV DeNovo) (1) Oct-02 OK B (6.1%) N/A 60 2
effection
Total Detad (JV DeNovo) Detada (JV DENOvO) Detada</td><td>Pursue: Firstow: Firstow: Entance Entance Entance Endand (JV DeNovo) (h) Oct-02 OK B (6, 1%) NA 60 2 Total Oct-02 OK B (6, 1%) NA 60 2 Total Oct-02 CA H (2, 4%) \$ 60.000 60 1 Ototac CA H (2, 4%) \$ 60.000 60 1 1 OC Other Apr-02 CA H (2, 4%) \$ 60.000 60 1 OLIDE Apr-02 CA H (2, 4%) \$ 60.000 60 1 OLIDE Apr-02 CA H (2, 4%) \$ 60.000 60 1 OLIDE Apr-02 CA H (2, 4%) \$ 60.000 60 1 Decoder Apr-02 CA H (2, 4%) \$ 60.000 60 1 Products active aprivalent patients. <i>V centus rispresents</i> to the solutional econters in the deat. Ecoder of the centers and approximately 700 patients (saved prescenter of \$6.5MM). JV denovo for 5 new centers. Total patients saved pl</td><td>Pix-3402,
Entrologic
Biologic
Biologic
Display Firebus
Entrologic
Biologic
Total Pix-3402,
Entrologic
Biologic
Total OK B (6,1%) N/A 60 2 Jobalovory Coct-02 CK B (6,1%) N/A 60 2 Jobalovory Coct-02 CK B (6,1%) N/A 60 0 1 Jobalovory Coct-02 CA H (2,4%) S 60.000 60 1 Includes acute equivalent patients. JV centrus represents 100% ownership
(Includes acute equivalent patients. JV centrus and approximately 700 patients (saved pre G&A.EBITDA, Forecasted Yr. 1 census releacts Sapulpa and South-rest nuls. Patients activitient JV locations. Resolved hot spot with Tusa Nephrology saving 275 patients, 4 centers, and \$35.MM in pre G&A.EBITDA, Forecasted Yr. 1 census reflects Sapulpa and South-rest nuls. Patients additional potential JV
locations.</td><td>Price Price Price Effective Price Effective Price Effective Price Effective Price Cit-02 CK Delada (LV DeNovo) Oct-02 CK H (2.4%) Dol Chreat Apr-02 CA H (2.4%) S Dol Chreat Apr-02 CA H (2.4%) S S Dol Chreat Apr-02 CA H (2.4%) S S S S Includes acute equivalent patients. JV centrus into carat proportionale ownership
interest in the deal S S S S S S S S S S S S S S S S S</td><td>Pricator,
Effective
611502 Effective
611502 polidia (LV DeNovo)
(1) Cict.02 CK B (6.1%) N/A 60 2 olidiad (LV DeNovo) Cict.02 CK B (6.1%) N/A 60 2 olidiad (LV DeNovo) Cict.02 CK B (6.1%) N/A 60 2 Ucal Apr.02 CA H (2.4%) \$ 60.000 60 1 002 Citror asadena Purchase Rights (HS) (e) Apr.02 CA H (2.4%) \$ 60.000 60 1 012 Citror Apr.02 CA H (2.4%) \$ 60.000 60 1 02 Citror Apr.02 CA H (2.4%) \$ 60.000 60 1 Niculaes acute equivalent patents. <i>J</i> centers and approximate ownership interest. Noensoft \$ 60.000 60 1 Niculaes acute equivalent patents. <i>J</i> centers and approximate ownership interest. Noensoft \$ 1 1 Nectures and approximate ownership interest. Notations (or 5 new centers. Total patients saved plus new JV patients was 650. 1 1 Neq</td></td<> | Price Vice 91.2 NC Price Vice 61150/2 CK B (6.1%) N/A 60 2 oledad (V/ DeNovo) 00.0002 CK B (6.1%) N/A 60 2 oledad (V/ DeNovo) 00.0002 CK B (6.1%) N/A 60 2 0.02 Othor 0.02 Othor Apr.02 CA H (2.4%) \$ 60.000 60 1 0.02 Othor Apr.02 CA H (2.4%) \$ 60.000 60 1 0.02 Othor Apr.02 CA H (2.4%) \$ 60.000 60 1 0.1 runsae Frice and EBITDA reflect DaViras provainately 700 patients (saved pre G&A EBITDA of \$5.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. 1 1 Neighted accute equivalent patents. JV centers and approximately 700 patients (saved pre G&A EBITDA of \$5.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. 1 1 Neighted accute equivalent patents. At centers, and \$3.5MM in pre G&A EBITDA. For centers. Total patients saved plus new JV patients was 850. 1 1 Neighted accute equivalent patents. A centers, and \$3.5MM in pre G&A EBITDA. For centers. Total patients tot with Tulsa Nephrology saving 275 patients, and \$3.5MM in pre G&A EBITDA. For c
 | Produce and a south Creat Hospital (HS / JV DeNovo) (1) Oct-02 OK B (6.1%) N/A 60 2
effection
Total Detad (JV DeNovo) Detada | Pursue: Firstow: Firstow: Entance Entance Entance Endand (JV DeNovo) (h) Oct-02 OK B (6, 1%) NA 60 2 Total Oct-02 OK B (6, 1%) NA 60 2 Total Oct-02 CA H (2, 4%) \$ 60.000 60 1 Ototac CA H (2, 4%) \$ 60.000 60 1 1 OC Other Apr-02 CA H (2, 4%) \$ 60.000 60 1 OLIDE Apr-02 CA H (2, 4%) \$ 60.000 60 1 OLIDE Apr-02 CA H (2, 4%) \$ 60.000 60 1 OLIDE Apr-02 CA H (2, 4%) \$ 60.000 60 1 Decoder Apr-02 CA H (2, 4%) \$ 60.000 60 1 Products active aprivalent patients. <i>V centus rispresents</i> to the solutional econters in the deat. Ecoder of the centers and approximately 700 patients (saved prescenter of \$6.5MM). JV denovo for 5 new centers. Total patients saved pl | Pix-3402,
Entrologic
Biologic
Biologic
Display Firebus
Entrologic
Biologic
Total Pix-3402,
Entrologic
Biologic
Total OK B (6,1%) N/A 60 2 Jobalovory Coct-02 CK B (6,1%) N/A 60 2 Jobalovory Coct-02 CK B (6,1%) N/A 60 0 1 Jobalovory Coct-02 CA H (2,4%) S 60.000 60
 1 Includes acute equivalent patients. JV centrus represents 100% ownership
(Includes acute equivalent patients. JV centrus and approximately 700 patients (saved pre G&A.EBITDA, Forecasted Yr. 1 census releacts Sapulpa and South-rest nuls. Patients activitient JV locations. Resolved hot spot with Tusa Nephrology saving 275 patients, 4 centers, and \$35.MM in pre G&A.EBITDA, Forecasted Yr. 1 census reflects Sapulpa and South-rest nuls. Patients additional potential JV locations. | Price Price Price Effective Price Effective Price Effective Price Effective Price Cit-02 CK Delada (LV DeNovo) Oct-02 CK H (2.4%) Dol Chreat Apr-02 CA H (2.4%) S Dol Chreat Apr-02 CA H (2.4%) S S Dol Chreat Apr-02 CA H (2.4%) S S S S Includes acute equivalent patients. JV centrus into carat proportionale ownership
interest in the deal S S S S S S S S S S S S S S S S S | Pricator,
Effective
611502 Effective
611502 polidia (LV DeNovo)
(1) Cict.02 CK B (6.1%) N/A 60 2 olidiad (LV DeNovo) Cict.02 CK B (6.1%) N/A 60 2 olidiad (LV DeNovo) Cict.02 CK B (6.1%) N/A 60 2 Ucal Apr.02 CA H (2.4%) \$ 60.000 60 1 002 Citror asadena Purchase Rights (HS) (e) Apr.02 CA H (2.4%) \$ 60.000 60 1 012 Citror Apr.02 CA H (2.4%) \$ 60.000 60 1 02 Citror Apr.02 CA H (2.4%) \$ 60.000 60 1 Niculaes acute equivalent patents. <i>J</i> centers and approximate ownership interest. Noensoft \$ 60.000 60 1 Niculaes acute equivalent patents. <i>J</i> centers and approximate ownership interest. Noensoft \$ 1 1 Nectures and approximate ownership interest. Notations (or 5 new centers. Total patients saved plus new JV patients was 650. 1 1 Neq |
| apuipa & South Crest Hospital (HS / JV DeNovo) (f) 01:002 0K B (6 1%) N/A 60 2
oread (JV DeNovo)
Total Total Controls A South Crest Hospital (HS / JV DeNovo) (f) 01:02 04:02 0K B (6 1%) N/A <u>45</u> 00 0
Total 3:06 0.000 60 1
Total asadena Purchase Rights (HS) (e) Apr-02 CA H (2,4%) \$ 60.000 60 1
Includes acute equivalent patients. JV census represents 100% ownership.
Includes acute equivalent patients and approximately 700 patients (saved pre G&A EBITDA, of \$5,000 fo fo new JV patients was 850.
I) Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
I) Resolved hot spot with Tulsa Nephrology saving 275 patients. 4 centers, and \$3,5,000 in pre G&A EBITDA, Forecasted Yr. 1 census reflects Sapulpa and Southcreat units. Partners have identified 3 additional potential JV locations. | up & South Crest Hospital (HS / JV DeNovo) (f) Energive
6(15002 OK B (6.1%) N/A 60 2 add (JV DeNovo) Oct-022 CA B (6.1%) N/A 60 2 add (JV DeNovo) Oct-022 CA B (6.1%) N/A 60 2 adma (JV DeNovo) Apr-02 CA H (2.4%) \$ 60.000 60 1 adma Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1 adma Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1 adma Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1 adma Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1 adma Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1 adma Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1 adma Purchase Rights (HS) (e) Apr-02
 | abilita & South Crest Hospital (HS / JV DeNovo) (f) 0ct-02 0K B (6 1%) N/A 60 2
oled ad (JV DeNovo) (f) 0ct-02 0K B (6 1%) N/A 60 2
Job data
Job data
Jo data
Job data
Jo data
Job data
Job data
Job d
 | ablida & South Crest Hospital (HS / JV DeNovo) (f) 0ct-02 DK B (6.1%) N/A 60 2
oledad (JV DeNovo) (f) 0ct-02 DK B (6.1%) N/A 60 2
Job 1
Job 1 | apulpa & South Crest Hospital (HS / JV DeNovo) (f) 0ct-02 OK B (6.1%) N/A 60 2
oread (JV DeNovo) (f) 0ct-02 OK B (6.1%) N/A 60 2
Total
0.02 Cthor
3.08 0.000 60 1
1. 0ct-02 CA H (2.4%) 5 60.000 60 1
1. 0ct-02 CA H (2.4%) 1 0ct-02 CA H (2.4%)
 | entective
apula & South Crest Hospital (HS / JV DeNovo) (f) 0ct-02 OK B (6.1%) N/A 60 2
Total
10 Oct-02 OK B (6.1%) N/A 60 2
30 Other
30 Oct-02 OK B (6.1%) N/A 60 0
10 Oct-02 OK H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 60 1
10 Oct-03 C A H (2.4%) S 60.000 1
10 Oct-03 C A H (2.4%) S 60.000 1
10 Oct-03 C A H (2.4%) S 60.000 1
10 Oct-03 C A H (2.5%) S 0 Oct-03 C A H (2.5%) S A H (2.5%)
 | pupa & South Crest Hospital (HS / JV DeNovo) (†) 01-02 CK B (6 1%) NA 60 2
01-02 CA B (6 1%) NA 60 2
1 Dal
1 Dal
02 Othor
3 den burchase Rights (HS) (e) Apr.02 CA H (2 4%) \$ 60,000 60 1
1 Durchase Price and EBITDA reflect DaVid's pro rata proportionate ownership.
Purchase Price and EBITDA reflect DaVid's pro rata proportionate ownership.
Purchase Price and EBITDA reflect DaVid's pro rata proportionate ownership.
Purchase Price and EBITDA reflect DaVid's pro rata proportionate ownership.
Purchase Price and EBITDA reflect DaVid's pro rata proportionate ownership.
Purchase Price and EBITDA reflect DaVid's pro rata proportionate ownership.
Purchase Price and EBITDA reflect DaVid's pro rata proportionate ownership.
Purchase Price and EBITDA reflect DaVid's pro rata proportionate ownership.
Purchase Price and EBITDA reflect DaVid's pro rata proportionate ownership.
Purchase Price and EBITDA reflect DaVid's pro rata proportionate ownership.
Purchase Price and EBITDA reflect DaVid's pro rata proportionate ownership.
Purchase Price and EBITDA reflect DaVid's Prorease Price and EBITDA reflect DaVid's Prorease Price and EBITDA reflect DaVid's Prorease David on Purchase Price.
Acquisition of Purchase Rights. Option exercise from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients. 4 centers, and \$3.5MM in pre G&A EBITDA. Forecested Yr. 1 census reflects Sapulpa and Southcreat units. Partners have identified 3 additional potential JV locations. | entecive
61560 Creat Hospital (HS / JV DeNovo) (†) 01-02 CA B (6 1%) NA 60 2
Total
Total
02 Chan 10% Oct-02 CA H (2 4%) 5 60.000 60 1
War 26 2
02 Chan 12 April 200 60 1
10 Loctase Rights (HS) (e) Apr-02 CA H (2 4%) 5 60.000 60 1
Purchase Rights (HS) (e) April 20 Similar solution and solution and solution and solution and the analytic solution and solution and the analytic solution and | ablice & South Crest Hospital (HS / JV DeNovo) (f) 60:02 CK B (6 1%) N/A 60 2
oread (JV DeNovo) (f) 60:02 CK B (6 1%) N/A 60 2
Total
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U Data
U | addia & South Crest Hospital (HS / JV DeNovo) (f) 0Ct-02 OK B (6.1%) N/A 60 2
oledad (JV DeNovo) (f) 0Ct-02 OK B (6.1%) N/A 45
0Ct of 3
0Ct of 2 Apr-02 CA H (2.4%) \$ 60,000 60 1
Decretase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60,000 60 1
Decretase Price and EBITDA reflect DaVia's pro-ordionate ownership
Decretase Price and EBITDA reflect and EBITDA reflect EBITDA Forecasted Vr. 1 census reflects Sapulpa an
 |
| apuipa & South Creat Hospital (HS / JV DeNovo) (f) 01:002 OK B (6 1%) N/A 60 2
oledad (JV DeNovo) 00:002 OK B (6 1%) N/A 45 00 2
Total Total Denovo) 00:00 C (f) 00:000 00 1
Total Purchase Rights (HS) (e) Apr-02 CA H (2 4%) \$ 60,000 60 1
includes acute equivalent patients. JV census represents 100% ownership.
I) Priculaes acute equivalent patients. JV census represents 100% ownership.
I) Priculaes acute equivalent patients. JV census represents 100% ownership.
I) Priculaes acute equivalent patients and approximately. To patients (saved price G&A EBITDA of \$5,000 fo 1 h
Resolved hot spot by renewing 6 centers and approximately. To patients (saved price G&A EBITDA of \$5,000 hot. Total patients saved plus new JV patients was 850.
I) Resolved hot spot with Tutisa Nephrology saving 275 patients, 4 centers, and \$3,50M in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcreat units. Partners have identified 3 additional potential JV locations. | upa 8 South Crest Hospital (HS / JV DeNovo) (f) 0ct-02 OK B (6 1%) NA 60 2
dad (JV DeNovo) 0ct-02 CA B (6 1%) NA 45 0 1
Total Total 2000 (f) 0ct-02 CA B (6 1%) NA 60 00 f0 1
2 Other 2 Apr-02 CA H (2.4%) 5 60.000 60 1
adena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) 5 60.000 60 1
2 Other 2 Apr-02 CA H (2.4%) 5 60.000 60 1
curchase acute equivalent patents. <i>JV</i> enersis represents 100% ownership.
Apr-02 CA H (2.4%) JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Vergined average based on Purchase Price and approximately 700 patients (saved pre 6A EBITDA of 5.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Vergined average based on Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Councision of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | apipa & South Crest Hospital (HS / JV DeNovo) (f) 0c1-02 OK B (6 1%) N/A 60 2
oledad (JV DeNovo) 0c1-02 CA B (6 1%) N/A 60 2
Total
OOZ Chor
asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
Includes acute equivalent patients. JV census represents 100% ownership.
I) Furchase Price and EBITDA reflect DaVira's pro rata proportionale ownership interest in the deal
() Purchase Price and EBITDA reflect DaVira's pro rata proportionale ownership interest in the deal
() Resolved hot spot by thrown of centes and approximately 700 patients (saved pre G&A EBITDA (5 new centers. Total patients saved plus new JV patients was 850.
() Resolved hot spot by thrown of centes and approximately 700 patients (saved pre G&A EBITDA (5 new centers. Total patients saved plus new JV patients was 850.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | apripa & South Creat Hospital (HS / JV DeNovo) (f) 0ct-02 OK B (6.1%) N/A 60 2
oledad (JV DeNovo) 0ct-02 CA B (6.1%) N/A 45
Total
002 Cthor
3306 Thor
3306 Thor
3506 Thor
3506 Thor
3506 Thor
3007 Thor
3008 Thor
30
 | apuja & South Crest Hospital (HS / JV DeNovo) (f) 01-012 OK B (6 1%) N/A 60 2
oledad (JV DeNovo) (f) 01-02 CA B (6.1%) N/A 45 0 2
Total
002 Cthor
asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
Includes acute equivalent patients. JV census represents 100% ownership
Includes acute equivalent to patients (aved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 650.
I) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | puipa & South Crest Hospital (HS / JV DeNovo) (f) 00:002 OK B (6 1%) N/A 60 2
Jedda (JV DeNovo) (f) 00:002 CA B (6 1%) N/A 45
Total 306
Total 2
302 Chror 306
302 Chror 3
302 Chror 3
303 Chror 3
302 Chror 3
302 Chror 3
302 Chror 3
302 Chror 3
302 Chror 3 | pulpa & South Creat Hospital (HS / JV DeNovo) (†) 0170/2 OK B (6 1%) N/A 60 2
Total Total (HS / JV DeNovo) (†) 01402 CA B (6 1%) N/A 45 0 01402 CA B (6 1%) N/A 45 0 1
Total Total Purchase Rights (HS) (e) Apr-02 CA H (2 4%) \$ 60.000 60 1 1
22 Other and EBITDA reflect De Nvira's por rata proporting to rate and EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Megalited not spot virchase Rights Option exercisable from 36 to 48 months after Madicare certification date.
Aquisition of Purchase Rights Option exercisable from 36 to 48 months after Madicare certification date.
Resolved not spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A.EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcreat units. Partners have identified 3 additional potential JV locations. | puip & South Crest Hospital (HS / JV DeNovo) (†) 01-02 OK B (6 1%) NA 60 2
Jedad (JV DeNovo) Detect Hospital (HS / JV DeNovo) (†) 00-02 CA B (6 1%) NA 45 0
Total 2014
03 Other
Ma 45 45 0
10 Ctrass Rights (HS) (e) Apr-02 CA H (2 4%) \$ 60,000 60 1
Purchase Rights (HS) (e) Apr-02 CA H (2 4%) JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
10 Includes acute equivalent patients. JV census represents 100% connership.
10 Includes acute equivalent patients. JV census represents 100% connership.
10 Includes acute equivalent patients. JV census represents 100% connership.
10 Includes acute equivalent patients. JV census represents 100% connership.
10 Resolved hot spot by renewing 6 centers and approximately 700 patients (saved price G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
10 Resolved hot spot by renewing 6 centers and approximately 700 patients (saved price G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
10 Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare centification date.
10 Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after
Medicare centification date.
10 Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare centification date.
10 Acquisition of Purchase Rights. Potion exercisable from 36 to 48 months after Medicare centification date.
10 Acquisition of Purchase Rights. A centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | apripa & South Creat Hospital (HS / JV DeNovo) (f) 0ct-02 0K B (6 1%) NA 60 2
oled ad (JV DeNovo) 0ct-02 0K B (6 1%) NA 45 0 7
Total 0ct 02 0C 0 1
002 Cthor 3 0 0 0 1 0 0ct-02 0C A H (2 4%) \$ 60,000 60 1 1
Includes acute equivalent patients. JV census represents 100% ownership.
I) Includes acute equivalent patients. JV census represents 100% ownership.
I) Includes acute equivalent patients. JV census represents 100% ownership.
I) Includes acute equivalent patients. JV census represents 100% ownership.
I) Furchase Rights (HS) (e) Aprice 120 Vides of the ownership.
I) Furchase Rights of the one of the form of the ownership interest in the deal.
I) Furchase Rights of the one of the ownership interest in the deal.
I) Furchase Rights of the one of the ownership interest in the deal.
I) Furchase Rights of the one of the ownership interest in the deal.
I) Furchase Rights of the one of the ownership interest in the deal.
I) Furchase Rights of the ownership interest in the deal.
I) Furchase Rights of the one of the ownership interest in the deal.
I) Furchase Rights of the one of the ownership interest in the deal.
I) Furchase Rights of the reference and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | apuipa & South Creat Hospital (HS / JV DeNovo) (f) 0ct-02 0K B (6 1%) N/A 60 2
oledad (JV DeNovo) 0ct-02 0A B (6 1%) N/A 45 0
Total
Out OP
Total
Out OP
Total
Out OP
Out OP
 |
| reported a source concernation of the function of the field of the fie | and a down creat respirat (N2) V DeNov(); UCLO2 CA B (6.1%) NA 40 C 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
 | addition of Packword (NS) (NS) (NS) (NS) (NS) (NS) (NS) (NS)
 | Total Approximates recent (To FUNDERVOL)) Oct-02 CA B(6.1%) NiA 45 C 20 C 2
 | Addition of Purchase Rights (HS) (e) Apr-02 CA B (6.1%) NA 00 2 Total 308 UN 000 Cthor 300 Cthor 308 (HS) (e) Apr-02 CA B (6.1%) NA 00 C (f) 308 (f) 1 Total 308 Cthor 300 Cthor 300 Cthor 300 Cthor 300 Cthor 300 (f) 1 Total a participants (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 (f) 1 Tortalse Rights (HS) (e) Apr-02 CA H (2.4%) Y denovo for 5 new centers. Total patients saved plus new JV patients was 850. Therake Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal (f) Purchase Rights (HS). We are a proportionate ownership interest in the deal (f) Purchase Rights (HS) (e) Apr-02 CA H (2.4%) Y denovo for 5 new centers. Total patients saved plus new JV patients was 850. Stesovide not spot y rehearing of scenters and approximately 700 patients (aved pre G&A EBITDA of \$0.500 for 5 new centers. Total patients saved plus new JV patients was 850. Stesovide not spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. For casted Yr. 1 census reflects Sapulpa and Southcreat units. Partners have identified 3 additional potential JV locations.
 | a provide a count creat respiration (NS) (NS) (NS) (NS) (NS) (NS) (NS) (NS) | add (JV DeNovo) DCL02 CA B (6 1%) NA 0 2 adda (JV DeNovo) DCL02 CA B (6 1%) NA 0 2 adda (JV DeNovo) DCL02 CA B (6 1%) NA 0 2 22 Chror 22 Chror Apr-02 CA H (2.4%) \$ 60.000 60 1 addena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1 Purchase Price and EBITDA reflect Davita's pro rata proportionate ownership interest in the deal Escoude dot sport by remove of approximately 700 patients (saved pre G&A EBITDA of \$9:5MM). JV denovo for 5 new
centers. Total patients saved plus new JV patients was 850. Resolved hot sport by remeaning 6 contract approximately 700 patients (saved pre G&A EBITDA forecasted Yr. 1 census reflects Saulpa and Southcrest units. Partners have identified 3 additional potential JV locations. Aquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Activates Saulpa and Southcrest units. Partners have identified 3 additional potential JV locations. Aquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Activates Saulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Activity Counce CA B (61%) NA Counce C Total Total 306 0 1 2 C C B (61%) NA Counce 2 C C C C B (61%) NA Conce 2 C C C D C | Addition of Purchase Rights (HS) (e) Agr.02 CA B(61%) NA 45 C 300 C 4 (61%) NA 45 C 4 (61%) NA 45 C 4 (61%) NA 40 C 4 (61%) 1 C 4 (61%) NA 40 C 4 (61%) 1 C 4 (61%) 1 C 4 (61%) NA 40 C 4 (61%) 1 C 4 (61\%) 1 C 4 (61 | addition of Polynovi) cutod voluces represent respiration of the V DeNovo) cutal voluces represent respiration of V DeNovo) cutal voluces represent respiration of V DeNovo) cutal voluces represent respiration of V DeNovo) cutal voluces represent respiration voluces represents 100% ownership. cutal voluces acute equivalent patients. JV census represents 100% ownership. cutal voluces acute equivalent patients. JV census represents 100% ownership. cutal voluces acute equivalent patients. JV census represents 100% ownership. cutates Price and EBITDA reflect Davira's procrata proportionate ownership interest in the deal. cutate average based on Purchase Rights. Other as the American voluce of \$5,5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. cutate average based on Purchase Rights. Other exercisible from 36 to 48 months after Medicare certification date. cutation of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. cutation of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. cutation of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. cutation of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |
| Occurrent (V) Control | March version March 43 44 44 44 44 43 43 44< | Model Model <th< td=""><td>Model Model <th< td=""><td>Model Model <th< td=""><td>Total Total <thtotal< th=""> <thtotal< th=""> <thto< td=""><td>Total to between the second memory of the second second and second secon</td><td>The start of the s</td><td>Model Model <th< td=""><td>Operation Mode 43 44</td></th<></td></thto<></thtotal<></thtotal<></td></th<></td></th<></td></th<> | Model Model <th< td=""><td>Model Model <th< td=""><td>Total Total <thtotal< th=""> <thtotal< th=""> <thto< td=""><td>Total to between the second memory of the second second and second secon</td><td>The start of the s</td><td>Model Model <th< td=""><td>Operation Mode 43 44</td></th<></td></thto<></thtotal<></thtotal<></td></th<></td></th<> | Model Model <th< td=""><td>Total Total <thtotal< th=""> <thtotal< th=""> <thto< td=""><td>Total to between the second memory of the second second and second secon</td><td>The start of the s</td><td>Model Model <th< td=""><td>Operation Mode 43 44</td></th<></td></thto<></thtotal<></thtotal<></td></th<> | Total Total <thtotal< th=""> <thtotal< th=""> <thto< td=""><td>Total to between the second memory of the second second and second secon</td><td>The start of the s</td><td>Model Model <th< td=""><td>Operation Mode 43 44</td></th<></td></thto<></thtotal<></thtotal<> | Total to between the second memory of the second second and second secon | The start of the s | Model Model <th< td=""><td>Operation Mode 43 44</td></th<> | Operation Mode 43 44 |
| Old Old Junction Junction< | Other Just 2
 | Old Just 5 60.000 60 1 002 Other Tasadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1 Tasadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1 Includes acute equivalent patients. JV census represents 100% ownership interest in the deal. Includes acute equivalent patients saved plus new JV patients was 850. 1 1) Purchase Price and EBITDA reflect DaVita's pro-rotanale ownership interest in the deal. Include average based on Purchase Price. 1 1 1) Weighted average based on Purchase Price. For 48 EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. 1 1 1) Weighted average based on Purchase Price. For 48 EBITDA, For exacts and estimate average based on Purchase Price. 4.6.0.000 5.6
 | Old June 9 002 Other 022 Other 022 Other 02 Other 032 Other "asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60,000 60 1 1) Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60,000 60 1 2) Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60,000 60 1 3) Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60,000 60 1 3) Purchase Rights out all a proportionate ownership interest in the deal. 1) Weighted a vertage based on Purchase Price.
 | Old Just
 | Out Just | Old Chron Description Description <thdescription< th=""> <thdescription< th=""></thdescription<></thdescription<> | Old Just
 | Old Under the source of th | Out Just |
| 002 Other
Tasadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
Includes acute equivalent patients. JV census represents 100% ownership.
I) Purchase Price ABITDA refect aprovation provimately. 700 patients (ased price acutive acute equivalent patients aved plus new JV patients was 850.
Stessived hot sport yrenewing 6 centers and aproximately. 700 patients (3.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Weighted average based on Purchase Price. | 2 <i>Other</i>
adena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) 5 60.000 60 1
rotudes acute equivalent patients. <i>JV</i> census represents 100% ownership.
Urchase Price and EBITDA reflect DaVita's pro rata proportionate ownership.
Vergiebted hot spot by renewing 6 cenetics and approximately 700 patients (saved price SAS EBITDA of \$5.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Vergination average Bead on Purchase Price and approximately 700 patients (saved price SAS EBITDA of \$5.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Vergination average Bead on Purchase Price and approximately 700 patients (saved price G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | 002 Other 002 Other 3 adden Purchase Rights (HS) (e) Apr-02 CA H (2.4%) 5 60.000 60 1 Includes acute equivalent patients. JV census represents 100% ownership interest in the deal. 1) Purchase Price and EBITDA reflect DaVita's provisionate ownership interest in the deal. 1) Weishold a verage based on Purchase Price. 3) Mathematical acute equivalent patients. JV census represents 100% ownership. 3) Purchase Price and EBITDA reflect DaVita's provinately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. 3) Mathematical average based on Purchase Price. 3) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. 3) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. 3) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | 002 Other 002 Other asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) 5 60.000 60 1 Purchase Rights (HS) (e) Apr-02 CA H (2.4%) 5 60.000 60 1 Purchase Rights (HS) (e) Apr-02 Apr-02 CA H (2.4%) 5 60.000 60 1 Purchase Rights (HS) (e) A centers in the deal. Weighted average based on Purchase Price. A cquisition of Purchase Rights. Option exercisable from 36 104 months after Medicare certification date. Acquisition of Purchase Rights. Option exercisable from 36 104 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | 002 Other
Tasadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
a) Includes acute equivalent patients. JV census represents 100% ownership
a) Purchase Price and EBITDA reflect DaVita's provisionate ownership
b) Purchase Price and EBITDA reflect DaVita's provisionate ownership
b) Purchase Price and EBITDA reflect DaVita's provisionate ownership
control of the owner of the ownership
control of the owner of the ownership
control of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
b) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and 33.5MM in pre G&A EBITDA. Forecasted Yr, 1 census reflects Sapulpa and Southcreat units. Partners have identified 3 additional potential JV locations.
 | Mo2 Other
sedena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
) Includes acute equivalent patients. JV census represents 100% ownership.
) Furchase Price and EBITDA reflect Davirats protocrionate ownership.
) Peoriohase Price and EBITDA reflect Davirats protocrionate ownership.
) Nesolved not spot by removing contens providents (saved price G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
) Nesolved versage based on Purchase Price.
) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | 02 Other
aadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
Includes acute equivalent patients. JV census represents 100% ownership.
Includes acute equivalent patients. JV census represents 100% ownership.
Revolved hot so by removing 6 context approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Weighted average based on Purchase Price.
Aquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tutsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | w2 Criher
Includes arcthese Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
Purchase Price and EBITDA reflect DaVint's pro-trait proportionate ownership.
I Purchase Price and EBITDA reflect DaVint's pro-trait proportionate ownership.
Resolved hot stop by removing 6 compares and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Neighted a verage based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations. | 002 Other
asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
a) Includes acute equivalent patients. JV census represents 100% ownership.
a) Purchase Price and EBITDA refloct and portoinate ownership interest in the deal.
b) Purchase Price and EBITDA refloct and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
b) Purchase Price and reproving 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
a) Weighted average based on Purchase Price.
b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
c) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | 002 Othor
asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
3) Includes acute equivalent patients. JV census represents 100% ownership
3) Purchase Price and EBITDA reflect DaVia's proportionate ownership interest in the deal
4) Purchase Price and EBITDA reflect DaVia's proportionate ownership interest in the deal
5) Purchase Price and EBITDA reflect DaVia's provimately 700 patients (saved price G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
5) Wershide average based on Purchase Price.
5) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
6) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$5.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
) Includes acute equivalent patients. JV census represents 100% ownership.
) Purchase Price and EBITDA reflect DaVita's proritate proportionate ownership interest in the deal.
) Purchase Price and EBITDA reflect DaVita's proritate proportionate ownership interest in the deal.
) Weighted average based on Purchase Price.
) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
) Resolved hot spot with Tutisa Mephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Scuthcrest units. Partners have identified 3 additional potential JV locations. | adena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
notuces acute equivalent patients. JV census represents 100% ownership,
urchase Price and EBITDA reflect DaVid's pro rata proportionate ownership,
versived hot spot venewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$5.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Verginition of version Reador on Purchase Price and approximately 700 patients (saved pre G&A EBITDA of \$5.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Verginition of versions of the one service able from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
i) Includes acute equivalent patients. JV census represents 100% ownership.
c) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
c) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
c) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
c) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
c) Weak of the spot by reinant go centers and approximately 700 patients (asved pre G&A.EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
c) Weak of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A.EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
Includes acute equivalent patients. JV census represents 100% ownership.
I) Purchase Price and EBITDA reflect DaVira's pro ratia proportionate ownership interest in the deal
I) Weighted average based on Purchase Price.
I) Weighted average based on Purchase Price.
I) Resolved hot spot with Tulsa Nephrology saving 275 patients, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
I) Includes acute equivalent patients. JV census represents 100% ownership.
3) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal
3) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal
3) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal
4) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal
4) Resolved hot spot yre thread approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
4) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
6) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | sadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
) Includes acute equivalent patients. <i>JV</i> census represents 100% ownership.
Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal
Prachase Price and EBITDA reflect DaVita's pro rata proportionate ownership.
) Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
) Weighted average based on Purchase Price.
) Vecquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | sadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
Includes acute equivalent patients. JV census represents 100% ownership.
Includes acute equivalent patients. JV census represents 100% ownership.
Resolved hot spot by removed effect. DaVita's pro rata proportionate ownership interest in the deal.
Resolved hot spot by remove deflect. DaVita's pro rata proportionate ownership interest in the deal.
Weighted average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tutsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Includes acute equivalent patients. JV cansus represents 100% ownership.
Includes acute equivalent patients. JV cansus represents 100% ownership.
Includes acute equivalent patients. JV cansus represents 100% ownership.
I Puctrase Price and EBITDA reflect DaVita's pro rait proportionate ownership interest in the deal.
I Resolved hot stop thermony 6 contrast proportionate ownership interest in the deal.
I Vereighted average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
Includes acute equivalent patients. JV census represents 100% ownership.
I) Purchase Price and EBITDA reflect Davita's pro rata proportionate ownership interest in the deal.
I) Purchase Price and EBITDA reflect Davita's pro rata proportionate ownership interest in the deal.
I) Resolved not spot by recharse Area of approximately 700 patients (saved pre G&A EBITDA of \$9:5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
I) Resolved a versage based on Purchase Price.
I) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | asadena Purchase Rights (HS) (e) Apr-02 CA H (2.4%) \$ 60.000 60 1
Includes acute equivalent patients. JV census represents 100% ownership.
I) Purchase Price and EBITDA reflect DaVira's provisionate ownership.
I) Purchase Price and EBITDA reflect DaVira's provisionately 700 patients (saved pic G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
I) Weighted average based on Purchase Price.
I) Weighted average based on Purchase Price.
I) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| Includes acute equivalent patients. JV census represents 100% ownership. Purchase Price and EBIDA reflect Davita's pro rata proportionate ownership interest in the deal. Resolved hot spot by renewing 6 centers and approximately 700 patients (saved presents and sources) Resolved hot spot by renewing 6 centers and approximately 700 patients (saved presents). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. Weighted average based on Purchase Price. Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tutisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | ncludes acute equivalent patients. JV census represents 100% ownership,
burchase Price and EBITDA reflect DaVita's pro-rata proportionate ownership interest in the deal.
Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$5.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Vergined average based on Purchase Price. From 36 to 48 months after Medicare certification date.
counstition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Includes scule equivalent patients. JV census represents 100% ownership. Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal. Resolved find spot by renewing 6 centers and approximately 700 patients (saved price 56 kBITDA of \$0.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. Resolved not spot by renewing 6 centers and approximately 700 patients (saved price 56 kBITDA of \$0.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. Resolved not spot by renewing 6 centers and approximately 700 patients (saved price 56 kBITDA of \$0.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. Aquisition of Purchase Rights. Option newcisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tutsa Nephrology saving 275 patients, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Includes acute equivalent patients. JV census represents 100% ownership. Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal. Resolved not spot by remving 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. Weight a verga ear on Purchase Price. Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tuisa Nephrology saving 275 patients. 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Includes acute equivalent patients. JV census represents 100% ownership. Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal. Resolved hot spot by renewing 6 centers and approximately 700 patients (saved price G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. Weighta de regressent of the centers and approximately 700 patients (saved price G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. Weighta de regressent of the centers and approximately 700 patients (saved price G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. Weighta de regressent of the centers and approximately 700 patients (saved price G&A EBITDA total). Activation of Purchase Rights. Partners have identified 3 additional potential JV locations. Resolved hot spot with Tutsa Nephrology saving 275 patients, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Includes acute equivalent patients. JV census represents 100% ownership.
) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
) Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pric G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
) Weighted and spot by renewing 6 centers and approximately 700 patients (saved pric G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
) Weighted and spot by renewing 6 centers and 50 for 48 months after Medicare certification date.
) Weighted not spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Includes acute equivalent patients. JV census represents 100% ownership.
Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
Repetived hor spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9:5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Weighted a verage based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tutsa Nephrology saving 275 patients, 4 centers, and \$3:5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Includes acufe equivalent patients. JV census represents 100% ownership.
Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
Negbried average thermony 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Weghted average based on Purchase Price.
A equisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Includes acute equivalent patients. JV census represents 100% ownership. Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal. Resolved hort spot by renewing 6 centers and approximately 700 patients (saved price G& EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. Resolved hort spot by renewing 6 centers and approximately 700 patients (saved presented as the patient structure). Total patients (saved precent for the deal. Resolved hort spot by the purchase Price. Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hort spot with Tutsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Includes acute equivalent patients. JV census represents 100% ownership. Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal. Resolved not spot by renving 6 centers and approximately 700 patients (saved price G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. Weighted average and participants on Purchase Price. Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| Includes acute equivalent patients. JV census represents 100% ownership. Purchase Price and EBITDA reflect Davita's pro rata proportionate ownership interest in the deal. Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pire G&A EBITDA of \$95MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850. Weightied average based on Purchase Price. Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tulsa Nephrilogy saving 275 patients. 4 centers. and \$3.5MM in pie G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | roludes acule equivalent patients. JV census represents 100% ownership interest in the deal.
Jurchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
Verghed hot spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Vergined average based on Purchase Price.
Consistion of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Secolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Includes acule equivalent patients. JV census represents 100% ownership.
) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
) Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
1) Weighted average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
) Resolved hot spot with Tutsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Includes acule equivalent patients. JV census represents 100% ownership.
) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
) Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pile G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
1) Weighted average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Includes acule equivalent patients. JV census represents 100% ownership.
) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Weighted average based on Purchase Price.
) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Includes acule equivalent patients. JV census represents 100% ownership.
) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
) Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
) Weighted average based on Purchase Price.
) Weighted average based on Purchase Price.
) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Includes acute equivalent patients. JV census represents 100% ownership.
Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Weighted average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | I Includes acute equivalent patients. JV cansus represents 100% ownership.
Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Weighted average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicarte centification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Includes acule equivalent patients. JV census represents 100% ownership.
) Purchase Price and EBITDA reflect DaVita's pro raproportionate ownership interest in the deal.
) Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
1) Weighted average based on Purchase Price.
A causistion of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Includes acule equivalent patients. JV census represents 100% ownership.
) Purchase Price and EBITDA reflect DaVita's pro rata proportionate ownership interest in the deal.
) Resolved hot spot by renewing 6 centers and approximately 700 patients (seved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
1) Weighted average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
|) Includes acute equivalent patents. JV census represents 100% ownership interest in the deal.
Purchase Price and EBITD reflect Davids por rounde womership interest in the deal.
Preveate Price and Purchase Price.
Weighted average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | ncludes acute equivalent patents. U consus represents 100% ownership, interest in the deal.
Auchase Price and EBITDA reflect DaVita's prorata proportionate ownership interest in the deal.
Resolved hot spoty renewing 6 centers and approximately 700 patients (seved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Regeined average base do no Purchase Brits.
December average base on Purchase Brits. Option exacting the Madicare certification date.
Requisition of Purchase Rights. Option events, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Includes acute equivalent patients. JV census represents 100% ownership, interest in the deal.
) Purchase Price and EBITDA reflect Davia's proportionate ownership interest in the deal.
Megoined average based on Purchase Price.
) Weignide average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$5.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Includes acute equivalent patents. JV census represents 100% ownership interest in the deal.
Purchases Price and EBITDA reflect Davids proportionate ownership interest in the deal.
Resolved not soft by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 650.
Neighted average based on Purchase Price.
Acquisition of Purchases Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tutsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Includes acute equivalent patients. JV census represents 100% ownership,
) Purchase Price and EBITDA reflect DaVids proportionate ownership interest in the deal
) Purchase Price and EBITDA reflect and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
) Resolved not spot by the remain 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
) Weighted average based on Purchase Price.
) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) includes acute equivalent patients. JV census represents 100% ownership interest in the deal.
) Purchase Price and EBITDA related DaVids provincinate ownership interest in the deal.
() Resolved Price and EBITDA related DaVids provinciately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
() Weighted average based on Purchase Price.
() Vecipited average based on Purchase Price.
 | Prictudes acufe equivalent patients. V census represents 100% ownership,
Prictuase Price and EBITDA reflect DaVia's pro rate proportionate ownership interest in the deal.
Resordent spot by renewing enails and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 650.
Weighted average based on Purchase Price.
Aquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Pincludes acute equivalent patients. JV census represents 100% ownership, interest in the deal.
Pivchase Price and EBITA reflect DaVita's pro ratia proportionate ownership interest in the deal.
Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pice G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Neighted average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pie G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pie G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Includes acute equivalent patients. JV census represents 100% ownership.
Purchase Price and EBITDA reliable province whership interest in the deal.
Resolved price and EBITDA reliable provimately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Neighted average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Includes acute equivalent patients. JV census represents 100% ownership,
Purchases Price and EBITA reflect Davids proportionate ownership interest in the deal.
Resolved not soft prenewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Neighted average based on Purchase Price.
Acquisition of Purchases Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| b) Purchase Price and EBIDA reflect Davita's pro rata proportionate ownership interest in the deal.
Resolved hot spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Supplicited average based on Purchase Price.
A Quisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
I) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Purchase Price and EBITDA reflect DaVita's prorationate ownership interest in the deal.
tesolved hot spot by renewing 6 centers and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Vergibled average por Purchase Price. The manufacture of the G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Vergibled average por Purchase Price. The manufacture of Purchase Rights. Partners have identified 3 additional potential JV locations.
esolved hot spot with Tulsa Nephrology saving 275 patients, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Purchase Price and EBITDA reflect DeVita's providentie ownership interest in the deal.
Negolioed house of the mage of centers and approximately 700 patients (saved price G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
1) Wegnade average based on Purchase Price.
•) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Purchase Price and EBITDA reflect DaVita's proving the proportionate ownership interest in the deal.
Secoled hot stop by remeaning 6 enters and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 650.
I) Weighted average based on Purchase Price.
s) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | b) Purchase Price and EBITDA reflect DaVia's provisionate ownership interest in the deal.
() Resolved to stort by renewing 6 and approximately 700 patients (saved price G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
(1) Neighted average based on Purchase Price.
() Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Furchase Price and BBITDA reflect Davids pro rata proportionate ownership interest in the deal.
Nesolved not spot by Renew and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
) Vespined average based on Purchase Price.
) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, a centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Purchase Price and EBITDA reflect Davlia's pro rate proportionate ownership interest in the deal.
Purchase Price and EBITDA reflect Davlia's pro rate provimately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Weighted average based on Furchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tutsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Purchase Price and EBITDA reflect DaViris pro rata proportionate ownership interest in the deal.
Secored bio from g6 content and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
J Vergined average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephroiogy saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations. |) Purchase Price and EBIDA reflect Davids proportionate ownership interest in the deal.
Resolved hot spot by the Genets and approximately 700 patients (saved pre G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
1) Weighted average based one purchase Price.
3) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Purchase Price and EBITDA reflect DaVia's proving an eventing interest in the deal.
Secoled hot pot by the many 6 centers and approximately 700 patients (saved price G&A EBITDA of \$9.5MM). JV denovo for 5 new centers. Total patients saved plus new JV patients was 850.
Weighted average based on Purchase Price.
3) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. |
| c) resorved not spot by teneming oremets and approximately four patients (saved pre cever pre cever press). The sovie process the marked press and approximately four patients (saved pre cever press) weighted area press base press. Total patients saved press press. Total patients press press. Total patients press pre | resolved not spot by retermine or exproximately four patients (seved pe GoA Exit DA or \$5.3MM). JV denovo not 5 new centers. Total patients seved prior new JV patients was obt.
Veighted average and on Purchase Price 3 and 5 to 48 months after Medicare certification date.
scutistion of Purchase Rights. Patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Werbyner on synd by herming or emprovinately four parents (aveu pre Goon Ebit DA of as SMM). Jv denovo for 5 new centers. Total parents saved prus new Jv parents was obv.
1) Werbyned average on Purchase Price.
9) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
9) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Treadyer for the many or employing the tear of the tear to be tead and the tear to any second of a new centers. Total patients saved pressing the many or many or the approximatery for patients faved pressing and average passed on Purchase Price.
 | Presorved not spot where we have and approximately four patients (aveau pre Goon Ebit DA or as John). Jv venovo for 3 new centers. Total patients saved prus new Jv patients was objuily and solved pressent of the contrast price.
 | Tresolver in taper by the memory of parents (saved pre Content to second). Jy denover of a new centers, rotal parents saved prus new Jy parents was object and approximately from 36 to 48 months after Medicare certification date.
) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Weighted average based on Purchase Price.
Weighted average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tutsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Weighten developed with a solution of the solution is taken pre device the for a second is the venters. Total patients save price and proximatery four patients was solut.
Weighten average based on Purchase Price.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Tresorver on cask of yeareming or an approximatery fou patients (saved pre doct EntLPd of \$5.5MM). Ju denovorion on the cashers, for a patients saved price mer Ju patients was occu.
Weighted average based Dirchase Frice.
S) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
S) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
S) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Wershow an one way be referring to emprovinately you patents (aavee pre GoA EDI LA or \$4.5MM). Jy venovo for 5 new centers. Total patents saved prus new Jy patents was obt.
Wershow and a verage baseforming to frass Price.
A cquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. |
|) wegned average base proce.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Besolved hot spot with Tutsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV tocations. | weigned average bested on Fundase Frice
organisation average and sweichsable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) wegned average based on Functasse Price.
e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
f) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) wergined average based on Functiase Price.
e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) wegined average based on Fuctnase Price.
e) Aquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
f) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) wergined average based on Furchase Fine.
) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | weigned average based on Fuchase Frice.
Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) weighed average based on Purchase Frice.
) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | a) wegned average based on Furchase Fine.
e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
f) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | i) wegned average based on Functasse Price.
s) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| s) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | counsition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 35 to 49 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 49 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 35 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 46 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| |
 |
 |
 |
 |
 | | |
 | |
| | esoned in sportant to serve and stability and stables + contents, + contents, + contents, and \$C.S.M.M. III pre
 |
 |
 |
 |
 | | |
 | |
| resolved not spot with take reprincing's saving 2/5 parients, 4 centers, and 35.5mm in pre Cev Edit DA. Forecested 17.1 centers fenecis Sepulpa and Southcrest units. Farthers have identified 5 additional puterinal JV locations. | esored not spot with tuse reprincingly saving 2/5 patients, 4 centers, and \$5.5MM in pie God Ebit DA. Forecasted 7r. I census reneats Septida and Soundest units. Partners have roemand 5 additional potential 57 rocaucits.
 |
 | resolved not spot win Luisa Nepmology Saving 275 patients, 4 centers, and \$5.5MM in pre GoA Ebit DA. Forecasted 71.1 census fenects Sapupa and Soundrest units. Partients have identified 5 additional potential JV locations.
 |
 |
 | resorve not spot wint tuse reprincing's saving 2/5 parentis, 4 centers, and \$5.5MM in pie CoA EDITUA. Forecasted 11.1 centus fenecis Sapupa and Soundrest units. Partners have reentined 5 auditional potential 54 locations. | resorved not spot with turks reprincingly saving 2/2 parients, 4 canters, and \$5.5MM in pie Gord EDI LA. Forecasted 17.1 centures sapupa and soundrest units. Farthers have identified 3 additional potential 57 locations. |
 | |
| Hesolved hot spot with Tuisa Nephrology saving 2/5 patients, 4 centers, and \$3.5MM in pre G&A EBH UA. Forecasted Yr. T census reflects Sapulpa and Southcrest units. Pathers have identified 3 additional potential JV locations. | esoived hot spot with Tulsa Nephrology saving 2/5 patients, 4 centers, and \$3.5MM in pre G&A EBH DA. Forecasted Yr. T census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Kesolved hot spot with 1 uisa Nephrology saving 2/5 patients, 4 centers, and \$3.5MM in pre G&A EBI LA. Forecasted Yr. 1 census feitects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | resolved not spot with Luisa Nephrology saving 2/5 patients, 4 centers, and \$5.5MM in pre G&A EBILDA. Forecasted Yr. 1 census reflects Sapupa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Kesolved hot spot with 1 uisa Nephrology saving 2/5 patients, 4 centers, and \$5.5MM in pre G&A EBI LDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Kesolved hot spot with 1 uisa Nephrology saving 2/5 patients, 4 centers, and \$5.5MM in pre G&A EBI LA. Forecasted Yr. 1 census feitects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Nesolved not spot with Tuisa Nephrology saving 2/5 patients, 4 centers, and \$3.5MM in pre d&A EBITUA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Kesoved not spot with Tulsa Nephriology saving 2/5 patients, 4 centers, and \$3.5MM in pre C&A EBITUA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Hesolved hot spot with Tulsa Nephrology saving 2/5 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. T census reflects Sapupa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | resolved hot spot with 1 uisa Nephrology saving 2/5 patients, 4 centers, and \$5.5MM in pre G&A Ebit DA. Forecasted Yr. 1 census reflects Sapupa and Southcrest units. Partners have roentified 3 additional potential JV locations. |
| Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | esoived hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcreet units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Resolved hot spot with Tulsa Nephrology saving 2/5 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| Resolved hot spot with Tutsa Nephrology saving 275 patients. 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | esolved hot spot with Tulsa Nephrology saving 275 patients. 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcreat units. Partners have identified 3 additional potential JV locations. | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcreat units. Partners have identified 3 additional potential JV locations. |
| production of process regime. Option exercised in the content and \$3.5MM in pite G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | expression of increase name and more and more and more and more and the second of the
 | requestion or excrete hypers. Option exercised on the content of the medicare continuous of the content of the
 | requestion or increase regime. Option particulation of the content and successful of the content and southerest units. Partners have identified 3 additional potential JV locations. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | requirement of the second of t | production or increase regime. Option sources on one of the monetane connection and the second of th
 | Are desired for access representation of the manual and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Provision of devices regions option exercised and models of SiSMM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | requestion or burges regions controlled in our second and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | requestion or reviewed regimes. Open exercised on 50 to the intervation rate.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
|) Audustrum or ruchase reguls. Option exercisation not to a montas and medicar centrication date.
Resolved hot spot with Tusa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pie G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | evolution or relates regulations. Option evolutions and medicate centruction date:
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or processes regins. Option exercised in formatical and medicare centination and the second of the second and southcrest units. Partners have identified 3 additional potential JV locations. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Audustron or Fuctorese regins. Option exercised in the contents and medicate centructuon date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or processe regins. Option exercised in one 3 or 40 months and medicare centineation date.
 |) Advance of Pricese regine. Option exercised in four 30 to 40 months and medicare centineation date.
 | Acudemont of recrease rugue. Option exercised in on so to 40 months and medicate centration date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | r Audustront or Fuctuase regime. Option exercised and mourcare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Auduation of Fuctorase regine. Option statiosable from 50 to months and medicare centrication date.
 |) Advision of Pricinase regins. Option exercised in formal and medicare centineation date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| ry equisition or encodes engine. Option exercisation so to 40 montris and medicate centrication date. | equisition of Functiones regime. Option exercisable from so to 40 montris after medicate certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Functiese frights. Option exercised in months are medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or futurase regins. Option exercisation months and medicate certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | r Acquisition or Futoriase frights. Option exercisable from 30 to 40 months arter medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putronase regins. Option exercisable from 50 to 40 montris arier medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase rights. Uption exercisable from so to 40 months and medicate centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | requision of Fuctivase rugins. Option evancisation so to 40 montris and medicate certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Puctorase regins. Option exercisation so to 40 montris and medicate centrication date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Futoriase rights. Option exercisable from 30 to 40 months are medicate centrication date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| ry equisition or encodes engine. Option exercisation so to 40 montris and medicate centrication date. | equisition of Functiones regime. Option exercisable from so to 40 montris after medicate certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Functiese frights. Option exercised in months are medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or futurase regins. Option exercisation months and medicate certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | r Acquisition or Futoriase frights. Option exercisable from 50 to 40 months arter medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putronase regins. Option exercisable from 50 to 40 montris arier medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase rights. Uption exercisable from so to 40 months and medicate centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | requision of Fuctivase rugins. Option evancisation so to 40 montris and medicate certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Puctorase regins. Option exercisation so to 40 montris and medicate centrication date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Futoriase rights. Option exercisable from 30 to 40 months are medicate centrication date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| ry equisition or encodes engine. Option exercisation so to 40 montris and medicate centrication date. | equisition of Functiones regime. Option exercisable from so to 40 montris after medicate certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Functiese frights. Option exercised in months are medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or futurase regins. Option exercisation months and medicate certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | r Acquisition or Futoriase frights. Option exercisable from 50 to 40 months arter medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putronase regins. Option exercisable from 50 to 40 montris arier medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase rights. Uption exercisable from so to 40 months and medicate centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | requision of Fuctivase rugins. Option evancisation so to 40 montris and medicate certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Puctorase regints, uption exercisation so to 40 montris and medicate centrication date. Acquisition of Puctorase regints, uption exercisation so to 40 montris and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Futoriase rights. Option exercisable from 30 to 40 months are medicate centrication date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
|) Acquisition or Purchase Rights. Uption exercisation from -so to 48 months after Medicate certification date. | equisition of Purchase rights. Option exercisable from 36 to 46 months after Medicate centrication date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Purchase Rights. Uption exerciseden from 35 to 46 months after Medicare certification date.
I Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putchase Ngms. Uption exercisable from 36 to 46 months and Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Purchase Rights. Uption exercisable from -50 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putchase Natins. Uption exercisable from -50 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase Highs. Uption exercisable from 36 to 46 months and Medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Functivase rughts. Uption evercisable from 36 to workts and medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Putchase Rights. Uption exercisable from 36 to workts and medicate centration date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Purchase Rights. Uption exercisable from -50 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
|) Acquisition or Purchase Rights. Uption exercisation from -so to 48 months after Medicate certification date. | equisition of Purchase rights. Option exercisable from 36 to 46 months after Medicate centrication date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Purchase Rights. Uption exerciseden from 35 to 46 months after Medicare certification date.
I Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putchase Ngms. Uption exercisable from 36 to 46 months and Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Purchase Rights. Uption exercisable from -50 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putchase Natins. Uption exercisable from -50 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase Highs. Uption exercisable from 36 to 46 months and Medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Functivase rughts. Uption evercisable from 36 to workts and medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Putchase Rights. Uption exercisable from 36 to workts and medicate centration date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Purchase Rights. Uption exercisable from -50 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| ry equisition or Fuctoriase regins. Option exercisation not to 40 montris and medicate certrication date. | equisition of Functiones regime. Option exercisable from so to 40 montris after medicate certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | r) Acquision or Functiase rights. Option exercised entities and medicare centercation date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | r) Acquisition or Functedee Regins. Option exercisatione months arter medicare centrication date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | r) Acquisition or Functiase regins. Option exercisatione incom 30 to 40 montris arrent medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putronase regins. Option exercisable from 50 to 40 montris arier medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase rights. Option exercisable from so to 40 months and medicate centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | requision of Fuctivase rugins. Option evancisation so to 40 montris and medicate certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | r) Acquisition or Futurase regins. Option exercisation so to 40 montris and medicate certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | r) Acquision or Functiase rights. Option exercised in months are medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| contraction or Purchase Rights: Uption exercisable from -so to 46 months and Medicate certification of all
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrast units. Partners have identified 3 additional potential JV locations. | equisition of Purchase rights. Option exercisable from 36 to 46 months after Medicate centrication date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | I) Acquisition or Purchase Rights. Uption exercisable from 36 to 40 months after Medicate certification date. I) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition or Purchase Rights. Uption exercisable from -50 to 46 months after Medicare certrication date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition or Purchase Rights. Uption exercisable from 35 to 46 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putchase Natins. Uption exercisable from -50 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase Highs. Uption exercisable from 36 to 46 months and Medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Functivase rughts. Uption evercisable from 36 to workts and medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition or Putchase Rights: Uption exercisable from 36 to 86 months and Medicare centrication date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition or Purchase Rights. Uption exercisedent from 30 to 40 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| contraction or Purchase Rights: Uption exercisable from -so to 46 months and Medicate certification of all
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrast units. Partners have identified 3 additional potential JV locations. | equisition of Purchase rights. Option exercisable from 36 to 46 months after Medicate centrication date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | I) Acquisition or Purchase Rights. Uption exercisable from 36 to 40 months after Medicate certification date. I) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition or Purchase Rights. Uption exercisable from -50 to 46 months after Medicare certrication date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition or Purchase Rights. Uption exercisable from 35 to 46 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putchase Natins. Uption exercisable from -50 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase Highs. Uption exercisable from 36 to 46 months and Medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Functivase rughts. Uption evercisable from 36 to workts and medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition or Putchase Rights: Uption exercisable from 36 to 86 months and Medicare centrication date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition or Purchase Rights. Uption exercisedent from 30 to 40 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
|) Acquisition or Purchase Rights. Uption exercisation from -so to 48 months after Medicate certification date. | equisition of Purchase rights. Option exercisable from 36 to 46 months after Medicate centrication date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Purchase Rights. Uption exerciseden from 35 to 46 months after Medicare certification date.
I Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putchase Ngms. Uption exercisable from -so to 46 months and Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Purchase Rights. Uption exercisable from -50 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Putchase Natins. Uption exercisable from -50 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase Highs. Uption exercisable from 36 to 46 months and Medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Functivase rughts. Uption evercisable from 36 to workts and medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition or Putchase Rights. Uption exercisable from 36 to workts and medicate centration date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition or Purchase Rights. Uption exercisable from -50 to 46 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
|) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | counstion of Purchase Rights. Option exercisable from 35 to 48 months after Medicare centrication date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 35 to 49 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 35 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 35 to 49 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 35 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase Rights. Option exercisable from 36 to 48 months after Medicarle certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare centrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 35 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 49 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
|) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | counsition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 49 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date.
I Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 35 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Puchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
I Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 35 to 48 months after Medicare certification date.
I Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| equisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coulsifion of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 49 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 35 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option evercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 49 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| execution of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Pathers have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option evercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. |
| execution of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Pathers have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option evercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| c) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. () Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Pathers have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certriciation date. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certriciation date. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certriciation date. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
f) Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certriciation date. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&AEBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certrication date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certriciation date. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certriciation date. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certriciation date. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV focations. |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certriciation date. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | coquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | a) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. b) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. c) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. f) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$5.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicate certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | cquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tutsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | x) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. (i) Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$5.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | cquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | s) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. () Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$5.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | cquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | s) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. () Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$5.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | cquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | s) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. () Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$5.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | cquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | s) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. () Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$5.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |
| e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
() Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | cquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
esolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 |) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations.
 | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. Resolved hot spot with Tulsa Nephrology saving 275 patients, 4 centers, and \$3.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. | e) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date.
 | s) Acquisition of Purchase Rights. Option exercisable from 36 to 48 months after Medicare certification date. () Resolved hot spot with Tuisa Nephrology saving 275 patients, 4 centers, and \$5.5MM in pre G&A EBITDA. Forecasted Yr. 1 census reflects Sapulpa and Southcrest units. Partners have identified 3 additional potential JV locations. |

.

Deal Depot								-		Closed	Closed Deals 2003
Deal Name	Date of Close	State	Market Segment	Purchase Price	(q)	Patients (a)	Centers	RR	Year 3 Cash on Cash	EBITDA Year 1	(b) Price/Pt
2003 Acquisitions											
Rockford - Midway	May-03	Midwestern US	G (3.5%)	\$ 23,0	23,000,000	437	£	21.3%	15.8%	\$ 4,831,784	ŵ
Borri Secours Atri - Saginaw	May-03 Mev-03	A V	B (6.1%) A (9.0%)	\$4'0 2.0	00,000	172	~ +	16.0% 16.7%	15.0%	1,388,153	23.234 27.027
Hurley	Jun-03	W	A (9,0%)	17.3	2,000,000	5 gg	- m	17.1%	15.3%	3 501.953	
Washington Pansh	Jui-03	۲	C (5.7%)	8	850,000	19	~	9.0%	12.8%	109.592	
Dr. Pierce - Franklin Diatysis Center	Aug-03	W	E (4.5%)	1,3	1,350,000	Ř	-	18.6%	15.3%	326,609	
SWORC Owenstrying & Tell City	Sep-03 Oct-03	53	B (6.1%)	2,5	50,000	72	۰ ر	17.0%	16.0%	711.989	35,212
Valuer (c)	Oct-03	AG AG	A (9:0%) F (4.5%)	40 4 4	6,430,000 1 500,000	142	NC	11.4% AM	13.6% NA	1,246.784 NA	
HRG St. Louis	Oct-03	WO	H (2.4%)	<u>,</u>	700,000	88		17.3%	14.6%	83.375	
Eaton Canyon (c)	Oct-03	CA	H (2.4%)	1,1	1,133,400	22	0	AN	AN	AN	
Nebraska Health System	Nov-03	NE / IA	A / B (9.0% / 6.1%)	12,2	12,250,000	292	ŝ	24.8%	19.1%	3,494,085	
Dr. Handelsman - North Georgia Kidney Care Marvland	Nov-03 Dec-03	A G A	E (4.5%) E (4.5%)	00 v	800,000 7 400 000	18	. c	16.1%	14.4%	182,362	44,444
DIALYassist	Dec-03	AZ A	E (6.1%)	1.2	1.250.000	45	4 0	15.1%	15.0% 26.4%	1.910,444 338 646	40,664 28.077
Total		1		\$ 82,5	82,513,401	1,912	52	18.3% (g)	15.5% (g)	\$ 18,	5 44,921 (g)
2003 JVs											
Tustin (JV DeNovo)	Mar-03	CA	H (2.4%)		AA	44	2				
Riverside (HS / JV DeNovo) (f)	Mar-03	CA	H (2.4%)		AN	225	4				
Rockford (JV DeNovo)	May-03	Midwestern US	G (3.5%)		٩N	60	2				
Dr. Buchsbaum (JV DeNovo) Sue City (IV DeNovo)	May-03	Ā ţ	B (6.1%)		AN	8	* 1				
oun ouy (JV DeNovo) Cleveland Clinic (Westin Dialveis) (IV DeNovo)	May-U3 Sec-03	¥ II	B (6.1%) E (0.3%)		AN N	67	•••••				
Michigan (HS / Partial divestiture / JV) (e)	Oct-03	Ĭ	B (6.1%)	2.8	2.850.000	7 4 69	- 0				
East Ft. Lauderdale (JV DeNovo)	Oct-03	F	F (2.2%)		AN	40	-				
Lawrenceburg (Partial divestiture / JV)	Nov-03	z	B (6.1%)	8	800,000	44	F				
Southern Hills (JV DENOVO)	Dec-03	Ž	B (6.1%)	1	AN 2 550 000	42	- ;				
10/61					M),UU	999	9				
2003 Other		:	:								
Childronia Hanning (455.0)	Jul-03		NA NA		AN S	AN S	13				
Cullidren's Hospital (MSA) Gonzales/Atvarado (HS / PD carve-out) (i)	Jul-U3 Anr-03	Washington D.C.	F (2.2%) H (2.4%)		NA 175.000	22 NA	₹~ ∀ N				
Total		5	(or 1	\$	175,000	55	14				
2003 Divestitures											
Sait Lake City (h)	50-INL	UT	B (6.1%)		AN	AN	e				
Total Acondictione Durchase Drive by Oundar											
rotal Acquisitions Furchase Frice by Guarter First Quarter				÷	,						
Second Quarter				ч	47,150.001						
ruru Quarter Fourth Quarter				9, 5 7, 9	3,900,000 31,463,400						
 (a) Includes acute equivalent patients. JV census represents 100% ownership. (b) Purchase Price and EBITDA reflect DaVita's non-rate procontionate ownership interest in the cleat. 	esents 100% ownership ta proportionate owners	the interest in the deal									
(c) Valuer and Eaton Canyon are buy-outs of the minority interest in the JV. For this analysis, pro-rata patients are included - however center numbers are not counted as facilities were arready owned by DVA (Valuer and Eaton Canyon included - Italities rescentively). Purchase minor and cancer to arready	ity interest in the JV. Fe	or this analysis, pro-ra	ths analysis, pro-rata patients are included - however center numbers are not counted as facilities were already owned by DVA (Variner and Eaton Canyon included 2 and maintained or the included - canyon included 2 and maintained or the included - canyon counted - canyon co	Nowever center num	bers are not co	ounted as facilities	were aiready or	whed by DVA (V.	ainer and Eaton Can	yon included 2 ar	ŭ
	Removed to a money							neinhiaich hnion	on ir im nika sonial shr	i upuni.	
(d) Acquisition of Baxter's Vascular Access Program	d buildout contro of 3 odd	itional do acua factitu	525)	in and C & C BITD & 11 foodi	and the second	010 046 040 V	5. otoo 100 - 111 -	n V tooto soto soto v	, 44 for an 100000 \$	c

(d) Acquisition of Baxler's Vascular Access Program
(e) Includes pro rata interest of 11 existing facilities and buildout costs of 2 additional de novo facilities. Resolved hot spot saved \$17.1MM in pre G&A EBITDA, 11 facilities, and renewed 1.076 DaVita patients. 69 patients reflect Year 1 census of the 2 de includes pro rata interest of 11 existing facilities and buildout costs of 2 additional de novo facilities in C (5 7%) market segment, and Gand Blanc facility in A (9 0%) market segment.
(e) Includes pro rata interest of 11 existing facilities in E (4.5%) market segment. Yisliants and Jackson facilities in C (5 7%) market segment, and Gand Blanc facility in A (9 0%) market segment.
(f) Transaction contemplated derovos in Riverside, Norco, Hemet, Chino, Banning, and Lake Elsinore. To date, Lake Elsinore opened, Norco, Riverside, and Vicatipa derovos in process. Census figures represent Lake Elsinore census as of 7/04 + Year 13 derovos. Includes a 10 year (+1 year tail) MDA renewal. Also includes 750 renewed DVA patients and \$11.4MM saved pre G&A EBITDA.

(g) Weighted average based on Purchase Price.
(h) Legal settlement whereby 2 of the 3 factities were closed down
(i) Resolved hot spot saving 217 patients and \$1.9MM in pre G&A EBITDA. DaVita PD program had 35 patients at the time of transaction

pot	
Del	
Deal	

2004	
ΥTD	
Deals	
Closed	
<u> </u>	l

1 1	(1) 2173, 2173, 2174, 21	Deal Name	Date of Close	State	Market Segment	Purchase Price		(8) Patients (b)	Centers	IRR	Year 3 Cash on Cash	EBITDA Year 1	increments (a) CMLs	incremental Unit Mix (By # of Facilities) CMLs CMLs Folitical High Hipper Mix	f Facilities) High Hipper Mix	Price/Pt
(1) (0 1 <th1< th=""> <th1< th=""> <th1< th=""></th1<></th1<></th1<>									•	I					
(1) ((1) (1) <td>Kidney Care lowa</td> <td>Mar-04</td> <td>Ā</td> <td>A/B (9.0%/6.1%)</td> <td>5 14</td> <td>000 000</td> <td>346</td> <td>c</td> <td>34.76</td> <td></td> <td></td> <td>c</td> <td>L</td> <td>L</td> <td></td>	Kidney Care lowa	Mar-04	Ā	A/B (9.0%/6.1%)	5 14	000 000	346	c	34.76			c	L	L	
M 1	0 0	Long Beach Memonal (Acutes)	Mar-04	CP 1	H (2,4%)	<u>+</u>		9 E		94./.1.7 742.94				лc	<u>م</u>	
10% 10% <td>10% 10%<td>Battle Creek</td><td>Apr-04</td><td>W</td><td>A (9.0%)</td><td>5.</td><td>400,000</td><td>3 <u>6</u></td><td></td><td>15.2%</td><td>13.4%</td><td>777 633</td><td>Þe</td><td></td><td></td><td>21,283 53,821</td></td>	10% 10% <td>Battle Creek</td> <td>Apr-04</td> <td>W</td> <td>A (9.0%)</td> <td>5.</td> <td>400,000</td> <td>3 <u>6</u></td> <td></td> <td>15.2%</td> <td>13.4%</td> <td>777 633</td> <td>Þe</td> <td></td> <td></td> <td>21,283 53,821</td>	Battle Creek	Apr-04	W	A (9.0%)	5.	400,000	3 <u>6</u>		15.2%	13.4%	777 633	Þe			21,283 53,821
1 N N N N 0	1 N	Dr. Bravo Cross	Apr-04	¥۲	B (6.1%)	3	400,000	53	-	16.0%	14.0%	415,024	0	0	-	45,283
1000000000000000000000000000000000000	1000000000000000000000000000000000000	Bogalusa	May-04	¥ ¥	C (5 7%)		503,993 120,000	A R	.	NA 17 64	NA NA	AN ac	۹ ۷	00	0 0	AN 20 00
17.% 17.% <th< td=""><td>31.% (1.0.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1</td><td>Big Sandy (e)</td><td>Jun/Dec-04</td><td>KY and WV</td><td>A/C (9.0%/5.7%)</td><td>°.</td><td>224,000</td><td>154</td><td>- 4</td><td>16.7%</td><td>14.9%</td><td>1,289,708</td><td>0</td><td>00</td><td>5 ന</td><td>33,971</td></th<>	31.% (1.0.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	Big Sandy (e)	Jun/Dec-04	KY and WV	A/C (9.0%/5.7%)	°.	224,000	154	- 4	16.7%	14.9%	1,289,708	0	00	5 ന	33,971
11.7 11.7 12.3 12.00 1	11 11<	Hillmed	Jun-04	SS	D (4.4%)	20	732,000	8.30	·- (31.2%	23.7%	203,184	· 1	0	0	24,400
11 12 13<	1105 1105 1105 1105 1105 1105 1105 1105	RCM	Jul-04	5	B/E (6.1%/4.5%)	17.	500,000	509 700	n m	10.1%	14.2%	4,245,379 2 362 336	0 0	00	сл г	84,426 65 200
373% 10% 20% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 10% 11% 10% 10% 0 0 0 10% 11% 10% 10% 0 0 0 0 11% 10% 0 0 0 0 0 11% 10% 0 0 0 0 0 11% 11% 0 0 0 0 0 0 11% 11% 0 0 0 0 0 0 11% 11% 0 0 0 0 0 0 11% 12% 10% 0 0 0 0 0 11% 10% 0 0 0 0 0 0 11% 10% 0 0 0 0 0 0 11% 10% 0 0 0 0 0 0 10% 0 0 0 0 0	132% 10% <td>Innovative Comber Island Emers (6</td> <td>Jul-04</td> <td>¥</td> <td>A/B (9.0%/6 1%)</td> <td>13,</td> <td>100,000</td> <td>199</td> <td>5</td> <td>11.9%</td> <td>13.1%</td> <td>1,960,073</td> <td>· ~</td> <td>0</td> <td>- 17</td> <td>65,829</td>	Innovative Comber Island Emers (6	Jul-04	¥	A/B (9.0%/6 1%)	13,	100,000	199	5	11.9%	13.1%	1,960,073	· ~	0	- 17	65,829
30.35 (1.0) 10.00 (1.0)	0.03 (N) 0.03 (N) 0.03 (N) 0.0 (N)	Savannah/Statesboro (g)	Aug-04 Aux/Nov-04	58	H (2.4%) R/D (6.1%/4.4%)	- 0	,590,000 146,507	116	~ ~	23.2%	19.0%	428,458	0,	0 0	0,	13,707
MM MM<	Mill (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Chicago Heights (Partial Acquisition/JV) (h)	Aug-04	7	B (6.1%)	o ni	754.000	8	• -	26.2%	19.3%	6, rde, ed.0 8.31, 697	- c			46,7U0 27.540
8 4% 110% 15,443.322 4 0 16 6,373 170% 173% 10,943 0 0 0 1 1 173% 123% 10,333 0 1 0 <	6 1% 110% 15,40,302 1 0 16 6,33 10% 12% 0,043 0<	Eastmont (Acquisition of Remaining Interest) (i)	Sep-04	ð.	H (2.4%)	÷	137,380	100	٢	NA	AN	¥	0	0	- 0	11,374
10% 1/2% 1/2% 1/2% 0 </td <td>10% 12% 10% 0<!--</td--><td>Physicians Diatysis, Inc. (J)</td><td>Sep-04</td><td>AL. CT, MA,</td><td>NA</td><td>150,</td><td>000,000</td><td>1,757</td><td>24</td><td>8.4%</td><td>11.0%</td><td>15,849,362</td><td>4</td><td>0</td><td>16</td><td>85,373</td></td>	10% 12% 10% 0 </td <td>Physicians Diatysis, Inc. (J)</td> <td>Sep-04</td> <td>AL. CT, MA,</td> <td>NA</td> <td>150,</td> <td>000,000</td> <td>1,757</td> <td>24</td> <td>8.4%</td> <td>11.0%</td> <td>15,849,362</td> <td>4</td> <td>0</td> <td>16</td> <td>85,373</td>	Physicians Diatysis, Inc. (J)	Sep-04	AL. CT, MA,	NA	150,	000,000	1,757	24	8.4%	11.0%	15,849,362	4	0	16	85,373
100 N 04333 N 04333 N 0 N N 5,14 1,13 1,14 1,13 1,14 1,14 1,14 1,14 1,14 1,14 1,14 1,14 1,14 1,14 1,14 1,14 1,14 1,14 1,14 1,14 1,14	1000 1035 100 1035	New Orteans Metropolitan Dialvais	Oct-04	<	G (3.5%)		702 000	c	•	16,74	10 C F F	1003 011	c	c	¢	
11.75 15.35 <th< td=""><td>11.35 1.1.75 11.35 1.1.75 11.35 1.1.75<</td><td>Contract Dialysis (Acutes) (k)</td><td>Oct-04</td><td>ΪŽ</td><td>G (6.1%) B (6.1%)</td><td></td><td>281.500</td><td>9</td><td>- c</td><td>17.0%</td><td>94.77.71</td><td>(18,000) FAD 4E1</td><td></td><td>- -</td><td>5</td><td>AN A</td></th<>	11.35 1.1.75 11.35 1.1.75<	Contract Dialysis (Acutes) (k)	Oct-04	ΪŽ	G (6.1%) B (6.1%)		281.500	9	- c	17.0%	94.77.71	(18,000) FAD 4E1		- -	5	AN A
17.3% 1.3% 0 2 1.0%/16 0	174% 132/10 0	Comprehensive Renal Care of Northiake (SpectraCare)	Nov-04	GA	B (Hidh B) / 6.1%	2	400.000	61	, .	18.3%	15.3%	425,280		Ęc	£ -	#21.0
11.7% (1) 12.3% (1) 5 37.088,761 0 5 3 74.560 11.7% (1) 12.3% (1) 5 37.086,761 0 5 3 74.560 11.7% (1) 12.3% (1) 5 37.086,761 5 3	11.7% (1) 12.3% (1) 3 3.108,701 0 5 30 3 74,500 11.7% (1) 12.3% (1) 5 3.108,701 0 5 30 3 74,500 11.7% (1) 12.3% (1) 5 3.108,701 0 5 30 3 74,500 11.7% (1) 12.3% (1) 5 3.108,701 6.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 11.0% (2) 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 11.0% (2) 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 5.0% 5.0% 5.0% 5.0% 11.0% (2) 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 5.0% 5.0% 20.0% (2) 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% (2) 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% (2) 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% (2) 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% (2) 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0% 10.0% 5.0%	Down River Kidney Center	Nov-04	W	E (Med B) / 4.5%	ເດັ	500,000	148		17.4%	14.2%	1,902,176	00	00	- 0	04,189 64,189
 e. C.M.s and Follocal Gaals are defined by Transaction Devotors Happi Hopse Mar as following as following and an event Band A or El 60 Nr. or 1 Nr. Jamag use and Montana are the privring prioritial states 	 e. C.M.S. and Political douts are defined by Transaction Dependence e. Bigh Highor Max are defined as Ruinas are file priving political stees e. are and Montana are file priving political stees a. are and Montana are file priving political stees 	Total					841,470	3,957	3	11.7% (!)	'ε		•	2	36	74.566
· · · ·	· · ·	200 1000									2		•	•	8	
Percentersts		Brighton (Western Nephrology) (JV DeNovo)	Feb-04	co	C (5 7%)		AN	ų,	-				Chill o and Boliton	t dente are defined t	his Transaction	
	· · ·	Kannapolis (Partial DivestitureJV)	Feb-04	Q N	B (6.1%)		300,000	<u>8</u> 2					- Critic and Foundation Directors	hourson and enson in	ny reasonation	
egeoments.	Bigreements	DPC (owa (JV DeNovo) North Tutes/Greenwood / 8/ Dobloue)	Mar-04	₹	A/B (9.0%/6.1%)		¥ Z	121	2				 High Hipper Mix is 	s defined as facilities	s which fall within	
• egeoments.	agreements inflerest in the centers	Numit I user of een wood (3Y trentow) Summit/Dr. Haastrom (JV DeNovo)	Mar-04	5č	B (6.1%)		A N	43 36					the Bain A or B (0	0% or 6 1%) rating		
Cynthyrgyner (amerillander) and amerillander and amerillander <thand ame</thand 	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Tidewater Kidney Services (HS/JV DeNovo)	Jun-04	× *	B (6.1%)		V V	96 04					- 10WB BUG WOULDUP	a are the primary po	write an array of	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Dr Magnus-Lawson (Downtown Houston) (JV DeNovo) (m)	Jun-04	¥	C (5.7%)		NA	98								
Christian (V) (Krick (Herning) Kristian (Herning) <td>$\begin{array}{c ccccccccccccccccccccccccccccccccccc$</td> <td>Sapuipa (Partial Divestiture/JV) Fartem / IV DeNovol (m)</td> <td>10-04</td> <td>₹¢</td> <td>B (6.1%) D (6.4%)</td> <td></td> <td>AN .</td> <td>8</td> <td>÷</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Sapuipa (Partial Divestiture/JV) Fartem / IV DeNovol (m)	10-04	₹¢	B (6.1%) D (6.4%)		AN .	8	÷							
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Charge, V() (New (i)) New (i) New (i) </td <td>Dr. Hines (JV / MDA Renewal)</td> <td>No-Yor</td> <td><u> </u></td> <td>B (6.1%)</td> <td></td> <td>A N</td> <td>275</td> <td>- 0</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Dr. Hines (JV / MDA Renewal)	No-Yor	<u> </u>	B (6.1%)		A N	275	- 0							
Matrix for function (1) Desite	Constrained Constrained <thconstrained< th=""> <thconstrained< th=""></thconstrained<></thconstrained<>	Durango (JV DeNiovo)	Nov-04	83	B (6.1%)		MA	40	-							
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	TotalDecideDecid	Est Grove (JV Letvovo) (n) Muskogee (Partial Divestiture)	Dec-04	ð ð	H (2.4%) A (9.0%)		NA NA	54 N 4								
TotalTotal 3 <	Total \mathbf{i}	Southcrest (Partial Divestiture/JV)	Dec-04	ð	B (6.1%)		AN	ž	AN AN							
Add Descriptions Multiply (March Part) Multiply (March Part) <thm< td=""><td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td><td>Total</td><td></td><td></td><td></td><td></td><td>300,000</td><td>795</td><td>16</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></thm<>	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Total					300,000	795	16							
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	2004 Divestitures / Other														
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c} \label{eq:constraints} eq:cons$	North Philly Panama City (Manacement Accessment)	Mar-04	PA D	G (3.5%)	÷.	300,000	107								
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Proversity 14 hypertension Accor (MDA) on (M) Octol MO G(15) MO Proversity 12 hypertension Accor (MDA) on (M) Doctol MO G(15) MO Proversity 12 hypertension Accor (MDA) on (M) Doctol MO G(15) MO 1 start 20-relation (Falling Area) Doctol MO G(15) MO MO 1 start 20-relation (Falling Area) Doctol MO G(15) MO MO 1 start 20-relation (Falling Area) Doctol G(15) MO MO MO 1 start 20-relation (Falling Area) Doctol G(15) MO MO MO 1 start 20-relation (Falling Area) Doctol G(15) MO MO MO 1 start 20-relation (Falling Area) Doctol G(15) MO MO MO 1 start 20-relation (Falling Area) Doctol G(15) G(15) MO MO 1 start 20-relation (Falling Area) Doctol G(15) G(15) MO MO 1 start 20-relation (Falling Area) Doctol G(15) G(15) G(15) G(15) 1 start 20-relation (Falling Area) Doctol G(15) G(15) G(15) G(15) 1 start 20-relation (Falling Area) Doctol G(1	Conmed (Acute Contract)	to-unp	L AO	C(5.7%)	2	NOU,UUU	e Se	N *							
Construction Nording Month Nordin Month Nording Month Nording Mo	$ \begin{array}{c} \label{eq:constraints} \\ \mathematical constraints and a Volks, which is a constraint of the constraints of the constra$	Neptrology & Hypertension Assc. (MDA only)	Oct-04	0 W	B (6.1%)		NA	51								
All and Diversiment (MC) (10) Deckin C, MC) (11) Deckin C, MC (12) MC	In the many channel (Hetsper (MOA)(i) Decidi Ci MAN)(i) Decidi Ci MAN) All man Develatione (Hetsper (MOA)(i) Decidi Ci MAN)(ii) Decidi Ci MAN All Acquinitores Parchael (Hetsper (MOA)(i) Decidi Ci MAN)(iii) Table (Iii) MAN Fat Activitiones Parchael Price by Channel Fat Acquinitores Parchael Price Price Channel Fat Acquinitores Parchael Price Price Channel Fat Acquinitores Parchael Price Channel Fat Acquinitores Parchael Price Price Channel Fat Acquinitores Parchael Price Channel Fat Acquinitores Parchael Price Price Channel Fat Acquinitores Parchael Price Price Channel Fat Acquinitores Parchael Price Channel Fat Acquinitores Parchael Price Channel Fat Acquinitores Parchael Price Price Parchael Fat Acquinitores Parchael Price Parchael Price Parchael Price Price Parchael Fat Acquinitores Parchael Price Parchael Price Parchael Fat Acquinitores Parchael Price Parchael Fat Acquinitores Parchael Price Parchael Price Parchael Price Parchael Fat Acquinitores Parchael Price Parchael Price Parchael Fat Acquinitores Parchael Parchael Price Parchael Parchael Fat Acquinitores Parchael Parchael Parchael Fat Acquinitores Parchael Parchael Parchael Fat Acquinitores Parchael Parchael Parchael Parchael Fat Acquinitores Parchael Parchael Parchael Parchael Parchael Fat Acqui	Frovo (notspot) East Dearborn (Partial Divestiture and JV DeNovo)	Nov-04	5 2	D (4.4%) F (4.5%)	-	NA 302 116	88	- 0							
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Hand Dordlander Hand Dordlander Fraudrich Keinswan) Des old GA E (4.35) MA 36 MA Table ULCU, N(MC) Reason) Des old GA E (4.35) MA MA MA Table ULCU, N(MC) Reason) Des old GA E (4.35) MA MA MA France ULCU, N(MC) Reason) Des old GA E (4.35) MA MA MA France ULCU, N(MC) Reason) Des old GA E (4.45) MA MA MA France ULCU, N(MC) Reason) Table Reason Table Reason Table Reason Table Reason Table Reason Table Reason France Reason E (4.5) Table Reason Table Reason Table Reason Table Reason Table Reason Table Reason France Reason E (4.5) Table Reason Table Reason Table Reason Table Reason Table Reason Table Reason France Reason E (4.5) Table Reason Table	Los Prados - Pharma (Acquisition)	Dec-04	A O	NA		181,011	NA N	NA.							
Total Acquirations Purchase Price by Quarter Enclose Price Price <t< td=""><td>Text Acquirations Purchase Price by Quarter Euclide Price Euclide Price Euclide Price Field Acquiration Service Price Price 3 44000.000 5 55/130 Field Acquire 5 54/300 5 55/300 5 55/300 Field Acquire 5 54/300 5 5/300 5</td><td>Atlanta Divestiture / Dr. Cleveland (Hotspot / MDA) (o) Harbor UCLA (MDA Renewal)</td><td>Dec-04 Dec-04</td><td>A A O O</td><td>E / 4.5% H (2.4%)</td><td></td><td>A N A N</td><td>368 NA</td><td>A N A</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Text Acquirations Purchase Price by Quarter Euclide Price Euclide Price Euclide Price Field Acquiration Service Price Price 3 44000.000 5 55/130 Field Acquire 5 54/300 5 55/300 5 55/300 Field Acquire 5 54/300 5 5/300 5	Atlanta Divestiture / Dr. Cleveland (Hotspot / MDA) (o) Harbor UCLA (MDA Renewal)	Dec-04 Dec-04	A A O O	E / 4.5% H (2.4%)		A N A N	368 NA	A N A							
Fract Andream Fraction by datated and the second current fraction in the second current fract	ran Any Antonia Providence in a constraint of the constraint of th	Total A contractions Durchase Dates in Octave						ļ								
Second Quarter 15,379,883 5,0146 Thrid Quarter 15,379,883 5,0146 Torunt Career 220,697,977 5,74,833 Funch Quarter 12,973,500 5,44,633 Funch Quarter 12,973,500 5,44,633 Funch Quarter 10,100,000,000,000,000,000,000,000,000,	Second Caurer The Cound Caurer The Cound Caurer The Cound Caurer The Cound Caurer Fund Caurer Fund Caurer Fund Caurer (1) Premeare not Relit for A reflect Davita's priving a propertionate and the second to the second caurer (1) The Meet active appropriate of the second to the second to the second to the second to the second caurer (1) Correlates prive leader (1) The Antime The The Second to the	First Quarter					4~	FICE/PT								
Third Quarter 220.067.97 57.93.76 Fourh Ouarter 12.373.500 5.4.433 Fourh Ouarter 12.373.550 5.4.433 (a) Purchase Price and EBITDA refeet DaVita's pro rata proportionate ownership interest in the deat 12.373.550 5.4.433 (a) Purchase Price and EBITDA refeet DaVita's pro rata proportionate ownership interest in the deat 12.373.550 5.4.433 (a) Purchase Price and EBITDA refeet DaVita's pro rata proportionate ownership interest in the deat 10.1003 back downership 5.4.433 (c) Hond Sead de averal resulting on the statism contracts in 10.1003 back downership 5.4.433 (c) Hond Sead de averal resulting on the assumption profession of the current program at a hospital. The entities of the current program at a hospital. The entities of the current program at a hospital. The entities of the current invession of the current program at a hospital. The entities of the current program at a hospital. The entities of the current invession in whitekburg facility closed in forone. The entities of the current investory the hold of totals. The entities of the current area accuration of Chinage reference in a second reference concerts associated with tab business. 10.4416 (f) Arquitistic of Cash in Cash in Cash in Cash in the business. (f) Arquitistic of Cash in Cash in Cash in Cash in the current is a sociated in tub. 2.4.43 (f) Arquistic of Cash in Cash in Cash in the current is a social of the field concerts of the current second and to current second and to curr	Tind Guarder 220.667.07 5,79.378 Fourth Outarter 12,973.500 5,44.63 Fourth Outarter 12,973.500 5,44.63 Fourth Outarter 12,973.500 5,44.63 Fourth Outarter 10,100 descriptions are reserved in 0,100 konneshy 12,973.500 5,44.63 (1) Includes acchire and EBITDA refeet DaVia's promas preserved in 0,400 konneshy 12,973.500 5,44.63 (1) Include such acchire and manner preserved in 0,400 konneshy 10,400 10,400 (1) Include such acchire and manner preserved in 0,400 konneshy 10,400 10,400 (1) Include such acchire and manner preserved in 0,400 konneshy 10,400 10,400 (1) Include such acchire and manner th ropportion and manner through and the calce program manner through and the calce progr	Second Quarter					• ••	40,146								
 Purchase Price and EBITDA reflect DaViars pro rata proportionate ownership interest in the deal Purchase Price and EBITDA reflect DaViars pro rata proportionate ownership Purchase active emptial patients: V events represents 100% when exhibits Purchase active emptial manuality of events in the meaning ownership Purchase active emptial manuality of events in the meaning ownership Purchase active emptial manuality of events in the meaning ownership Purchase active emptial manuality of events in the meaning ownership Purchase active manuality and active program at a hospetial. Therefore, no center was notated in totals Patient active active in separate transactions in which Savarnach octaed in neurons active program active actinet active active active active active active active active a	 Pirchase Price and EBITDA reflect DAVias from tara proportionate owneithy interest in the deal. Pirchase Price and EBITDA reflect DAVias from tara proportionate owneithy interest in the deal. Purchase price based over an ennour pactor from assuming contract is not leminated. The maximum amount payable is 5660K. Purchase price based over an ennour pay dover line assuming contract is not leminated. The maximum amount payable is 5660K. Purchase price based over an ennour pay dover line assuming contract is not leminated. The maximum amount payable is 5660K. Preve efforts the properties of the four BPS Savidy facilities called program at an equivalent payable is 5660K. The word fuel our BPS Savidy Survey from a to Posptal. The maximum amount payable is 5660K. The word fuel our BPS Savidy Survey Machines. The word fuel our BPS Savidy survey facilities called program as an equivalent of the pay treactions called program. The word fuel our BPS Savidy Survey Machines. The word fuel our BPS Savidy Survey Savidy Survey Savidy and Saster and Savid on the savid in Savid and Savid and savid savid in August 2004 and Salteshout of threaded in a Via partners for this dual are inclusive of all four Bpg Sandy facilities. Advice RIPS A fourthy and the exceeding and the Savid savid facilities of the savid s	Third Quarter Fourth Quarter				12.6	69 69	79,378 54,453								
 (1) Or black prive an environment of a vortine program at a hospital. Therefore, no center was indicated in totals: (1) Or black prive an environment of a vortine program at a hospital. Therefore, no center was indicated in totals: (1) A prive of the force and environment of vortine program at a hospital. Therefore, no center was indicated in totals: (1) A prive of the force and environment of vortine program at a hospital. Therefore, no center was indicated in totals: (1) A prive of the force and were closed in separate transactions in which searenable closed in August 2004. The numbers for this deal are inclusive of all four Big Sandy facilities. (1) Medie and acquise for closed in separate transactions in which searenable closed in August 2004 and Statesboro was closed in November 2004. (1) Resolution of threatened ligations: A partnets privetably Dark a course. (2) A purption of threatened ligations of the partnet with tab business. (3) A curuation of 75% of business accounder with tab business. (4) A quustion of 75% of business accounder with tab business. (4) A quustion of 75% of business accounder and and states in which shares accounder and and states and and and and a second of MUDAs for 10 by howed enters. (4) A duustion of 75% of business accounder and and and a 15 patient and 74 at 15 PTDA, reflect and 70 at 15 PTDA,	 Clore the force shower an examined managed. The refore, no caller was minuted and the manufacture of an acute program at a hospilar. Therefore, no caller was minuted and the manufacture of an acute program at a hospilar. Therefore, no caller was minuted in trades. Clore of the fourd a Reinval and acute program at a hospilar. Therefore, no caller was minuted in trades. Annue of the fourd a Reinval and acute program at a hospilar. Therefore, no caller was minuted in trades. Annue of the fourd a Reinval and a cute program at a hospilar. Therefore, no caller was minuted and the acute of the fourd by distributed in trades. Annue four of Chicago Heights, resulting in a V panneship whereby Derivate owns of Statesborn was closed in November 2004. The numbers for this deal wave closed in which Savarnab closed in August 2004 and Statesborn was closed in November 2004. Recouldon of the advante indigato. Recouldon of Chicago Heights, resulting in a V panneship whereby Delivita owns 51% and partners own 49%. Recouldon of Chicago Heights, resulting in a V panneship whereby Delivita owns 51% and partners cond. Recouldon of Chicago Heights, resulting in a V panneship whereby Delivita owns 51% and partners own 49%. Recouldon of Chicago Heights, resulting in a V panneship whereby Delivita owns 51% and partners own 49%. Recouldon of Chicago Heights, resulting in a V panneship whereby Delivita owns 51% and partners own 49%. Recouldon of Chicago Heights, resulting in a V panneship whereby Delivita owns 51% and partners own 40%. Recouldon of Chicago Heights, resulting in a V panneship. Recouldon of Chicago Heights, resulting in a V panneship, whereby Delivita owns 51% and partners own 49%. Recouldon of Chicago Heights, resulting in a V panneship. Recouldon of Chicago Heights, resulting in a V panneship, and the Recomber 2004 and	(a) Purchase Price and EBITDA reflect DaVias provide prop (b) Purchase Price and EBITDA reflect DaVias provide prop (b) Purchase and equivalent patients. JV census represents (b) Purchase and equivalent patients. JV census represents	ontionate ownership 100% ownership.	interest in the deal			•									
 The twenter Intruption Substrations is the NAMG. The twenter Intruption Substrations is the NAMG. The twenter Intruption Substrations is the NAMG. The twenter Intrust of the Seal were closed in sequence in a Wath NAMG. Made a ratial acquisition of Chicago Pregnit are associated with a business. Materia (RIC, Cash on Cash, 'T (EIITD) in the economics associated with a business. Acquisition of T5% of business associated with a business. Acquisition of 75% of business associated with a business. Magines Lawson meetal on Functionation and Via related 100% of business. Magines Lawson meetal on Factoria. Patient and Year 1 EBITDA reflect 100% of business. Magines Lawson meetal on Factoria. Patient and Year 1 EBITDA reflect 100% of business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of 75% of business associated with a business. Acquisition of acquisition of hostons invested in the Each busine activintion of MUAs for 100% of the acduis of poly-owned c	 The user all human discrete fueld of SVARS, VI with NAMG. The metal metal provide Riversise. LLC (66%40%, JV with NAMG.) The metal metal registric metal and solver registric metal and solver registric metal and solver registric metal and solver registric metal metal and solver registric metal re	(c) Functase price tasked over an earnout part over time assi (d) Long Beach Memorial was an acquisition of an acute prog (e) Three of the four Big Sandy facilities closed in June 2004.	uming contract is not gram at a hospital. T whereas the Whites	i terminated. The m herefore, no center sbura facility closed	aximum amount payable was included in totals. in December 2004. The n	s \$660K. umbers for this de	al are inchisive o	if all four Rio Sam	dv facilities							
 (t) Made partial acquisition of Chicago Heapits, resulting in a V partnership whereby DaVita owns 51% and partners own 49%. (i) Menca (Marc Cash on Cash, Y T EHITDA) include economics associated with tab business. (i) Menca (Marc Cash on Cash, Y T EHITDA) include economics associated with tab business. (i) Menca (Marc Cash on Cash, Y T EHITDA) include economics associated with tab business. (i) Menca (Marc Cash on Cash, Y T EHITDA) include economics associated with tab business. (i) Menca (Marc Cash on Pucies) associated with tab business. (ii) Menca (Marc Cash on Cash, Y T EHITDA) include economics associated with tab business. (i) Menca (Marc Cash on Pucies) associated with 2 partners invested in the Downlown Houston de novo. Each of the 4 doctors signed new 15-mile non-compete agreements. (i) Magues Lawson invested in the East Houston de novo and Fadem and Nis 2 partners invested in the Downlown Houston de novo. Each of the 4 doctors signed new 15-mile non-compete agreements. (i) Magues Lawson invested in the East Houston de novo and Fadem and Nis 2 partners invested in the Downlown Houston de novo. Each of the 4 doctors signed new 15-mile non-compete agreements. (i) Magues Lawson invested in the East Houston of MOAs for 10 wokly-owned centers. (i) As a separate transaction include resolution of holsoly via actention of MOAs for 10 wokly-owned centers. 	 (h) Made partial acquisition of Chicago Heapits, resulting in a V partnership whereby DaVita owns 51% and partners own 49%. (h) Mators (HRC, Cash on clash), Yr (EHITDA) include economics associated with tab business. (i) Acquisition of 75% of business associated with 2b business. (i) Acquisition of 75% of business associated with 2b business. (ii) Acquisition of 75% of business associated with 2b business. (ii) Acquisition of 75% of business associated with 2b business. (ii) Acquisition of 75% of business associated with 3b business. (ii) Magnust associated with 9 acute contracts. Patent and Year 1 EBITDA reflect 100% of business. (ii) Magnust associated with 9 acute contracts. Patent and Year 1 EBITDA reflect 100% of business. (ii) Magnust associated with 9 acute contracts. Patent and Year 1 EBITDA reflect 100% of business. (ii) Magnust associated with 16 acute modifies is 20 patients, physicians have an opportunity to purchase up to 12.5% quiltient and his 2 partners, which DVAs for 10 wholly-owned centers. (i) Resolution of hotsport with Capital Neptriclogy via extention of MDAs for 10 wholly-owned centers. (i) Resolution of hotsport with Capital Neptriclogy via extention of MDAs for 10 wholly-owned centers. (i) Resolution of hotsport with Capital Neptriclogy via extention of MDAs for 10 wholly-owned centers. (i) Resolution of hotsport with Capital Neptriclogy via extention of MDAs for 10 wholly we are patients. Physicians have an opportunity to purchase up to 12.5% quilty inferest in the context via signed MDA. Total errors of the 5 facilities is 420 patients. Physicians have an opportunity to purchase up to 12.5% quilty inferest in the context. 	(f) Acquired through DaVita-Riverside, LLC (60%/40% JV with (g) The two facilities of this deal were closed in separate trans	h NAMG). sactions in which Sa	vannah ckosed in A	joust 2004 and Stateshorr	was closed in No	vember 2004	0								
nde	n de 116.	(h) Made partial acquisition of Chicago Heights, resulting in a (i) Decodution of theorem difference.	JV partnership when	reby DaVita owns 5	1% and partners own 49%											
n de	ab nade Stander	 Metrics (IRR, Cash on Cash, Yr 1 EBITDA) include econom 	nics associated with	tab business.												
nde	n de îts	(k) Acquisition of 75% of business associated with 9 acute co. (I) Weighted average based on Purchase Price.	atracts. Patient and	Year 1 EBITDA ref	fect 100% of business.											
(b) So-a starbard starbard on included resolution of horizont with Gathian Paperborn of MADs for 10 Moly-owned centers	(n) As a separate transaction, included resolution of holes of with Gapital Nephrelogy via actention of MUAs for 10 wholly-conned centers (o) Resolution of hotspot via signed MDA. Total census of the 5 facilities is 420 patients, of which DVA's starte is 366 patients. Physicients have an opportunity to purchase up to 12.5% equity interest in the centers	(n) Magnus-Lawson invested in the East Houston de novo an	nd Fadem and his 2	pertners invested in	the Downtown Houston d	Provo Each of the	he 4 doctors sign	ed new 15-mile n	on-compete agre	sements.						
	(u) resolution incision was signed mLM. I dial official software a transmission withing the station is Physicians have an opportunity to purchase up to 12.5% equily inferest in the centers.	(n) As a separate transaction, included resolution of hotspot w	vith Capital Nephrok	sgy via extention of	MDAs for 10 wholly-owner	1 centers.			,							

Case 1:09-cv-02175-WJM Document 35-1 Filed 12/23/11 USDC Colorado Page 59 of 97

Closed Deal Activity 060509 printable.xis

9/10/2008

<u>6</u>	
Del	1
<u>ea</u>	
ă	

2005	
Ę	
Deals	
Closed	

ties) Itbesv Mix Price/Pt Txin FY05	 41 47 41 47 41 47 5 1 447 5 1 20 5 1 20 5 1 20 5 1 20 5 1 21 5 1 21 5 1 25 5 1 2 2 25 5 1 2 2 2 25 5 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	34 5 70.280 (e) 186.058 23 5 71.725 (e) 144.586 naecton 1.68 within sistes	
incremental Unit Nix (6v # of Facilities) CMLa Political Hide Hisee Mix	00000000000000000000000000000000000000	5 0 34 CHALS and Political deals are defined by Transaction Devotors Devotors Devotors that a defined as facilities which fail within the Ban A or B (9) Vis of 5 1%, laring Towa and Montana are the primary political states	
EBITDA EBITDA Year 1(a)	 342,499 342,499 300,129 420,031 420,031 420,033 420,033 420,033 420,255 469,531 469,535 469,535	13.5% (e) 5 28.722.820 13.7% (e) 5 28.421.880 25.421.889 7.70	
Year 3 IRR Cash on Cash	81 82 82 82 82 82 82 82 82 82 82 84 82 84 84 84 84 84 84 84 84 84 84 84 84 84	15.3% (e) 13. 16.4% (e) 13.	
(b) Centers		39	2
Purchase Pri <u>ce</u> (a) <u>Patients</u> (b)	1575 000 38 350 0000 16 350 0000 16 1600 0000 40 192 00000 40 27 200 0000 41 192 0000 42 7 500 0000 42 7 500 0000 42 7 500 0000 43 7 500 0000 43 7 500 0000 43 7 800 000 43 8 400 000 84 19 000 000 84 19 000 000 85 2 500 000 164 19 000 000 85 2 500 000 164 10 000 000 85 2 500 000 164 10 000 000 85 11 000 000 85 11 000 000 85 11 000 000 85	166. 103. 931 2.063 138. 603. 631 2.23 138. 603. 631 2.23 1.5680. 600 1.5680. 600 1.5680. 600 1.23 1.5680. 600 1.23 630. 600 1.23 630. 600 1.23 630. 600 1.33 641 1.23 642 0.000 1.46 1.23 1.55 1.33 1.40 1.41 1.41 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.45 1.4	ti\$2.1 million) ₀ TX
Market Segment	H (2.4%) D (4.4%) D (4.4%) A (9.0%) A (9.0%) A (19.0%) B (1.5.7%) A (19.0%) B (1.5.7%) B (1.5.7%) A (19.0%) A (19.0%	Н (4 5%) Н (2 5%) Н (2 5%) Н (2 5%) Н (2 5%) Н (2 6%) Н (2	e 10 m/ Jeal I on de novo model. Is the divestiture of 70% of East
e State	⋧⋬₽╏⋩⋸⋐ [⋤] ⋾⋛⋩₽⋷౾೫₽⋩⋩⋧⋧	≥3553555555555555555555555555555555555	no ship stiterest in the c in numbers are based in numbers are based in a conclude fine centers are loca
Date of Close	Mar 40 Mar 40 Ma	(Inice) Jan-05 Jan-05 Mar-05 Mar-05 Mar-05 Mar-05 Sec-0	occop for relative proportionale owner is expressed 100% conversit so expression Cash and EBITDA Vita owns 60% re- compliance hot spot y. No cash expended as tra indDA for the third facility i.MDA for the third facility
Deel Name	2005 Acquisitions LAPD Searce (Partal Acquisition / JV) Searces (Partal Acquisition / JV) Atmosa (c) Atmosa (c) Atmosa (c) Atmosa (c) Atmosa (c) Atmosa (c) Atmosa (c) Atmosa (c) Searce and (c) Searce are a fillinois Searce are a	Total Total (acctuding Tomassee Kidney Clinica) Total (acctuding Tomassee Kidney Clinica) 2005 J/S Eusisville (Partial Divestiture / JV DeNovo) Historica (JV DeNovo) Monoci DeNosis (Fartial Divestiture) Marysville (JV DeNovo) Di Provenzano / St Clase (JV De Novo) Affree (JV BeNovo) Di Provenzano / St Clase (JV De Novo) Ban Anton Karley (Partial Divestiture) (() Macono Karley (Partial Acquistori) (() Macono Karley (Partial Acquistori) (() Macono (JV DeNovo) Macono (JV DeNovo	(a) Purchase Price and EBITDA reflect DeVita's pronet proportionale ownership interast in the deal (b) Purchase Price and EBITDA reflect DeVita's pronet approximation ownership interast in the deal (c) No acquisition model means U census and Set and EBITDA numbers are based on de nois model (d) This is a JV acquisition transaction where DeVita owns 60%. (d) This is a JV acquisition transaction where DeVita owns 60%. (d) This is a JV acquisition transaction where DeVita owns 60%. (d) This is a JV acquisition transaction where DeVita owns 60%. (d) This is a JV acquisition transaction where DeVita owns 60%. (d) Partial usual acquisition transaction where DeVita owns 60%. (f) Partial usual acquisition transaction where a CHPIX, No each activate activation also molides the divestiture of 70% of East Macon. (f) Partial usual activation for the NM for the third facility. The centers are located in Afington. Grapewire, and Hisbon. (i) DV chosed a centeris to a MDA for the third facility. The centers are a located in Afington. Grapewire, and Hisbon.

2006	
ΥTD	
Deals	
Closed	

Constrained Constrained <thconstrained< th=""> <thconstrained< th=""></thconstrained<></thconstrained<>	1 1	Deal Name	Date of Close	State	Market Segment	Transaction Value (s)	Patients (b)	Centers	IRR	Year 3 Cash on Cash	EBITDA Year 1	(e) CMLs	Incremental Unit Nix (By # of Facilities) MLs Political Hipper Mix	Facilities) High Hipper Mix	Price/Pt	Ix in FY06
00000 000000 000000 00000000 0000000 000000000000000 <td>00000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 0000000 000000000 000000000000000000 0000000</td> <td>suo</td> <td>5</td> <td>=</td> <td></td>	00000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 000000 0000000 000000000 000000000000000000 0000000	suo	5	=												
0 1	000000000000000000000000000000000000	ž	Latrue Feb-06	2 2			555 86	1 7 (1	18.1% 14.3%	14 5% 11 4%		t 0	00	40	\$ 62.754 \$ 95.313	31 896 12 672
0 0 1 0	0 1	Family Health. (nc.)	Apr-06 Apr-06	<u>⊖</u> {		4	534 18	9.	16 2% TPD	13.8% TEO		ω <	0	4	\$ 82.397	57.672
M0000 H1	M0000 H1	merlin	Jun-06	Ì		7,680,000	124	-	15.3%	13.3%		0		50	8 6	1,944
200000 10 1 11/h 11	00000 000000 00000 000000 000000 000000 000000 000000 000000 000000 000000 000000 0000000 0000000 0000000 0000000 0000000 00000000 00000000 00000000 000000000 0000000000 00000000000000000 000000000000000000000000000000000000		-00-100 101-006	S A Q		e	52 141	⊷ თ	17 4%	10.2% 13.1%		0,	00	~~ ¢	£ 5	4,368
1 1 <th1< th=""> 1 1 <th1< th=""></th1<></th1<>	(1) (1) <td>ticut</td> <td>90-des 8-7-0</td> <td>58</td> <td></td> <td>0.0</td> <td></td> <td>8</td> <td>17.1%</td> <td>14.1%</td> <td></td> <td>) (1</td> <td>0</td> <td>3 (4</td> <td>191</td> <td>6,494</td>	ticut	90-des 8-7-0	58		0.0		8	17.1%	14.1%) (1	0	3 (4	191	6,494
00000 0 <td>000000000000000000000000000000000000</td> <td></td> <td>Nov-D6</td> <td>3E</td> <td></td> <td>·) •~</td> <td></td> <td>~ ~</td> <td>16 7% 14 7%</td> <td>14 1% 13 4%</td> <td></td> <td>00</td> <td>00</td> <td>o +</td> <td>48</td> <td>3, 187 606</td>	000000000000000000000000000000000000		Nov-D6	3E		·) •~		~ ~	16 7% 14 7%	14 1% 13 4%		00	00	o +	48	3, 187 606
330000 13 1 9.03 11.03 2 0.04 1 2 0.04 1 1 1 1 </td <td>33000 23 1 0.03 1.1 0.03 1.1 0.03 1.1 0.03 1.1 0.03 1.1 0.03 0.03 1.1 0.03 <th0.03< th=""> <th0.03< th=""> <th0.03< th=""></th0.03<></th0.03<></th0.03<></td> <td></td> <td>Nov-06 Nov-06</td> <td>ч ¥</td> <td></td> <td>~ 0</td> <td>38 49</td> <td></td> <td>16.6% 21.3%</td> <td>10.7% 16.4%</td> <td>\$ (180.320)</td> <td></td> <td>00</td> <td>. 0 .</td> <td>333</td> <td>912</td>	33000 23 1 0.03 1.1 0.03 1.1 0.03 1.1 0.03 1.1 0.03 1.1 0.03 0.03 1.1 0.03 <th0.03< th=""> <th0.03< th=""> <th0.03< th=""></th0.03<></th0.03<></th0.03<>		Nov-06 Nov-06	ч ¥		~ 0	38 49		16.6% 21.3%	10.7% 16.4%	\$ (180.320)		00	. 0 .	333	912
2000 131 24 131X (c) 134X (c) </td <td>2000 151 101 M(s) 101</td> <td></td> <td>Dec-06</td> <td>GA</td> <td>'</td> <td>10</td> <td>25</td> <td></td> <td>%56 7.2%</td> <td>114%</td> <td>\$ 391,477</td> <td>></td> <td></td> <td>~ .</td> <td>88</td> <td>1.176 624</td>	2000 151 101 M(s) 101		Dec-06	GA	'	10	25		%56 7.2%	114%	\$ 391,477	>		~ .	88	1.176 624
67136 20 20 20 761136 20 7 2 76126 20 7 2 76120 20 7 2 76120 20 7 2 76120 20 7 2 76120 20 7 2 76120 20 46 7 1 700000 2 7 2 2 7000000 2 7 2 2 7000000 2 7 2 2 7000000 23 7 2 2 711 1 2 2 2 2 7000000 33 7 2 2 2 7130 101 2 2 2 2 7130 103 23 7 2 2 7130 134 2 2 2 2 7130 134 2 2 2 2 7131 13 2 2	67136 20					83.	1,578	7		13.4%		12	0	10		
71.130 20 2 2 2 75.130 2 7 3 1 75.130 2 7 3 1 75.130 2 7 3 1 75.130 2 7 3 1 75.130 2 7 3 1 75.130 2 7 3 1 75.100 2 7 3 1 75.100 2 7 3 1 75.000 2 7 3 1 75.000 10 1 1 1 7000 10 11 1 1 7000 10 11 1 1 7000 10 11 1 1 7000 10 11 1 1 7000 10 10 1 1 7000 10 10 1 1 7000 10 10 1 1 7000 10 10 1 1 7000 10 10 1 1 7000 10 10 1 1 7000 10 <t< td=""><td>71.130 20 2 - - 75.130 2 1 3 - - 75.130 2 7 3 - - 75.130 2 7 3 - - 75.130 2 7 3 - - 75.130 2 7 3 - - 75.130 2 7 1 - - 75.131 2 7 1 1 - 700 Pres 3 7 1 1 - 700 Pres 3 7 1 1 - 700 Pres 3 1 1 1 - 700 Pres 3 1 1 1 - 700 Pres 3 1 1 1 - 700 Pres 1 1</td><td>a Doctori Decente a Chi De Alterno</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	71.130 20 2 - - 75.130 2 1 3 - - 75.130 2 7 3 - - 75.130 2 7 3 - - 75.130 2 7 3 - - 75.130 2 7 3 - - 75.130 2 7 1 - - 75.131 2 7 1 1 - 700 Pres 3 7 1 1 - 700 Pres 3 7 1 1 - 700 Pres 3 1 1 1 - 700 Pres 3 1 1 1 - 700 Pres 3 1 1 1 - 700 Pres 1 1	a Doctori Decente a Chi De Alterno														
660000 35 Y 73 1 75.129 67 Y 3 1 700 Phote 40 Y 1 3 700 Phote 27 Y 3 1 700 Phote 27 Y 3 1 700 Phote 27 Y 3 1 700 Phote 27 Y 1 1 700 Phote 27 Y 1 1 700 Phote 27 Y 1 1 700 Phote 7 Y 1 1 711 1 1 1 713 1 22 217.336 1.031 22 217.336 1.031 22 217.336 1.031 23 71.40 40 1 71.51 1.03 2 71.51 1.03 2 71.51 1.03 2 71.52 23 3 71.51 1.03 2 71.51 1.03 2 71.51 <td>66:000 57 Y 3 1 75:173 7 1 70:170 48 3 70:170 48 3 70:170 2 1 70:170 2 1 70:170 3 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 71:11 1 1 71:11 1 1 71:11 1 1 71:11 1 1 71:11 1 1 71:11 1 1 71:11 1 1 71:11 1 1 <td< td=""><td>u (Fatuai Divestitute/JV De NOVO) • Novo)</td><td>Apr-06</td><td>₹0 50</td><td></td><td></td><td>52 53 73</td><td>cı +</td><td></td><td></td><td></td><td>- CMLs and Politic</td><td>al deals are defined</td><td>by Transaction</td><td></td><td></td></td<></td>	66:000 57 Y 3 1 75:173 7 1 70:170 48 3 70:170 48 3 70:170 2 1 70:170 2 1 70:170 3 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 70:171 1 1 71:11 1 1 71:11 1 1 71:11 1 1 71:11 1 1 71:11 1 1 71:11 1 1 71:11 1 1 71:11 1 1 <td< td=""><td>u (Fatuai Divestitute/JV De NOVO) • Novo)</td><td>Apr-06</td><td>₹0 50</td><td></td><td></td><td>52 53 73</td><td>cı +</td><td></td><td></td><td></td><td>- CMLs and Politic</td><td>al deals are defined</td><td>by Transaction</td><td></td><td></td></td<>	u (Fatuai Divestitute/JV De NOVO) • Novo)	Apr-06	₹0 50			52 53 73	cı +				- CMLs and Politic	al deals are defined	by Transaction		
375.129 3 7 3 1 00. Price 1 1 1 1 00. Price 3 1 1 1 00. Price 10 1 1 1 00. Price 16 1 1 1 00. Price 1 1 1 1 00. Price 1 1 1 1 1 00. Price 1 1 1 1 1 1 00. Price 1	375.129 37 1 375.129 37 1 300 Prese 37 1 301 Prese 37 1 302 Prese 37 1 301 Prese 37 1 301 Prese 37 1 302 Prese 37 1 313 Prese 1 1 313 Prese 1 1 314 Prese 1 1 315 Prese 1 1 315 Prese 1 1 315 Prese 1 1 315 Prese 1 1	rtial Divestiture/JV De Novo)	May-06	ξ			33 Yr 3					 High Hipper Mix i 	s defined as facilitie.	s which fall within		
300 0000 40 11 10000 00 Prese 20 Yr 11 10000 00 Prese 21 Jost 22 217.300 1031 22 217.300 1031 22 217.300 1031 22 217.300 1031 22 217.300 1031 23 217.300 1031 23 22 1031 23 232 S56 11 11 00000 11 11 00000 11 11 00000 11 11 00000 11 11 00000 11 11 00000 11 11 00000 11 11 00000 11 11 00000 11 11 00000 11 11 00000 11 11 00000 11 11	300 000 40 1 300 Pres 20 40 1 300 Pres 20 1 1 300 Pres 30 1 1 300 Pres 30 1 1 311 22 1 2 312 33 2 1 313 2 1 1 314 40 1 1 315 1 1 1 316 1 1 1 317.30 1 1 1 318 1 1 1 319 2 1 1 321 2 1 1 321 3 1 1 3315 1 1 1 3316 1 1 1 3315 1 1 1 3310 1 1	JV De Novoj	May-06 May-06	5≚		Ź	26 Yr 3 57					the Bain A or B (0 % or 6 1%) rating			
000 Price 45 11 000 Price 25 11 000 Price 25 11 000 Price 25 11 000 Price 26 11 000 Price 1031 22 247.308 1031 22 153.465 33 7 153.465 33 7 153.465 33 7 153.465 13 000 000 533 7 153.465 44 000 000 14 000 000 13 247.308 13 000 000 533 153.465 13 000 000 14 000 000 54 11 11 22 13 000 000 54 000 000 54 000 000 54 000 000 55 11 11 22 11 235 1 246 4 000 000 54	000 Price 45 11 000 Price 25 11 000 Price 25 11 000 Price 25 11 000 Price 26 11 000 Price 1031 22 247.338 1031 22 247.338 1031 22 133.455 30 1 000 000 533 7 133.455 30 1 000 000 533 7 133.455 30 1 000 000 53 1 000 000 53 1 000 000 53 1 000 000 54 4 000 000 53 1 00000 53 1 000000 53 1 000000 53 1 000000 53 1 000000 53 1 000000 53 1 000000 53 1 000000 53 1 <	rithership (Partial Divestiture / JV)	Jun-06	Ż		7.240.000	408	- 0								
000 PTE 22 Y:3 1 000 PTE 23 Y:1 1 000 PTE 24 1031 22 247:336 1031 22 247:336 1031 22 247:336 1031 22 247:336 1031 22 247:336 1031 22 247:336 1031 22 33:35 7 4 000 000 644 4 000 000 13 1 000 000 14 4 000 000 15 1 000 000 15 1 000 00 15 1 000 00 15 1 000 00 15 1 000 00 15 1 000 00 15 1 000 00 15 1 000 00 15 1 000 00 15 1 000 00 15 1 000 00 15 1 000 00 15 1	000 Pres 22 Y:3 1 000 Pres 23 Y:1 1 000 Pres 23 Y:1 1 000 Pres 23 Y:1 1 000 Pres 24 Y:1 1 000 Pres 24 1031 22 000 Pres 33 7 1031 000 Pres 33 7 1031 000 D00 533 7 13 000 D00 644 4 4 000 D00 644 1 1 000 D00 644 1 1 000 D00 142 2 1 000 D00 13 24 1 000 D00 14 1 1 000 D00 13 2 1 000 D00 13 2 1 000 D00 13 2 1 000 D00 14 1 1 000 D00 13 1 1 000 D00 13 3 1 000 D00 16	V De Novo) De Novoj	Jun-06	нð	B (6.1%)	De Novo Price	46 Yr 1									
000 Prese 31 71 1 000 Prese 33 71 1 000 Prese 36 71 1 000 Prese 36 71 1 000 Prese 36 7 1 000 Prese 36 7 1 000 Prese 37 1 1 000 Prese 37 1 1 000 Prese 37 1 2 247 313 23 7 2 247 316 1.031 22 247 316 1.031 22 247 316 1.031 22 247 315 1 1 000 000 53 7 000 000 54 1 000 000 1 1 000 000 54 1 000 000 1 1 000 000 1 1 000 000 1 1 000 000 1 1 000 000 1 1 000 000 1 1 000 000 1 1 000 000 1 1 000 000 1 1 000 000 1	000 Prese 31 Yr 1 000 Prese 33 Yr 1 000 Prese 36 Yr 1 000 Prese 36 Yr 1 000 Prese 36 Yr 1 000 Prese 37 Yr 1 000 000 33 7 032 000 33 7 032 000 33 7 032 000 33 7 032 000 33 7 032 000 1 1 032 000 1 1 032 000 1 1 032 000 1 1 032 000 1 1 032 000 1 1 032 000 1 1 032 000 1 1 032 000 1 1 033 000 1 1 034 000 1 1 035 000 1 1 035 000 1 1 036 000 1 1 038 000 1 1 039 000 1 1 <tr< td=""><td>/ De Novo)</td><td>Aug-06</td><td>۶č</td><td>B (6, 1%)</td><td>De Novo Price</td><td>32 Yr.3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr<>	/ De Novo)	Aug-06	۶č	B (6, 1%)	De Novo Price	32 Yr.3									
000 Prese 28 71 1 000 Prese 28 71 1 000 Prese 7 11 11 000 Prese 31 11 1 000 Prese 31 11 1 000 Prese 31 11 1 000 Prese 33 7 1031 000 001 533 7 13 000 001 533 7 13 000 001 533 7 13 000 001 533 1 1 000 001 533 1 1 000 001 533 1 1 000 001 543 4 1 000 001 543 4 1 000 001 543 4 1 000 001 54 4 1 000 001 54 4 1 000 001 54 4 1 000 001 54 4 1 000 001 54 4 1 000 001 53 1 1 000 001 53 4 1 000 001 53 1 1 000 001 54 <td>000 Prese 26 71 1 000 Prese 70 11 1 000 Prese 103 22 13.3 B 1031 22 13.4 B 1031 23 13.4 B 13 4 13.4 B 13 4 13.4 B 13 4 14.4 B 13 4 15.5 (a) 4 4 15.5 (a) 4 4 16.0 (b) 4 4 17.6 (c) 1 1 17.8 B 1 1 18.8 B 1 1 19.9 (c) 1 1 10.1 (c) 1 1 10.2 (c) 1 1 11.8 B 1 1 11.8 B 1 1<</td> <td>De Novo)</td> <td>Aug-06</td> <td>N</td> <td>B (6.1%)</td> <td>De Novo Price</td> <td>5 5</td> <td>* **</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	000 Prese 26 71 1 000 Prese 70 11 1 000 Prese 103 22 13.3 B 1031 22 13.4 B 1031 23 13.4 B 13 4 13.4 B 13 4 13.4 B 13 4 14.4 B 13 4 15.5 (a) 4 4 15.5 (a) 4 4 16.0 (b) 4 4 17.6 (c) 1 1 17.8 B 1 1 18.8 B 1 1 19.9 (c) 1 1 10.1 (c) 1 1 10.2 (c) 1 1 11.8 B 1 1 11.8 B 1 1<	De Novo)	Aug-06	N	B (6.1%)	De Novo Price	5 5	* **								
Source District District <thdistrict< th=""> <thdistrict< th=""> <th< td=""><td>Source 20 11 1 Source 10 11 1 Source 10 11 1 Source 10 11 1 Source 101 2 103 Source 103 22 Str336 103 22 Str336 103 22 Str335 103 23 Str355 103 23 Str355 103 1 Str355 103 1 Str355 1 4 Str355 1 1 Str350 1</td><td>0VO) Anselna (11/ DeNove)</td><td>Aug-06</td><td>2</td><td>A (9.0%)</td><td>De Novo Price</td><td>26 Yr1</td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<></thdistrict<></thdistrict<>	Source 20 11 1 Source 10 11 1 Source 10 11 1 Source 10 11 1 Source 101 2 103 Source 103 22 Str336 103 22 Str336 103 22 Str335 103 23 Str355 103 23 Str355 103 1 Str355 103 1 Str355 1 4 Str355 1 1 Str350 1	0VO) Anselna (11/ DeNove)	Aug-06	2	A (9.0%)	De Novo Price	26 Yr1	-								
Solution 17 11 1 Solution 10 11 2 Solution 103 2 3 Solution 13 2 3 Solution 14 4 4 Solution 1 1 1 Solution 1 1 1 1	Solution 17 11 1 Solution 10 1 2 Solution 103 2 103 Solution 103 22 103 Solution 103 22 103 Solution 103 22 103 Solution 53 7 103 Solution 53 7 103 Solution 53 1 1 Solution 53	V DeNovo)	001-00	ž	B (6.1%) C 4.4%)	De Novo Price Device Price	26 Yr1 76 Xr1									
500 Price 106 11 1 500 Price 34 11 1 500 Price 1031 22 513 A 1031 22 513 A 1031 22 513 A 1031 22 513 A 153 7 513 A 153 7 513 A 153 1 52 B 13 4 000 00 53 1 55 B 13 4 000 01 54 1 55 B 1 4 000 01 54 1 55 B 1 4 55 B 1 4 56 B 1 1 57 B 1 1 50 B 1 1	500 Price 106 11 1 500 Price 34 11 1 500 Price 1031 22 513.36 1031 22 513.45 1031 22 533 7 133 533 7 133 534.45 30 13 535.66 544 8 000.000 544 8 005.000 544 8 005.000 544 8 005.000 54 4 005.000 54 4 005.000 54 4 005.000 54 4 005.000 54 4 005.000 53 6 005.000 53 6 005.000 53 6 005.000 53 6 005.000 53 6 005.000 53 6 005.000 53 6	JV DeNovo)	Oct-06	X I	A (9.0%)	DeNovo Price	11 0/ 17 Yri									
So Phee 3t /11 1 So Phee 3t /11 1 So Phee Yr1 1 No 450 1 3 ISA 450 644 8 4 No 132 13 4 No 13 4 4 No 13 14 4 No 13 14 4 No 13 14 4 No 13 14 4 No 14 4 4 No 1 1 2 <td>So Pres 3t 1 1 30 Pres Yrr 1 1 31 Pres 1031 22 31 Abs 50 4 31 Abs 4 4 31 Abs 4 4 31 Abs 1 2 32 Abs 3 1 32 Abs 3 1 32 Abs 3 1 33 Abs 4 4 34 Abs 4 4 35 Abs 4 4 36 000 1 2 1 37 Abs 4 4 4 37 Abs<td>DeNova)</td><td>Oct-06</td><td>CA</td><td>H (2,4%)</td><td>DeNovo Price</td><td>106 Yr1</td><td>- 74</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td>	So Pres 3t 1 1 30 Pres Yrr 1 1 31 Pres 1031 22 31 Abs 50 4 31 Abs 4 4 31 Abs 4 4 31 Abs 1 2 32 Abs 3 1 32 Abs 3 1 32 Abs 3 1 33 Abs 4 4 34 Abs 4 4 35 Abs 4 4 36 000 1 2 1 37 Abs 4 4 4 37 Abs <td>DeNova)</td> <td>Oct-06</td> <td>CA</td> <td>H (2,4%)</td> <td>DeNovo Price</td> <td>106 Yr1</td> <td>- 74</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	DeNova)	Oct-06	CA	H (2,4%)	DeNovo Price	106 Yr1	- 74								
Soc Fride Yrt 1 247.336 1.031 22 247.346 1.031 22 247.346 1.031 23 001.000 533 7 003.000 533 7 004.000 644 4 005.000 1.122 13 005.000 1.122 13 005.000 1.132 13 005.000 1.132 13 005.000 1.132 13 005.000 1.132 13 005.000 1.132 13 005.000 1.13 23 005.000 1.13 1 005.000 1.141 1 005.000 1.141 1 005.000 1.141 1 005.000 1.141 1 005.000 1.141 1.111 005.000 1.141 1.111 005.000 1.141 1.111 005.0000 1.14	Soc Price Y1 1 3138 1031 22 3138 1031 22 3138 1031 23 32,455 13 33 000,000 53 7 32,155 13 33 32,155 13 33 32,000 1,152 13 332,155 13 34 332,155 13 34 332,155 13 34 332,155 13 34 332,155 13 4 332,155 13 4 332,155 1 1 344 1 1 352,168 1 1 360,000 1 1 1 315,000 1 1 1 1 316,000 1 1 1 1 317,820 4,43 8 3 3 317,820 4,43 8 <	(JV URNOVO) Mar AccessiJV DeNovo)	Nov-06 Nov-06	X 4	B (6 1%) H (7 4%)	DeNovo Price DeNovo Price	15 S	÷.,								
247.336 1.031 22 001 000 533 7 NA 545 4 NA 112 13 NA 14 4 NA 13 8 NA 13 4 S32 LDS (a) 13 S48 000 (b) 41 A N N A N N S00 00 (b) 41 N N N A N 1 A N 1 A 1 1 A 2 1 A 1 1 A 1 1 A 30 1 A 30 1	3(1.356 1.031 22 3(1.356 1.031 22 15.345 33 7 15.345 33 1 000.000 5.3 7 001.01 5.3 7 002.020 5.3 1 003.020 1.162 1 003.020 1.162 1 003.020 1.13 2 003.020 1.13 2 004.020 1.13 2 005.000 1.13 2 005.000 1.13 2 005.000 1.14 2 005.000 1.15 1.1 005.000 1.1 2 005.000 1.1 1.1 005.000 1.1 1.1 005.000 1.1 1.1 005.000 1.1 1.1 005.000 1.1 1.1 005.000 1.1 1.1 005.000 1.1 1.1	40) (OA	Dec-06	ð	10/1-21/11	DeNovo Price	Yr1									
153.455 5.3 7 153.456 5.3 7 153.456 5.3 1 153.456 5.4 153.256 1 153.256	00.000 533 7 154.46 50 4 154.56 50 4 00.000 644 8 00.000 644 8 00.000 1192 13 555.000 11 3 550.000 14 13 550.000 14 1 00.000 14 1 00.000 14 1 00.000 14 1 00.000 1 1 00.000 1 1 00.000 1 1 00.000 1 1 00.000 1 1 00.000 1 1 00.000 1 3 00.000 1 1 00.000 1 3 00.000 1 4 00.000 1 4 00.000 1 4 00.000 1 4 <td></td> <td></td> <td></td> <td>1</td> <td>12</td> <td>1.031</td> <td>22</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>				1	12	1.031	22								
000 000 533 7 153 456 50 1 000 000 644 8 NA 1.192 13 988 000 1.192 13 988 000 243 4 332 126 10 243 988 000 NA NA 000 000 NA NA 00 0000 NA NA 00 0000 NA NA 00 0000 NA 1 00 0000 NA 1 00 0000 NA 1 000000 NA 1	000 000 533 7 154,456 500 4 000 000 644 8 000 000 644 8 000 000 1,192 13 000 000 13 56 000 000 14 13 000 000 14 13 000 000 14 14 000 000 14 14 000 000 14 14 000 000 14 14 000 000 14 14 000 000 14 14 000 000 14 14 000 000 14 14 000 000 14 14 000 000 14 14 000 000 13 14 000 000 13 14 000 000 13 14 000 000 13 14 000 000 13 14 000 000 13 14 000 000 13 14 000 000 13 14 000 000 13 14 000 000 13 14 000 000 14 15 000 000 14 15 <	es / Other														
15.4.95 50 1 15.4.95 50 1 000.000 644 8 000.000 644 8 000.000 1 52.25 1 58.000 1 24.7 2 20.000 1 24.7 2 20.000 1 27.2 1 20.000 1 27.2 1 20.000 1 27.2 1 20.000 1 27.2 1 20.000 1 27.2 1 20.000 1 27.2 1 20.000 1 27.2 1 27.2 1 27.2 1 20.000 1 27.2 2 27.2	15.4.95 30 1 100.000 644 4 200.000 644 3 200.000 644 3 200.000 644 3 200.000 132 3 200.000 14 3 200.000 14 3 200.000 14 1 200.000 14 1 200.000 14 1 200.000 13 1 200.000 13 3 217.820 105 1 200.000 13 3 217.820 4.053 3 217.820 4.053 3 217.820 4.053 3 217.820 4.053 3 217.820 4.053 3 217.820 4.058 2 217.820 4.058 2 218.5 4.059 2 218.6 4.050 3 218.6 4.050 3 218.6 4.050 3 218.6 4.050 3 218.7 4.050 3 218.6 4.050 3 218.6 4.050 3	uyout / Change of Control)	Feb-06	AL		4)	533	2								
NM 450 4 NM 132 13 NM 1122 13 88.000 1132 13 88.000 1132 13 88.000 1132 13 88.000 1142 13 88.000 1142 13 114 1 14 115 1 1 115 1 1 116 1 1 116 1 1 116 1 1 116 1 1 117 5 1 116 1 1 116 1 1 116 1 1 116 1 1 116 1 1 117.20 4.03 8 117.20 1.05 1.05 117.20 1.05 1.05 117.20 1.05 1.05 <t< td=""><td>NM 450 4 NM 113 8 NM 112 13 68.000 113 4 58.000 1 23 58.000 1 2 58.000 1 2 50.000 1 1 00.000 1 1 00.000 1 1 00.000 1 1 00.000 1 1 00.000 1 3 00.000 1 403 377.620 403 8 377.620 403 8 377.620 403 8 00.000 1 1 1 1 1 00.000 1 403 37.16.1 403 8 37.16.1 403 8 37.16.1 403 9 37.16.1 403 9 37.16.1 400 1 <td>estiture)</td><td>Feb-06</td><td>AN N</td><td></td><td></td><td>30</td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td></t<>	NM 450 4 NM 113 8 NM 112 13 68.000 113 4 58.000 1 23 58.000 1 2 58.000 1 2 50.000 1 1 00.000 1 1 00.000 1 1 00.000 1 1 00.000 1 1 00.000 1 3 00.000 1 403 377.620 403 8 377.620 403 8 377.620 403 8 00.000 1 1 1 1 1 00.000 1 403 37.16.1 403 8 37.16.1 403 8 37.16.1 403 9 37.16.1 403 9 37.16.1 400 1 <td>estiture)</td> <td>Feb-06</td> <td>AN N</td> <td></td> <td></td> <td>30</td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	estiture)	Feb-06	AN N			30	-								
00,000 644 8 00,000 644 8 86000 16 113 86100 16 11 87500 (1) 47 2 87500 (1) 47 4 87500 (1) 47 14 87500 (1) 47 14 87000 (1) 51 (1) 80000 (1) 50 (1) 80000 (1) 493 1 80000 (1) 493 1 877.80 493 877.80 400 50 mmethod free partnership. Cash outflow from DVA to Summerin 10 for contributed the Summerin of the time partnership. Cash outflow from DVA to Summerin 10 for contributed the Summerin of the time partnership. Cash outflow from DVA to Summerin 10 for contributed the Summerin of the time partnership. Cash outflow from DVA to Summerin 10 for contributed the Summerin of the time partnership. Cash outflow from DVA to Summerin 10 for contributed the Summerin of the time partnership. Cash outflow from DVA to Summerin 10 for contributed the Summerin of the time partnership. Cash outflow from DVA to Summerin 10 for contributed the Summerin of the time partnership. Cash outflow from DVA to Summerin 10 for contributed the Summerin of the time partnership. Cash outflow from DVA to Summerin 10 for contributed the Summerin of the time partnership. Cash outflow from the Control of the Summerin of the Control of the Control of the Summerin of the Control of th	00.000 644 8 00.000 644 8 88.000 16 113 88.000 15 11 00.000 1 47 NA 122.000 (1) 47 NA 122.000 (1) 21 1 100.000 (1) 31 1 100.000 (1) 33 1 100.000 (1) 33 1 100.000 (1) 33 1 100.000 (1) 33 1 100.000 (1) 493 6 11 100.000 (1) 100.000 1 100.000 (1) 100.000 (1) 100.000 1 100.000 (1) 100.000 (1) 100.000 1 100.000 (1) 100.0000 (1) 100.000 (1) 100.000 (1) 100.000 (1) 100.0000 (1) 10	A) Masoni (Diminit / Channel of Cantant	Feb-06	4			450	vt								
58.000 1.15 13 53.2.15 10 14 53.2.15 14 1 53.2.15 10 1 53.000 10 24 243 1 1 20000 10 2 20000 10 5 11 1 1 23 1 1 200 1 5 200 1 5 200 3 1 200 3 1 21 6 1 220 1 5 23 1 1 23 1 1 20000 1 4 20000 1 4 20000 1 4 20000 1 4 20000 1 4 20000 1 4 20000 1 4 20000 1	586.000 1.82 13 532.035 1.93 14 532.035 1.9 243 532.035 1.9 2.4 500.000 1.4 1.4 200.000 1.4 2.7 000.000 1.9 6 000.000 1.93 1 000.000 1.93 1 000.000 1.93 1 000.000 1.93 1 000.000 1.93 1 000.000 1.93 3 377.620 4.053 3 377.620 4.053 3 377.620 4.053 3 377.620 4.053 3 377.620 4.053 3 377.621 4.054 5 377.622 4.050 5 377.621 4.054 5 37.621 4.054 5 37.621 4.054 5 37.621 4.054 5	nosportauyour, criariga or control) ary Hotspot	Apr-06 Apr-06	U AC		40	49.5	ထင့်								
332 105 (a) 243 4 75 000 (b) 4 2 80 000 (b) 4 1 100 000 (b) 3 1 100 000 (c) 3 1 200 000 (c) 3 1 200 000 (c) 433 8 200 000 (c) 433 8 201 433 3 3 7	333.105 (a) 243 4 55.000 (b) 4 NA 000.000 (b) 4 1 000.000 (c) 5 (c) 000.000 (c) 5 (c) 000.000 (c) 4 3 000.000 (c) 4 4 000.000 (c)	amento, CA (Partial Divestiture)	May-06	55			195 195	<u>5</u> -								
875.000 (t) 47 2 805.000 N 51 1 820.000 (t) 51 1 820.000 (t) 25 (t) 6 (t) 800.000 (t) 25 (t) 6 (t) 800.000 (t) 493 8 877.820 493 493 57 877.820 493 493 493 67 877.820 493 493 67 877.820 493 493 67 877.820 493 493 67 877.820 493 493 493 67 877.820 493 493 493 67 877.820 493 493 493 493 67 877.820 493 493 493 493 67 877.830 493 493 493 493 67 877.830 493 493 493 493 493 493 493 493 493 493	875.000 (t) 47 2 875.000 (t) 51 1 820.000 (t) 51 (t) 820.000 (t) 35 (t) 6 (t) 800.000 (t) 35 (t) 6 (t) 800.000 (t) 453 1 877.620 4.053 57 877.620 4.053 57 877.620 4.055 877.640 4.055 877.640 4.055 877.640 4.055 8.0	()non()	May-06	AL		1,332,125	243	4								
00000 NA NA NA 270 (1) 5 1 1 NA 270 (1) 5 1 1 NA 270 (1) 5 1 1 20.000 (1) 3 1 1 20.000 (1) 3 1 1 20.000 (1) 493 6 1 20.000 (1) 493 7 21.48. Valuation done by D&P. by Applied Economics. The valuation methodology was on a multiple-bass and not a DCF-basis	000000 NA NA NA 270 (1) 1 (00.001) 20 (1) 6 (1) (00.000 (1) 20 (1) 6 (1) (00.000 (1) 403 (1) 6	ay (Buyout)	Jun-06	GA		675,000	47	2								
 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Way (00) 1 1 000 000 1 5 (1) 000 000 0 33 57 000 000 0 433 8 000 000 0 433 8 001 000 0 433 8 001 000 1 433 8 001 000 1 433 8 001 000 1 433 8 001 000 1 433 8 001 000 1 433 9 001 000 1 4 9 001 000 1 4 9 001 000 1 4 9 001 000 1 4 9 001 000 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	s (Divestiture/Hot Spot Resolution) (g) ai Divestiture)	Jun-06	A X		4,000,000	NA	٩v								
000000 () 35 0 1 0 000000 (x) 453 57 977.620 453 57 977.620 4.053 57 977.620 4.053 57 10 cline contributed the Summerin cline to the partnerstup. Cash outflow from DVA to Summerin fease for \$7.2 kt. Valuation done by O&P. by Applied Economics. The valuation methodology was on a multiple-basis and not a DCF-basis	000 000 () 35 () 1 () 00000 (x) 453 51 00000 (x) 453 57 00162 (x) 4033 57 00162 (x) 4033 57 017.620 4.053 57 01 4.055 724M. Valuation relindology was on a multiple-basis and not a DCF-basis by Applied Economics. The valuation methodology was on a multiple-basis and not a DCF-basis quivelent) which is 88.5.	(A)	Jul-06	Various		ND .824										
000 000 1433 1 0000 (t) 433 5 017.620 4.053 57 01.600 contributed the Summerin clinic to the partnership. Cash outflow from DVA to Summerin regres for \$7.24M. Valuation done by D&P. by Applied Economics. The valuation methodology was on a multiple-basis and not a DCF-basis	200 000 (k) 403 1 377.820 4.053 5 377.820 4.053 5 arrandom of the Summetion clinic to the partnership. Cash cutiflow from DVA to Summetion regress for \$7.24M. Valuation neticodology variation arranged from a DCF-basis by Applied Economics. The valuation meticodology variation a multiple-basis and not a DCF-basis quivelent) which is 88.5.	al Divestiture)	Aug-06	Ĕ		100.000										
50.000 (k) 433 5 577.620 4.033 57 sime controlled the Summerin clinic to the partnership. Cash cutilow from DVA to Summerin regas for \$7.24M. Valuation done by D&P. by Appleid Economics. The valuation methodology was on a multiple-bass and not a DCF-basis	50.000 (k) 433 8 57.520 4.053 57 clime controlled the Summentin clime to the partnership. Cash outflow from DVA to Summenin regas for 57.244. Valuation done by D&P. by Appleid Economics. The valuation methodology was on a multiple-basis and not a DCF-basis quivelent) which is 68.5.	ess Acquisition)	Sep-06	QW		1.200,000	97U	-								
977.620 4.053 57 clime contributed the Summeritin climic to the partneriship. Cash outflow from DVA to Summeritin fegae for \$7.2 kM. Valuation done by 0.6 P. by Applaid Economics. The valuation methodology was on a multiple-basis and not a DCF-basis	977.620 4.053 57 cidre controlled the Summerin clinic to the partnership. Cash outflow from DVA to Summerin regas for 57.24M. Valuation done by D&P. by Appleid Economics. The valuation methodology was on a multiple-basis and not a DCF-basis quirelent) which is 88.5.		9549X	×		3,500,000	493	æ								
i clime contributed the Summertin clinic to the partnership. Cash outflow from DVA to Summarian régas for 57.24M. Valuation done by D&P. by Applaid Economics. The valuation methodology was on a multiple-basis and not a DCF-basis	cline contrbuted the Summerian Junic to the partnership. Cash outflow from DVA to Summerian regas for \$7.24M. Valuation done by D&P. by Appled Economics. The valuation methodology was on a multiple-basis and not a DCF-basis quirelent) which is 88.5.				 ~	21	4.053	57								
olmo contrbuted the Summerich clinic to the partnership. Cash outflow from DVA to Summerin Neges for \$7.2km. Valuation tome by D&P. by Applaid Economics. The valuation methodology was on a multiple-basis and not a DCF-basis	i cimo contrbuted the Summerin cimic to the partnership. Cash outflow from DVA to Summerin Negation 57.24M. Valuation done by 06.0- by Appleid Economics. The valuation methodology was on a multiple-basis and not a DCF-basis quirelent) which is 68.5.	Value and EBITDA reflect DaVita's pro rata pula equivalent patients. JV census represents	proportionate ownerst is 100% ownership	inp interest in the	deal.											
even of the ST 21kH. Valendon done by GP. 19. Applied Economics. The valuation methodology was on a multiple-basis and not a DCF-basis by Applied Economics.	reverse some of a contract of the by QRP. The valuation for by Appled Economics. The valuation methodology was on a multiple-basis and not a DCF-basis dy Appled Economics. The valuation methodology was on a multiple-basis and not a DCF-basis quirelently which is 68.5.	ierage based on Transaction Value routed the South Las Vegas, North Las Vega	as. and West Las Veo	as clines to the c	actnership. The owners of the	Summarin clinic contribu	itad tha Summerlin	Abria to the next	Cost and and	tanan DV/A ta C. anana						
mout sector wirerest in relation to a more a more a more and the sprease was performed by Appled Economics. The valuation methodology was on a multiple-bass and not a DCF-basis moutes of the sprease sector and and a sprease and start are fully-valued at a \$2.25mm. The apprasal was performed by Appled Economics. The valuation methodology was on a multiple-bass and not a DCF-basis and the sprease and solar as the submethor was 5.35mm. The apprasal was performed by Appled Economics. The valuation methodology was on a multiple-bass and not a DCF-basis and not a multiple-bass and not a multiple-bass and not a multiple-basis and a not a multiple and a multiple and a multiple and a multiple and a multiple-basis and a not a multiple-basis and a not a multiple-basis and a not a multiple-basis and a multiple and a m	mounts user and were meaned and source and source and and source and and source of the valuation methodology was on a multiple-basis and not a DCF-basis byourd 30% menets in modelock and support source. The appracial was performed by Appled Economics. The valuation methodology was on a multiple-basis and not a DCF-basis and 178% in the source excerting and to start the source and the source excerting and the source content is DVAs. and 178% in the one excurrent by DVA and total or source and the	1 a 60% interast in Summerlin for \$7 68M Da	aVita sold a 40% inter	est in South Las	Vegas. North Las Vegas, and	West Las Vegas for \$7.2	4M. Valuation done	toy D&P.	riersnip. Cash outlow	trom DVA to Summer	lin owners in the am	ount of \$440k to resu	it in a 60%/40% join	t venture		
inerste in three Gambo-lepost occess centers in greater Phaselephia for Samm. Interste first PS Sa stake in Marcus energings of which one center is DVAs al of 21% of first released to PDVA, and a load of so centers of which one center is DVAs now 100% of first interest in Figure studies to SexOC-Davia Delysa Partners, L. P., which is 51% owned by DaVia Als 027856 JV is 33.5M – 51.5M in item loan and 20 M in revolving line of credit	rifes un trace solution age source and solution was 50mm. To 61 for the source age source and solution was 50mm. at 010° for farmingers in Foreward to Stort CDN and a load of the horis for one contrar is DNA is a foreward by DAVia. An 2012 FOG DV is \$3.5M – \$1.5M in term beam and \$2.0M in revolving line of credit. An 2012 FOG DV is \$3.5M – \$1.5M in term beam and \$2.0M in revolving line of credit.	in out its paramets 40% interest in PDI Alaba buyout of 30% interest in Woodslock and Elij	ima tor \$1 3mm. jay centers, which are	fully-valued at a	\$2.25mm. The appraisal was	performed by Applied Ec	onomics. The valua	tion methodology	v was on a multim ia -ha	isis and not a DCE-ha	20					
or 217 earliers. Zo state manusevee reaction was supported in the content of a supported and a content was supported and a content was and a content was and a content was and a content was and a content of a conte	al of 21 partients. Zo in statement interpreter our examination. Jai of 271 partients. Zo in statement and a factor of the content is DVAs nooi 100% of its interest in Floresule to SKOC-DaVita Dekyses Partners. L.P., which is 51% owned by DaVita nooi 100% of its interest in Floresule to SKOC-DaVita Dekyses Partners. L.P., which is 51% owned by DaVita is 5721690 Jai 5721690 Such Basting and statements. Therefore for a factor in number of patenets is 79 plus 95 (hemo equivalent) which is 18 heavital events is 79 plus 95 (hemo equivalent) which is 88.5	i interest in three Gambro-legacy access can bed 1160 of its 72 58, etc. 2000 in Michael Turi	iters in greater Philade	elphis for \$4mm.							20					
nou 100% of first interest in Finerestia in Finerestia Delayes Perfores. L.P., which is 51% owned by DeVita. nou 100 SACID - VI is 33.6M - 51.5M in interminant and 22.0M in revolving line of credit. A is 52.515.550 - 51.551 in interminant 22.0M in revolving line of credit.	omen 95 (hemo	red 11% of its 7.2.3% state in musicogee. Fu al of 270 patients, 26 in the one acquired by	mivakuatxon wes \$3.9n ⊡DVA, and a tota! of s	nm. Ix centers, of whi	ch one center is DVA's											
	er of patients is 79 plus 9.5 (hemo	ed 100% of its interest in Floresville to SAKD manual to SAKDC_IV is \$3.5M \$1.5M in term	DC-DaVita Dialysis Pa m Ioan and \$2 0M in a	rtners, L.P., which	h is 51% owned by DaVita.											
	er of patients is 79 plus 9.5 (hemo	A is \$237,699			ופתור											

Case 1:09-cv-02175-WJM Document 35-1 Filed 12/23/11 USDC Colorado Page 61 of 97

Closed Deal Activity 060509 printable xis

õ	
De	
ā	
å	

Closed Deals YTD 2007

000000000000000000000000000000000000	5 6000 7.200 5 55 5000 2.880 5 27 5800 2.840 5 27 56 3600 5 27 56 3600 5 27 56 3600 5 27 56 3737 5 27 56 4778 5 56 4.778 3726 5 56 4.778 3726 5 56 4.778 3726 5 56 4.778 3726 5 56 3.726 3772 5 56.41 (c) 0.6462 6 6 1.357 5 55 3.726 3.726 5 56.41 (c) 0.6462 6 6 1.357 3.726 5 55 3.726 3.726 5 56.41 (c) 0.6462	Date of	Date of Close	Blate	Market Segment		Transaction Vatue (8)	Patients (b)	Centers	RR	Year 3 Cash on Cash	EBITDA Year 1	(B)	Incremental CMLs	irscemental Unit Mix (By # of Facilities) Mis Political High Hipper Mix	actities) Hoh Hipper Mix	Price/Pt	Tx in FY07	x EBITDA
5 500 280 2 2500 280 5 000 291 2 235 280 2 235 230 2 235 750 2 235 750 2 235 4778 3 3559 4778 3 3559 3723 3 3559 3723 3 3559 3778 3 3559 3778 3 3554 3778 3 3554 3778 3 3554 3778 3 3554 3778 3 3554 3778 3 3555 3778 3 3555 3778 3 364 3778 3 364 3768 3 3768 3778 3 3768 3778 3 3768 3778	5 55 280 5 27 580 5 27 580 5 26 280 5 26 280 5 26 280 5 26 280 5 26 750 5 2757 220 5 3556 41776 5 5666 3722 5 5666 3776 5 5666 3776 5 5666 3776 5 5666 3776 5 5776 3776 5 5776 3776 5 5776 3776 5 5776 3776 5 5776 3776 5 5776 3776 5 5776 3776 6 6714 60 6 6714 60	Acr	-07	AR 12	High B(6.1%)	~ ·	300 000	8	2	¥5 69	27.0%	\$ 536.	923	0	o	2	\$ 6 000	7,200	06×
5 5/236 12.160 5 8.42 7.900 5 8.42 7.900 5 8.42 7.900 5 8.42 7.900 5 8.65 1.740 1 1.0252 3.750 8 9.00 3.751 1 1.0252 3.750 8 9.731 1.740 1 1.0252 3.756 8 9.731 3.756 8 9.731 3.756 8 9.731 1.740 7 9.731 9.736 8 9.731 1.740 8 9.731 1.740 8 9.731 9.736 9 9.731 9.736 9 9.731 9.736 9 9.731 9.736 9 9.731 9.736 9 9.731 9.736 9 9.731 9.736 9 9.731 9.736 9 9.732 9.736 9 9.736 9.736 9 9.736 9.736 9 9.736 9.736 9 9.736 9.736	5 27.356 12.160 5 8.42 7.000 5 8.42 7.900 5 8.65 7.400 5 8.65 7.750 6 8.77 2.250 8 9.855 4.776 5 8.655 3.316 8 8.555 3.316 5 8.453 3.316 5 8.453 3.316 5 8.451 10.57 5 8.451 10.57 5 8.453 3.316 5 8.453 3.316 5 5.56 3.316 5 5.56 3.316 5 5.316 8.453	-07	6	13	Low B(2.4%)		4 000 000	छ भू ह		10 D1	178%	8 %	98 S	00	0	0	\$ 65900	2,880	3 5 X
5 28 28 28 28 5 71 81 300 5 73 1 70 5 73 300 300 5 73 1 300 5 73 300 300 5 73 300 300 5 45 1 300 5 45 3 300 5 45 3 300 5 45 3 300 5 45 3 3 6 41 1 3 6 5 3 3 6 5 3 3 7 5 3 3 6 45 41 1 6 45 41 1	5 36400 7640 5 5731 7540 5 5731 7540 5 5731 7560 5 6567 340 6 6567 372 5 65667 3732 5 65667 3732 5 65667 3772 5 65667 3772 5 65667 3772 5 65667 3772 5 65667 3772 5 65667 3772 5 65667 3772 5 65667 3772 5 65667 3772 5 65667 3772 5 65667 3772	Har	-02	Ę	Med A (5 7%)		3 000 000	ន		17.4%	10 T		14 A	50	50	0 0	5 27 586	12.180	¥ 10 ×
3 21818 7.300 5 25737 7.200 6 56.50 4.773 5 56.50 3.723 5 56.40 3.723 5 56.40 3.723 5 56.41 (0) 6 66.51 3.723 5 56.41 (0) 6 66.11 (0)	3 21818 3.300 5 25757 2200 5 25555 4.1377 5 56462 4.1377 5 56462 3.728 5 56462 3.728 5 56462 3.728 5 56462 3.728 5 56462 3.728 5 56462 3.728 5 56462 3.728 5 56462 3.728 5 56462 4.148 6 64632 4.6632	Aud	66	2	Med C (2 2%)			8 <u>1</u>	-	18.3%	14 0%	\$ 645	587	0	00	00	5 28 452	7,560	55×
3 3791 1.740 6667 377 2.720 46.962 3.77 378 58.667 3.77 378 58.667 3.77 3.78 58.667 3.77 3.78 58.667 3.77 3.78 58.668 4.77 3.78 58.667 3.77 3.78 58.668 4.778 3.77 58.668 4.778 3.36 58.667 5.316 0.6662 58.668 4.778 3.36 58.668 4.778 3.36 58.668 4.778 3.36 58.668 4.778 3.316 58.668 4.618 0.0 68.67 5.316 0.0 58.688 5.316 0.0 58.688 5.316 0.0 58.688 5.316 0.0 58.688 5.316 0.0 58.688 5.316 0.0 58.688 5.316 0.0 58.688 5.316 0.0 58.688 5.316 0.0 58.688 5.316 0.0 59.798 5.316 0.0 59.798 5.316 0	\$ 27391 1.740 \$ 6667 576 \$ 6667 576 \$ 66867 13.72 \$ 86428 7.79 \$ 86428 7.79 \$ 86428 7.79 \$ 35559 3.316 \$ 45,181 (c) \$ 45,181 (c)	-GIA	101	5 1		<i>.</i> .		នន		17 3%	14 5%	500	850	a	0	-		3.300	57×
5 52 57 57 57 58 66 66 75 157 58 66 66 66 66 66 56 13 57 58 68 69 58 58 58 58 58 58 58 58 58 58 58 58 58	5 5 5 5 6 6 5 5 5 5 6 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 6 5 5 6 6 6 6 6 6 6 6 6 6	-one-	20-	A O	Low A(3.5%)	••		86		37.6%	14 3%	5 (6)	454) 20	0 (0	0		1.740	٨A
4 6 8 90 1 3 7 5 1 8 8 90 1 3 7 5 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 7 6 1 8 8 90 3 7 8 6 1 8 8 90 3 7 8 6 1 8 8 90 3 7 8 6 1 9 90 8 8 9 1 9 90 8 8 9 1 9 90 8 8 9 1 9 90 8 8 9 1 9 90 8 8 9 1 9 90 8 8 9 1 9 90 8 8 9 1 9 90 8 8 9 1 9 90 8 8 9 1 9 90 8 8 9 1 9 90 8 8 9 1 9 90 9 8 9 1 9 90 9 8 9 1 9 90 9 8 9 1 9 90 9 8 9 1 9 90 9 8 9 1 9 90 9 9 1 9 90	5 66,800 13,00 5 66,800 13,00 5 36,800 3176 5 36,401 60,858 5 36,401 60,868 5 36,401 60,868	Sep	20-	Fi	Low B(2 4%)	•	800.000	12		18 5%	145%		8	3 0		э с		2.220	7 1 ×
4.1.11 (c) 4.5.2 4.5.11 (c) 4.5.2 4.1.11 (c) 4.6.63 4.1.11 (c) 4.6.63	4 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	-bo	1-07	CA	Low A(3 5%)	-7	17 700 000	377	-	14 2%	13.2%	2 2341	100		» с			0/0	A S
3 58,942 3.722 3.722 3 55,555 3 55,555 3 56,510 (c) 64,652	3 58,942 3.72 3 555,55 3 555,55 3 555,55 3 752 3 752 5 7	NON	101	A C	High A(9.0%)	<u>م</u> .	B 125.000	198	64	166%	14 4%	\$ 781	687	2	0	2		4,776	104×
45.101 (c) 64.652	4 . 45.101 (c) 69.682	Å	10	52	High B(6 1%)	• •	15,750,000	115 844	n no	11 8% 18 2%	11 2% 15 0%	5 2.323.1 5 1.227	875 508		00	0 0	\$ 58,842 \$ 35,553	3.732 5.316	79×
						-	76.716.000	1.864	A				13	- -		2		66.652	
Not Not Not Not Not Reg 10 10 10 10 10 10 Reg 10 10 10 10	and bit bit bits																		
Note: Note: <th< td=""><td></td><td>FUEL</td><td>-02</td><td>đ</td><td>0.15 74.5</td><td></td><td>Dation Pros</td><td>28 (Vr 1)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>		FUEL	-02	đ	0.15 74.5		Dation Pros	28 (Vr 1)											
Multiple Distribution	Mark Ball (N) Description Descripion <thdescripion< th=""> <thdescrip< td=""><td>1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1</td><td>-04</td><td>ŝ</td><td>High B(61%)</td><td></td><td>DeNovo Pres</td><td>(1 11) 07</td><td></td><td></td><td></td><td></td><td></td><td>OMLs and Political d</td><td>eals are defined by</td><td>Transaction</td><td></td><td></td><td></td></thdescrip<></thdescripion<>	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	-04	ŝ	High B(61%)		DeNovo Pres	(1 11) 07						OMLs and Political d	eals are defined by	Transaction			
1 1	Number Number<	Mar-	-07	PA	High B(6 1%)		DeNovo Price							hiectors					
Marting Marting	Marting Display Display <t< td=""><td>Mar-</td><td>-07</td><td>ĸ</td><td>Med B(4.5%)</td><td></td><td>DeNovo Price</td><td>33 (Yr 1)</td><td></td><td></td><td></td><td></td><td></td><td>high Hipper Nix is de</td><td>shined as facilities w</td><td>duch fall within</td><td></td><td></td><td></td></t<>	Mar-	-07	ĸ	Med B(4.5%)		DeNovo Price	33 (Yr 1)						high Hipper Nix is de	shined as facilities w	duch fall within			
Marging N: Marging (15) Obsolutions Obsol	Note Note <th< td=""><td>Mart</td><td>-07</td><td>QW</td><td>High B(6 1%)</td><td></td><td>DeNovo Price</td><td>50 (Yr 1)</td><td></td><td></td><td></td><td></td><td>2</td><td>יה באוורא מרם (א טא</td><td>e or o 176/16/16/10</td><td></td><td></td><td></td><td></td></th<>	Mart	-07	QW	High B(6 1%)		DeNovo Price	50 (Yr 1)					2	יה באוורא מרם (א טא	e or o 176/16/16/10				
Marging Marging	Mergin (model) Cit Los (Cit Cit	Mar	-07	ΝΥ	Med B(4 5%)		DeNovo Price												
March Dirty March Dirty March Dirty Dirty <th< td=""><td>Mund Mund Mund Mund Mund Mund Mund Mund</td><td>May-</td><td></td><td>CA</td><td>Low B(2.4%)</td><td></td><td>DeNovo Price</td><td>33 (Yr 1)</td><td>ı</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Mund Mund Mund Mund Mund Mund Mund Mund	May-		CA	Low B(2.4%)		DeNovo Price	33 (Yr 1)	ı										
Margin Margin Sector NL Hold Bills House Price Marcine Sector House Price Sector House Price HousePrice House Price House Price </td <td>March M</td> <td>May-</td> <td></td> <td>OH / KY</td> <td></td> <td></td> <td></td> <td>134 (Yr 1)</td> <td>ŝ</td> <td></td>	March M	May-		OH / KY				134 (Yr 1)	ŝ										
MADD MADD <th< td=""><td>Model M</td><td>-VeM</td><td>-01</td><td>2<</td><td>Hidh Bi6 1%)</td><td></td><td></td><td>27 (Yr 1)</td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Model M	-VeM	-01	2<	Hidh Bi6 1%)			27 (Yr 1)	-										
00001 (0000) 0.0 <t< td=""><td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td><td>Aug</td><td>101</td><td>¥</td><td>Huah B(6 1%)</td><td></td><td>DeNovo Price</td><td>45 (Yr 1)</td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Aug	101	¥	Huah B(6 1%)		DeNovo Price	45 (Yr 1)	-										
0000 (0000) 0000 (0000) 0000 (0000) 0000 (0000) 00000 (0000) 00000 (0000) 00000 (0000) 00000 (0000) 00000 (0000) 00000 (0000) 00000 (0000) 000000 (0000) 000000 (0000) 0000000 (0000) 000000000000000000000000000000000000	0000 000 <td></td> <td>10-</td> <td>X:</td> <td></td> <td></td> <td>3</td> <td></td> <td>*</td> <td></td>		10-	X:			3		*										
Notify Leady Not Not Not Not Not Not Not Not Not Not	Model (model (model (model) Model (model) Model) Model		Ş Ş	59	Low B(2.4%)			B6 (Yr 1)	2										
Mode (Mode) Mode) Mode) <td>Image: Decision Control (0) Control (0)</td> <td>- DOI:</td> <td>20</td> <td>2 2</td> <td>00000</td> <td></td> <td></td> <td>35 (Yr 1)</td> <td></td>	Image: Decision Control (0)	- DOI:	20	2 2	00000			35 (Yr 1)											
Description 10 Description 2(11) 1 Among 7 H2 4(4) 5 7000 10 2000 Among 7 H2 4(4) 5 7000 12 2 1 Among 7 H2 4(4) 5 7000 12 2 1 Among 7 H4 4(4) 5 2000 12 2 1 Among 7 H4 4(4) 5 2000 12 2 1 Among 7 H4 4(4) 5 2000 12 2 2 Among 7 H4 4(4) 5 2000 12 2 2 Among 10 12 2 2 2 2 2 Among 10 12 2 <td>Teach Teach <th< td=""><td>- ACM</td><td>20</td><td>- A</td><td>10.0.000</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<></td>	Teach Teach <th< td=""><td>- ACM</td><td>20</td><td>- A</td><td>10.0.000</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	- ACM	20	- A	10.0.000														
Jancy CA Hol (c44) 5 7000 101 Acc7 CA HC41(A) 5 7000 MA Acc7 CA HC41(A) 5 7000 MA MA Acc7 CA HC41(A) 5 2000 MA MA Acc7 CA HC41(A) 5 2000 MA MA Acc7 MA MA MA MA MA MA Acc7 MA MA MA MA MA MA Acc7 MA MA MA MA MA MA Acc7 </td <td>Image: Inclusion of the stand of t</td> <td>Dec</td> <td>-02</td> <td>Z</td> <td></td> <td></td> <td></td> <td>26 (Yr 1)</td> <td>• •</td> <td></td>	Image: Inclusion of the stand of t	Dec	-02	Z				26 (Yr 1)	• •										
Janoff CA H(2.4%) Total 100 24 Maroff FX Herr B(14%) 1000 12 1 Maroff FX Herr B(14%) 20000 12 1 Maroff FX Maroff 2 2 2 Maroff FX Maroff 2 2 2 Alsoff Maroff FX 3 3 3 Maroff Maroff Maroff 2 2 2 Maroff Maroff Maroff	4 1,005 CA H(2.4%) 5 70.000 MA TX HH0.5(4%) 5 70.000 MA PA HH0.5(4%) 5 70.000 MA PA HH0.5(4%) 5 70.000 122 PA HH0.5(4%) 5 500.000 122 PA HM0.5(4%) 5 500.000 122 PA MM0.5(4%) 5 500.000 15 50 AR MM0.5(1%) 5 375.000 10 210 N FL MM1.6(1%) 5 375.000 10 200 N 200 00 11 200 N 200 00 11 200 N 200 00 11 200 00 11 200 N 200 00 11 200 00 11 200 00 11 200 00 11 200 00 11 200 00 11 </td <td></td>																		
JIN CI (March) CA (March) March (March) CA (March) March (March) March) March (March) March)	Mercy M						•	1.005	25										
Junct Monoding M	Mercy Network Mercy																		
March IX Hundler March	Norm Norm Norm Norm Norm Norm Norm Norm Norm Norm <td>C mol</td> <td>20</td> <td></td> <td>1100 0011</td> <td></td>	C mol	20		1100 0011														
March IA Han Uot 44 5 2000 12 3 March And Cit F Han Uot 44 5 20000 12 3 March F Han Uot 44 5 20000 12 3 March F Han Uot 44 5 20000 12 3 March F Han Uot 44 5 20000 12 3 And Cit F March 7 1 20000 12 3 Securit VVCA March 5 3 150000 12 3 Cocidy March 1 200000 1 2 1 2 Cocidy March 1 2 3 3 2 2 Cocidy March 1 3 3 3 3 3 Cocidy March 1 3 3 3 3 3 Cocidy March	March IA Hundled N 5 20000 112 3 March R Hundled N 5 20000 12 3 March R Hundled N 5 20000 12 3 March R Hundled N 5 20000 12 3 March R Hundled N 5 150000 13 2 March R Hundled N 5 150000 13 2 Security Viricle No 2 2 1 2 March R F 2 0 2 1 March No No 1 2 1 2 March No No No 1 2 2 March No No No 1 2 2 March No No 1 2 1 1 March No 1	TURN C	ž č	57	H(2 4%)	•	70 000	A N	-										
March In March	Marcy Marcy (Marcy) Marcy (Marcy) Marcy (Marcy) <thmarcy)< th=""> Marcy (Marcy) Marcy (Mar</thmarcy)<>		5 G	≤ 2			(e) 000,000	221	m										
March OR Hond Ref 5h \$\$ 55000 (1) 53 12 Ana-O7 F March F Hond Ref 5h \$\$ 150000 10 53 1 Ana-O7 F March F March 1 2 2 Ana-O7 F March 5 1500000 2 3 Sea-O7 VVGA March 5 3.060.000 10 20 Sea-O7 VVGA March 5 3.060.000 10 20 1 Co-O7 VVGA March 5 3.060.000 2.00 1 3 3 Co-O7 VVGA MA 5 3.060.000 2.00 1 3 3 Co-O7 VVGA MA 7 3 3.060.000 2.04 1 3 CVGA coversaria March 3 3.000000 3.02 1 3 3 3 3 3 3	March/ Aurol/ Aurol/ Cetal Aurol/ Cetal Aurol/ Cetal Aurol/ Cetal Aurol/ Aurol/ Aurol/ Aurol/ March/ Aurol/ March/ Aurol/ March/ Marc		Ş	۲,	1400 B(0 1 %)	•	200.000	42	-										
March As Hah Bit % 5 120000 (1) 50 2 Juncy1 F March F March 1 30000 (1) 20 2 Search VMA March F March 1 305000 (1) 20 2 Search VMA MA 560000 (1) 20 N 3 Search VMA MA 560000 (1) 20 N 3 Search VMA MA 560000 (1) 20 3 3 Search VMA MA 3 20000 (1) 20 1 3 Search VMA MA 3 2 3 1 3 Search VMA MA 3 2 3 1 3 <td>MeV As Hoh B6 1% 5 120000 () 50 Searcy L N MeV A Hoh B6 1%) 5 120000 () Searcy L Ned C (2 %) 3 3075000 (m) 211 3 Searcy V/Voc NA NA Searcy NA Corroly NA NA 3 3075000 (m) 211 Searcy V/Voc NA Searcy NA Searcy Corroly NA A 200000 (m) 201 3 Grass and currenty and currenty 80 5% DVA1 100% valuetoris \$3,000 00 Silvetorin deal also moludes 5 JV De Noosa - While Cain N, Turkey, and Coid Springs All centres are n CH Access that the mass of 1,000 00 Silvetorin deal also moludes 5 JV De Noosa - While Cain N, Turkey, and Coid Springs All centres are n CH First and the advectory 40% of the enter. Tail value 15 20000 Silvetorin value on KV First and the advectory 40% of the enter. Tail value 15 20000 Silvetorin value on KV First control Tail value Silvetorin Valuetori 15 SM Silvetorin Valuetori 10% First control Tail valuetori 1, 20000 Silvetorin Valuetori 14 20 Nices 14 centres are n CH Silvetorin 11 Turkey and Coid Springs All centres are n CH First control Tail valuetori 10% Tail valuetorin 10% Tarkey, partingeto</td> <td>-ABW</td> <td>ş</td> <td>E I</td> <td>Med B(4 5%)</td> <td>•</td> <td>505 000 (d)</td> <td>53</td> <td>-</td> <td></td>	MeV As Hoh B6 1% 5 120000 () 50 Searcy L N MeV A Hoh B6 1%) 5 120000 () Searcy L Ned C (2 %) 3 3075000 (m) 211 3 Searcy V/Voc NA NA Searcy NA Corroly NA NA 3 3075000 (m) 211 Searcy V/Voc NA Searcy NA Searcy Corroly NA A 200000 (m) 201 3 Grass and currenty and currenty 80 5% DVA1 100% valuetoris \$3,000 00 Silvetorin deal also moludes 5 JV De Noosa - While Cain N, Turkey, and Coid Springs All centres are n CH Access that the mass of 1,000 00 Silvetorin deal also moludes 5 JV De Noosa - While Cain N, Turkey, and Coid Springs All centres are n CH First and the advectory 40% of the enter. Tail value 15 20000 Silvetorin value on KV First and the advectory 40% of the enter. Tail value 15 20000 Silvetorin value on KV First control Tail value Silvetorin Valuetori 15 SM Silvetorin Valuetori 10% First control Tail valuetori 1, 20000 Silvetorin Valuetori 14 20 Nices 14 centres are n CH Silvetorin 11 Turkey and Coid Springs All centres are n CH First control Tail valuetori 10% Tail valuetorin 10% Tarkey, partingeto	-ABW	ş	E I	Med B(4 5%)	•	505 000 (d)	53	-										
March K No K Second March K Second V/VGA MA 5 31600.000 210 21 Second V/VGA MA 5 31600.000 10 200 Second V/VGA MA 5 31600.000 10 200 Second V/VGA MA 5 31600.000 10 200 Second V/VGA MA 5 31600.000 2.004 13 resents 10V6 somesting 05.404 10% setembor 14 13 13 resents 10V6 somesting 10.404 13 13 14 resents 10V6 somesting 10.404 13 14 14 resents 10V6 somesting 10.404 13 14 14 resents 10V6 somesting 14.400.000 31.400.000 31.400.000 14 resents 11.404 14.400.000 14.400.000 31.400.000 14 14.400.000 resents 11.404 14.400.000 14.400.000 14.400.000 14.400.000 14.400.000 resents 11.404 14.400.000 14.400.000 14.400.000 14.400.000 14.400.000 resents 11.404 14.400.000 14.400.000 14.	March K Name Name Name Name Cardy K March K 1500000 (i) 21 Cardy March K Second (i) 21 3 Cardy March K Second (i) 200 March Cardy March K Second (i) 200 March Cardy March Second (i) 200 March Cardy March March Second 1 Second 1 Constrained March Second 2.04 March March Constrained March Second 2.04 Cond March March March March M	- A8M	Ş	AK	HIGH B(51%)	\$	120.000 (f)	8	~										
Aux/off FL Med C(27h) \$ 305:000 (1) 21 3 Security Centry VM \$ 56:00000 (1) 234 13 Centry Med C(27h) \$ 56:00000 (1) 234 13 Centry Med C(27h) \$ 56:00000 (1) 234 13 Centry Med C(27h) \$ 50:00000 (1) 234 13 Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry Centry	March FL March K1 March K1 305.000 (n) 211 3 Secord V/GA N/G N/G N/G N/G N/G N/G Cetory V/GA N/G 1 2000 2.00 2.00 2.00 Cortory V/GA N/G 1 2 2.000.000 2.00 1 Cortorate connection interact in the classic 2 2.000.000 2.00 2.00 2.00 Cortorate risk interact (VGA connection interact) 0.05% birling (VGA connection interact) 2.000.000 2.004 10 Cortorate risk interaction fraction and alloc one of a all allo includes 5.1/ De Noocs - While Oak, Anderson Laboratory Allocation County) 1.01/ags, and Cold Spings All conters are in OH except Turlines and Cold spings All conters are in OH except Turlines and Cold spings All conters are in OH except Turlines and Cold spings All conters are in OH except Turlines and Cold sping which are in KY Cort Cortoration County Turlines (County) Turlines, and Count Spings All conters are in OH except Turlines and Cold sping which are in KY Sin Cold Spin County Turlines (County Turlines (County) 7.000.000 Sin counts are in CH Sin Cold Spin County Turlines (County Turlines	HUNP	20	Š		•	1 520,000 (h)		ભ										
Sec.07 V/GA NA 576.00000 (n) 2.000 NA 1 rial proprintmental ownerstip 1 3 3.006.000 (n) 2.00 NA reader structure 1 3 3.006.000 (n) 2.00 NA reader structure 1 3 3.006.000 (n) 2.00 NA reader structure 10% connerstip 1 3 3.006.000 Silventin deal also includes 5 JV De Nonce - While Cak, Anderson Lekenon(Warren County), Turhway, and Caid Spings All centers alle in CM except Turhway and Caid sping, which alle in KY reader all and match and an also includes 5 JV De Nonce - While Cak, Anderson Lekenon(Warren County), Turhway, and Caid Spings All centers alle in CM except Turhway and Caid sping, which alle in KY reader all and match and an all callos on the set of Turhway and Caid sping shi new Woodland and Bardistow centers. Total Wallabini s \$9.44 root behavening The Woodland and Bardistow centers. Total Wallabini s \$9.44 root behavening to the Woodland and Bardistow centers. Total Wallabini s \$9.44 root behavening to the Moodland and Bardistow centers. Total Wallabini s \$9.44 root behavening to the Moodland and Bardistow centers. Total Wallabini s \$9.44 root behavening to the Moodland and Bardistow centers. Total Wallabini s \$9.44 root behavening to the Moodland and Bardistow centers. Total Wallabini s \$9.44	Sec.7 Vic(A NA \$16,0000 (n) 200 NA 0 et al.7 Mi 1 20 NA 0 et al.7 Mi 1 20 NA 0 et al.7 Mi 1 200 NA 0 et al.7 Mi NA NA NA 0 et al.7 Mi Structure 16 Structure 16 Structure 16 0 et al.7 Mi Mi Mi Mi Mi 0 et al.7 Mi Mi Mi Mi Mi <td>Hout</td> <td>67</td> <td>F</td> <td>Med C (2.2%)</td> <td>•</td> <td></td> <td>211</td> <td>0</td> <td></td>	Hout	67	F	Med C (2.2%)	•		211	0										
Deck07 Mi 26 1 Transportionale onweigting interest in the class. 3 3.2.080.000 2.844 13 versatz 10% onweigting 1 3 32.080.000 2.844 13 versatz 10% onweigting 1 3 32.080.000 2.844 13 versatz 10% onweigting 1 3 32.080.000 Silventan deut also includes 5 JV De Noros - White Cas. Anderson Lebarroq/Varren County). Turivay, and Cald Spings All centers are in OH except Turivay and Cald Sping All centers are in OH except Turivay a	Oct-07 Mi 28 1 or state propriorious exercise interest in the data. 3 32.060,000 2.64 13 or state propriorious exercise interest in the data. 3 32.060,000 2.64 13 or state propriorious exercise interest in the data. 3 3000,000 Silverton rounds 5.17 De Noods - White Oak, Anderson Leatenor(Warren Caunty), Turlvay, and Cold Spinngs All centers are in OH except Turlvay and Cold sping which are in KV in a Addreson Latenor(Warren Caunty), Turlvay, and Cold Spinngs All centers are in OH except Turlvay and Cold sping which are in KV in a Addreson Latenor(Warren Caunty), Turlvay, and Cold Spinngs All centers are in OH except Turlvay and Cold sping which are in KV in a Addreson Latenor(Warren Caunty) Turlvay, and Cold Spinngs All centers are in OH except Turlvay and Cold sping which are in KV in a Addreson Latenor(Warren Caunty) Turlvay, and Cold Spinngs All centers are in OH except Turlvay and Cold sping which are in KV in a Addreson Latenor(Warren Caunty) Turlvay, and Cold Spinngs All centers are in OH except Turlvay and Cold sping which are in KV in a Addreson Latenor(Warren Caunty) Turlvay, and Cold Spinngs All centers are in OH except Turlvay and Cold sping which are in KV in a Addreson Latenor(Warren Caunty) Turlvay, and Cold Spinngs All centers are in OH except Turlvay and Cold sping which are in KV Statistical Statistical Bis in the Wooding of Bardstown renter. Total Valuation is \$9.04 Statistical Statistical Bis in the Wooding of Bardstown renter. Total Valuation is \$9.04 Statistical Statistical Bis in the Addreson Latenor(Warren Caunty) Turlvay, and Cold Sping All centers are in OH except Turlvay and Cold sping All sping Addreson Sping Ad	Sept	67	VAGA	AA			2,000	AN										
3 3.2.080.000 2.544 13 Triad proportionate ownerstip interest in the deal resents 100% conversion 2.54 13 resents 100% conversion resents 100% conversion 2.64 13 resents 100% conversion resents 100% conversion resents 100% conversion resents 100% conversion resents 100% conversion resents 11.400 voltable 5.1 Vbe Nooca - White Oak, Anderson Leitament/Warren Countyl, Turhkay, and Cold Springs All centers are in OH, except Turhway and Cold spring, which are in KY resents 100% conversion resents 11.400 voltable 5.9 Vbe Nooca - White Oak, Anderson Leitament/Warren Countyl, Turhkay, and Cold Springs All centers are in OH, except Turhway and Cold spring, which are in KY resents 11.400 voltable resents 11.400 voltable 5.9 M resents 11.4	3 32.060,000 2.64 13 To call proprior on an once on more of in the deal 2.64,000 14 To call proprior on an once of interest in the deal 2.64,000 14 To call proprior on the deal of the deal 2.60,000 Silvetan deal also includes 5 JV Cla Nores - While Clai, Anderson Lebarox(Warren Cumy) Turkey, and Clid Spirings All centers are in Clit, except Turkey and Clid Spirings All centers are in Clit, except Turkey and Clid Spirings All centers are in Clit, except Turkey and Clid Spirings All centers are in Clit. An observe JW, of the center field was also molder 5 JV Cla Nores - While Clai, Anderson Lebarox(Warren Cumy), Turkey, and Clid Spirings All centers are in Clit. All click and the center field was also molder 5 JV Cla Nores - While Clai, Anderson Lebarox(Warren Cumy), Turkey, and Clid Spirings All centers are in Clit. All click and the center field was also 000 a. Anderson difference of the center field was also 000 an elaberox (Warren Cumy), Turkey, and Clid Spirings All centers are in Clit. All click and transmitters are in Clit. a. Anderson difference of the center field was also 000 an observed warm of click Spirings All centers are in Clit. All click and transmitters are in Clit. a. Anderson difference of the center field was also 000 an observed warm of click and transmitters are in Clit. All click and transmitters are in Clit. a. Anderson difference of the center field was also 000 an observed warm of	Set.	01	ĨN				26	-										
rial proprintendia ownership interest in the deal reacts 100% conversion. reacter intervences reacter intervences in 21,000% valuation is \$3,000.000 Silverton feat also includes 5 JV De Noros - White Cak, Anderson Letamon (Warren County), Turfray, and Cold Springs All centers ale in OH, except Turfway and Cold spring, which are in KY reacter indensity 40% of DOP, valuation is \$3,000.000 Silverton feat also includes 5 JV De Noros - White Cak, Anderson Letamon (Warren County), Turfray, and Cold Springs All centers are in OH, except Turfway and Cold spring, which are in KY reacter technological on the reaction from the technological on the area of Cold Spring All centers are in OH, except Turfway and Cold spring All centers are in KY and additional 19% in the Woodland and Berclatom centers. Total Valuation is \$5 All and cold spring All centers are in OH, except Turfwar and Cold spring which are in KY as control.	Boc rate proportionate ownership more still in the data. presents 10% ownership more still solved in the data also includes 5 JV De Norce - While Cak. Anderson Lebranci (Varren Cuurty). Turfikay, and Cold Springs All centers are in CH except Turfikay and Cold spring. Which are in KY and sets find more than the first and the ownership of the owners \$3000,000. Stireford data also includes 5 JV De Norce - While Cak. Anderson Lebranci (Varren Cuurty). Turfikay, and Cold Springs All centers are in CH except Turfikay and Cold spring. Which are in KY in a Addressing 40% of the centers are in OH excert Turfikay and Cold spring which are in KY in a Addressing 56, in the Wooding and Bardstown centers. Total Vauation is \$5,8,M and cold spring. Turfikay and Cold Spring 40, his cach inpact 151,2000 as 10,000 \$5,1000					•	82.050.000	2.504	13										
ee center (mit 53 ges and currently 80 %). DVA, 100% valueton is \$3,000,000. Silverton deal also includes 5 JV De Noros - While Cas, Anderson Lebamor(Warren Country). Turfvay, and Cold Springs All centers are in OH, except Turfvay and Cold Spring All centers are in OH, except Turfvay and Cold Spring All centers are in CH, except Turfvay and Cold Spring All centers are in CH, except Turfvay and Cold Spring All centers are in CH. All All All All All All All All All Al	<pre>constraint of the Spice and currently \$0.5% DVA, 10% valueton is \$3,000,000. Silverton deal also includes 5 JV De Novos - White Cae. Anderson Leberroy Variver, County). Turkinay, and Cuid Springs All centers are in DH except Turkiney and Cuid spring, which are in KY current as Table and Antonio TX 2000,000. Silverton deal also includes 5 JV De Novos - White Cae. Anderson Leberroy Variver, Turkiney and Cuid spring, which are in KY current as Table and a final current if allows and cuid spring. All counts, Turkiney and Cuid spring, which are in KY current as Table and Turkine and cuid spring. All counts, Turkiney and Cuid spring with are in KY and and table and the current Turkine and Cuid Springs All current Turkiney and Cuid spring. All current Turkiney and Cuid spring. All current Turkiney and Cuid spring. All current Turkiney and Cuid Springs All current Turkiney and Cuid spring. All current Turkiney and Cuid spring. All current Turkiney and Cuid Springs. All current Turkiney and Cuid Spring. All current Turkiney and Cuid spring. All current Turkiney and Cuid Spring. All current to the current Turkiney and Cuid spring. All current Turkiney and Cuid spring. All current Turkiney and Cuid spring. All valuetons as 59.4 Current are an extent as the current to the Wood and Bardstoin context. Tai Valuetons as 59.4 Current All current to the current to the All current to the All</pre>	pro rata proportionate ov eoresents 100% overerst	whership interes the	st in the deal.															
Aversens. Lebranorit/writer County. Turkwar and Cudd Sornnas went on the access Turkwar and Cudd sornna which we in KY an additional 16% in the Vicodiand and Bardatown entries. Total Vaulations \$9.54. 3.26.000 3.26.000 3.20.000	in Addression Learand Warren Country. Turkew and Cold Somma All centers are in CH. excert Turkew and Cold Somma All centers are in CH. excert Turkew and Cold Somma All centers are in CH. Weiters and Sound	one center (with 53 pts sinters in San Antonio, 1 first and then divesting	s and currently i TX. 100% value 1.40% of the ce	80.5% DVA). 100 tton is \$1,400.000 Miter. Total vale is	^{1%} e valuation is \$3,000 0 \$ \$300,000	(000. Silvei	ton deal also includes	5 JV De Novos - V	Mhile Oak, Anders	ion. Lebarron(Warren C	čounty). Turfway, ar	nd Cold Springs	: All centers are	in OH, except furty	way and Cold spring	j, which are in KY			
	us CLY west 10.0000 13.20000 14.20000 14.20000 DVA Interest divested 19.2%. Art cach mapel 13.23.000	 Anderson, Lebanoni n an additional 16% in the C-6 Month 	(Warren County) the Woodland	v). Turtway and C and Bardstown ce	old Springs. All center Inters. Total Valuation	s are in Oh) is \$9.5M	t, except Turfway and C	Cold spring which a	ve in KY										
	137.0000 1837-1000 M. Kasamma and Grieferator. D'A hitterest divested is 40%. Net cach maper 15,123.0000	53.585.000																	
	- \$6//U00). Kasamme and Celebration. D/N Interest diversion 15/92/N, Net cash mpact \$1,20,000 Interiment	s \$1.200.000																	
		Ad / B. UUU	- V.V.																

9/10/2008

	x EBITDA	00 66, 66, 66, 78, 78, 78, 78, 78, 78, 78, 78, 78, 78		
(TD 2008	Tx In FY08	14 520 18 144 18 144 10 656 1 5 876 1 3 68 1 1 386 1 1 332 2 041 2 304 2 5 313		
Closed Deals YTD 2008	PricePt	 34 455 47 619 47 619 47 619 47 619 47 619 48 669 48 669 49 464 12 644 12 644 12 644 12 644 12 644 12 644 12 643 12 644 12 643 12 644 12 644 12 643 12 644 13 70 64 13 70 64 14 70 64		
Clo	सिक्तो मंध्रायूक्त सिह्	50000 00000 o	n admand	
	incremented Unit Mix. (By & of Facilitae) CHALsPoliticalHuan Husper Mix		cht, a na Paincul and ne chreat fa Transieran Da Paisae Ar Saor Aix a chriad an faithe ant a transier A chiefe (grade than 10%	
	(a) <u>Increment</u>	~000000000 <u>-</u>	 CMLs and Political Devices MLs. High Hyper MLs. High FR grade 	
	EBITDA Year 1	(123233) (123233) (1239555 5 749078 5 2887596 5 287799 5 136875 1 14411 5 1 148 410 5 1 148 410 5 1 148 410		
	Year 3 Ceenhon Ceenh	14.8% 14.2% 13.3% 12.3% 13.3% 13.3% 13.3% 13.3% 13.3% 13.3% 11.5% 11.5%		
	H H H	16.6% 16.2% 12.5% 14.0% 14.0% 15.5% 14.5% 13.3% 13.3%		
) Centers	40-004 8		× ···· · · · · · · · · · · · · · · · ·
	Petiente (b)	100 100 100 100 100 100 100 100 100 100	28 (Yr 1) 24 (Yr 1) 28 (Yr 1) 28 (Yr 1) 28 (Yr 1) 38 (Yr 1) 38 (Yr 1) 38 (Yr 1) 98 (Yr 1) 99 (Yr 1)	22 100 23 23 23 23 23 23 23 23 23 23 23 23 23
	Transaction Value (a)	3750 000 3750 000 3 1750 000 3 1750 000 3 1750 000 3 1750 000 3 1700 000 3 1100 000 3 1100000000000000000000000000000000000	Calification Proceedings Proce	 80.579 80.579 80.579 80.579 80.579 80.577 80.579 80.579 81.280 81.280 81.479 81.470 81.470
	Eet % HIPPERS	9 F - G O O S G O G O 9 F - G O O S G O G O 9 F - G O O S G O G O 9 F - G O O S G O G O 9 F - G O O S G O G O 9 F - G O O S G O G O 9 F - G O O S G O G O 9 F - G O O S G O G O 9 F - G O O S G O G O G O 9 F - G O O S G O G O G O 9 F - G O O S G O G O G O 9 F - G O O S G O G O G O 9 F - G O O S G O G O G O G O 9 F - G O O S G O G O G O G O 9 F - G O O S G O G O G O G O G O 9 F - G O O S G O G O G O G O G O G O G O G O	2.23% 2.34% 0.64% 0.64% 5.5% 0.09% 0.00% 0.00%	7 48 12 55 8 20 9 9 20 9 9 20 9
	State	朱Q백중Q부주인번독로	₽≶≈≈₽₽₿₽≥≈≈≈₽	1 1 X X X X X X X X X X X X X X X X X X
	<u>िलोक कर्त प्रोठक</u>	1-Feb-08 1-Aer-08 1-Aer-08 1-Aer-08 1-Aer-08 1-Aer-08 1-Aer-08 20 See-08 1-Der-08 1-Der-08	1.4m.08 1.4m.08 1.4m.09 25.Feb.08 25.Feb.08 1.4m.080.08000000000000000000000000000000	1-Jan (28 1-Fab 08 1-Fab 08 1-Fab 08 1-Mar 08 1-Mar 08 1-Mar 08 1-Mar 08 1-Jan
Deal Depot	Deel Name 2009 Acquietione	Fayatterile Coestar Coesta Coesta Coesta Varias Varias Coesta Paycon Faycon Former Sectors Sectors Cours	2000 J/rs Protector Fich, J (D. Noroci) Centernari (J (D. No. Noroci) Centernari (J (D. No. Noroci) Centernari (J (D. No. Noroci) Galaxa (J (D. Norocio) Mazadora (J (D. Rokono) Mazadora (J (D. Rokono) Delhi (J (D. Rokono) Delhi (J (D. Rokono) Natartora (J (D. Rokono) Santari (J V (D. Rokono)	Total Another Acute (1/V BUYOUT) Hearter Acuterer (1/V BUYOUT) Hearter Acut

•

•

õ	
De	
Deal	
	I

.

Closed Deals YTD 2009

٠

Deal Name	Date of Close	State	Eat % HIPPERS	F	Fransaction Value	(a) Patients (b) Centers) Centers	IRR	IRR with Lab	Year 3 COC	Yr 3 COC with Lab	EBITDA Year 1	Implied (a) Price/Pt	Tx in FY08	X EBITDA	Physicians
2009 Acquisitions																
Dualysis Services of Central Florida	1-Feb-09	FL	10.3%	\$	32,600,000	474	52 C	12 2%	14 0%	**** 5	10.5%	\$ 3173719	5 60 108	67 568	1034	÷
Renown	1-Feb-09	≥ Z	13 2%	4	1 024,000	2		16.2%	27.4%	9.5%	10.5%	,	5 10 940	12 355	42.4	. 7
Bakersfield Acutes	1-Feb-09	6A CA	6 7%	43	400.000	21	۸A	47 7%	47 7%	46.5%	46 5%	\$ 496,401	\$ 18.701	2.823	08×	AA AA
Klamath Falls	1-Mar-09	OR	7 5%	49	3,500,000	51	*-	16 1%	17 5%	12.1%	12 6%	\$ 648.614	\$ 68.627	6.120	5 4 G	-1
Timpanogos PD	1-Mar-09	5	10 7%	\$	1.050.000	80	-	14.3%	15.6%	10.6%	11 1%		\$ 131.250	960	2 9 ×	n
Muskogee(JV Buyout - 38 5%)	1-Mar-09	š	6 2%	s	1.424.500	18	•	19 1%	20 4%	12 7%	12 7%			2.218	58×	
(KS(JV Buyout-40%) Wheaton	1-Apr-09 1- hun-00	¥≯ ₹	50% 00%	<i>u</i> , u	3.280.000	20	0.0	83%	10 7%	10.2%	10 2%	\$ 561,880	\$ 46.857	7,560	58×	61
	00-1100-1	ç	0/0/0	9	000,000,0	ţ	V	PLC 77	24.U%	14,4%	10 070	CIT.000 ¢	\$ 41.00/	990.7	X D D	4
Total					45,978,500	820	15	13.8%	15.6% (c)	10.8% (c)	12.1% (c)	6.080.271	\$ 65.471 (c)	() 101,660	7.7 ×	36
2009 JVs																
Wesley Chapel (JV DeNovo)	1-Jan-09	14	6 7%		AN	٩N										
Kennestone - Royale Dialysis (JV DeNovo)	1-Jan-09	GA	11.2%		AN	٩N										
Fields Forest Fair (JV)	1-Mar-09	Ю	11 5%		AN	٩N										
Blue Grass/Williamstown (JV)	1-Mar-09	КY	9.2%		AN	¥										
Fields (JV)	1-Mar-09	P	115%		AN	AN										
Cypress Woods (JV)	1-Mar-09	X	5.6%		٩N	ΝA										
Pryor (JV)	1-Apr-09	š	6.0%		٩N	AN										
District Heights (JV DeNova)	1-May-09	Ш	15.3%		۹N	NA										
Total				.		-										
				-		8	7									
2009 Divestitures / Other																
East LA (Partial Divestiture - 20%)	1-Feb-09	ð		ы	(270.000)		~									
Zephyrhilis (Partiel Divestiture - 46%)	1-Feb-09	Ę		••	(690,000)											
Hennepin (Full Divestiture)	1-Feb-09	NM		\$	(170.000)		-									
New Springs (Partial Divestiture - 15%)	1-Feb-09	z		69	(173.339)		-									
La Grange (Partial Divestiture - 20%)	1-Feb-09	КY		\$	(244.872)		~									
NW Tucson (Partial Divestiture - 50%)	1-Mar-09	4Z		\$	(875.000)		-									
Sparks and Sterra Rose (Partial Divestiture - 60%)	1-Feb-09	Ž		•9	(1.570.800)		2									
Monroe (Full Divestiture)	1-Apr-09	۲		ŝ	(1,475,199)		е,									
Amery (Partial Divestiture - 25%)	1-Apr-09	5M		•9	(416.282)		-									
West Elk Grove (Partial Divestiture - 49%)	1-Apr-09	S		-u	(1.078,000)		**									
					(1 401 1011)											
					1125-525-11	>	ŧ									
(a) Transaction Value and EBITDA reflect DaVita's pro rela proportionate ownership interest in the deal	eta proportionate own	ership interest	t in the deal.													

(a) Transaction Value and EBTDA reflect Davias pro- else proportionate ownership interest in the deel (b) Includes acute equivalent patients. *VI census* represents pro reta ownership (c) Weighted average based on Transaction Value.

Case 1:09-cv-02175-WJM Document 35-1 Filed 12/23/11 USDC Colorado Page 65 of 97

Exhibit 7

DaVita Acquisition Transactions

			_				_		_		sumptions	
			Interest				Proj. Yr 1	EBITDA		Hipper	Plugged Or	Valuation @
Transaction	Closed	State	Purchased	Purchase Price	Centers	Patients	EBITDA	Multiple	IRR	comp.	Bus?	\$18 G&A
Nephroplex	Jan-06	IL	100%	\$ 13,900,000	4	222	5 2,810,873	4.9x	18.1%	NA	no	\$ 13,000,000
Diamond Dialysis	Feb-06	IL	100%	9,150,000	2	96	2,600,260	3.5x	14.3%	750	no	8,600,000
SANC Idaho	Apr-06	ID	100%	44,000,000	6	534	7,239,870	6.1x	16.2%	NA	no	41,300,000
Las Vegas Summerlin	Jun-06	NV	60%	7,680,000	1	124	3,028,000	2.5x	15.3%			
FMC Concord	Jun-06	NC	100%	700,000	1	52	250,747	2.8x	17.4%	NA	no	500,000
Cobb Paulding	Jul-06	GA	100%	3,000,000	3	141	617,606	4.9x	17.1%	750	no	2,350,000
Eastern Connecticut	Sep-06	СТ	100%	2,500,000	2	135	498,804	5.0x	17.1%	NA	287 vs 245	1,900,000
Grand Junction	Oct-06	СО	100%	3,740,000	1	89	505,116	7.4x	16.7%	750	5 @ 1,015	3,350,000
Dyersburg	Nov-06	ΤN	100%	1,150,000	1	29	94,074	12.2x	14.7%			
Amelia Island	Nov-06	FL	100%	1,300,000	1	38	(180,320)	NM	16.6%	750	14 @ 450	1,100,000
Virginia Beach	Nov-06	VA	100%	2,300,000	1	49	193,102	11.9x	21.3%	NA	300 vs 252	2,050,000
Atlanta Dialysis	Dec-06	GA	100%	3,250,000	1	52	391,477	8.3x	9.5%	NA	staffing	2,900,000
Little Rock	Apr-07	AR	100%	\$ 300,000	2	50 \$	535,923	0.6x	69.5%	750	4 @ 1250	\$ 225,000
Florida Hemo	May-07	FL	100%	1,977,000	1	30	59,066	33.5x	19.0%	750	253 vs 239	1,550,000
South Valley	Jun-07	CA	100%	4,000,000	1	145	935,429	4.3x	19.0%	750	EPO	3,300,000
Leesburg	Jul-07	FL	100%	3,000,000	1	50	443,227	6.8x	17.4%	750	12 @ 450	2,700,000
St. Cloud	Aug-07	FL	60%	3,585,000	1	126	645,987	5.5x	18.3%	750	265 vs 245	2,880,000
Hillmed	Aug-07	ОН	60%	1,200,000	1	55	209,099	5.7x	17.3%	750	6@455	900,000
RCP Hialeah	Aug-07	FL	100%	1,100,000	1	29	(161,454)	NM	17.6%	750	1 @ 750	850,000
Hialeah	Sep-07	FL	100%	800,000	1	12	(47,130)	NM	18.5%	750	4 @ 305	600,000
Bakersfield	Oct-07	CA	100%	17,700,000	1	377	2,341,001	7.6x	14.2%	750	294 vs 262	14,400,000
Erie	Nov-07	PA	100%	8,125,000	2	199	781,687	10.4x	16.6%	750	279 vs 262	7,300,000
Dr Dahhan	Dec-07	CA	100%	18,300,000	3	311	2,323,875	7.9x	11.8%	750	staffing	16,400,000
SKI	Dec-07	AZ	50%	15,750,000	8	443	1,227,508	12.8x	18.2%	750	306 vs 260	13,500,000
Fayetteville	Feb-08	AR	100%	\$ 3,790,000	4	110 \$	6 (423,233)	NM	16.6%	750	10 @ 1050	\$ 3,100,000
Decatur	Apr-08	GA	100%	8,000,000	2	168	1,209,252	6.6x	16.2%	750	277 vs 269	7,100,000
Coastal	May-08	FL	100%	5,400,000	1	111	749,078	7.2x	12.5%	750	260 vs 239	4,800,000
Kansas	Jun-08	KS	100%	18,750,000	3	189	2,887,596	6.5x	14.0%	750	350 vs 310	17,750,000
Trover	Aug-08	KY	100%	1,100,000	1	87	220,739	5.0x	15.5%	750	1 @ 780	600,000
Payton	Sep-08	ОН	100%	28,275,000	3	295	4,306,975	6.6x	14.5%	950	WACC - g	26,100,000
Stemmer	Dec-08	FL	100%	10,000,000	1	111	1,288,987	7.8x	17.4%	2,500	2 Aetna OON	9,400,000
Caucus	Dec-08	IA	100%	14,000,000	2	170	1,148,410	12.2x	13.3%	750	320 vs 303	13,000,000
Central Florida	Feb-09	FL	100%		5	474 \$		10.3x	12.2%	2,500	WACC, HC	\$ 29,800,000
Timpanogos PD	Mar-09	UT	100%	1,050,000	1	8	359,332	2.9x	14.3%	750	290 vs NA	990,000
Kant Tucker (proposed)	Jun-09	CA	100%	71,000,000	13	1,145	6,305,764	11.3x	6.1%	2,500	WACC & g	
Totals				362,672,000	<u>83</u>	6,255	48,569,947	<u>7.5</u> x				254,295,000
Totals (2007-2008)				165,152,000	<u>40</u>	3,068	20,682,023	<u>8.0</u> x				146,455,000

DaVita Divestiture Transactions

			Transaction			Interest			
Divestitures	Closed	State	Director	Analyst	Location #	Divested	Valuation *	Centers	Patients
SAKDC	Apr 07	тх	David Finn				¢560.000	3	122
	Apr-07	PA	David Finn			100%	\$560,000	3	42
Reading KHC Silverton	May-07				LOC 3443	100%	\$200,000	•	53
	May-07	OH	Paul Dorsa				\$505,000	1	
Little Rock	May-07	AR	0" 0		LOC_1864 & 3615		\$120,000	2	50
Central Kentucky	Jun-07	KY	Giles Caver		LOC_0555 & 2055		\$1,520,000	2	
IMS / St. Cloud	Aug-07	FL		Chris Pannell	LOC_0170, 0178, 4013	40%	\$3,075,000	3	211
Ionia	Oct-07	MI	Giles Caver		LOC_2252		•	1	26
Hemet	Feb-08	CA	Ken Leidner		LOC_0878	40%	\$260,000	1	92
Manzanita - At Home	Feb-08	CA			LOC_6016	49%	\$143,898	1	
Columbus	Mar-08	OH	Finn / Menezes	Chris Pannell	LOC_2318, 3354, 3454, 3566	40%	\$4,208,177	3	297
TRC Colorado	May-08	CO	Ken Leidner	Ben Chiu		49%	\$1,396,757	2	
Mountain West Dialysis,LLC	Jun-08	CO	Ken Leidner	Ben Chiu		49%	\$2,412,786	6	628
Waynesboro	Jul-08	GA	Giles Caver				\$139,769	1	31
Shadow Dialysis	Oct-08	CA			LOC_1930	49%	\$1,296,338	1	
Wauseon	Nov-08	OH	John Walcher		LOC_2254	10%	\$223,150	1	
Shadow Dialysis	Nov-08	CA			LOC_1930	10%		1	
Mainplace	Dec-08	CA	John Walcher	Ben Chiu	LOC_0884	36%	\$1,400,000	1	
East LA	Feb-09	CA			LOC_2541	20%	\$3,850,000	2	
Zephyrhills	Feb-09	FL	Demetrius Menezes	Sheila Bruch	LOC_4068	46%	\$1,500,000	1	
Hennepin	Feb-09	MN	John Walcher		LOC_0244	100%	\$170,000	1	
New Springs	Feb-09	IN				15%	\$1,155,592	1	
La Grange	Feb-09	KY			LOC_2148	20%	\$1,224,358	1	
NW Tucson	Mar-09	AZ		Ben Chiu	LOC_2325	50%	\$1,750,000	1	
Sparks and Sierra Rose	Feb-09	NV	Ken Leidner	David Barbetta	LOC_0844, 2015	60%	\$2,618,000	2	162
Monroe	Apr-09	LA	Ben Jacobs			100%	\$1,475,199	3	
Amery	Apr-09	WI	John Walcher		LOC_1966 or 4305	25%	\$1,665,128	1	
West Elk Grove	Apr-09	CA	John Walcher	Alan Zhang	LOC_2343	49%	\$2,200,000	1	

* It remains to be determined which of these are 100% valuations and which are the proceeds received for the pro rata interest sold.

Case 1:09-cv-02175-WJM Document 35-1 Filed 12/23/11 USDC Colorado Page 68 of 97

Exhibit 8

Rocky Mountain							Transao	Iransaction Summary
Acauisition Metrics					Forecasted Closing Date:	sing Date:		May-06
Total Purchase Price Total IRR. Total IRR. Total IRR. Mult. of Yr 1EBITDA Mult. of Yr 1EBITA Mult. of Yr 1EBITA Mult. of Yr 1EBITDA - Recur. Outpl. Capex Mult. of Yr 1 Net Income Mult. of Yr 1 Net Income Yr 3 Cash on Cash Return	t. Capex		 39,496,669 3.5% 4.4% 10.3X 11.4x 11.4x 12.8x 10.6x 21.5x 8.9% 					
<u> Outpatient Business Only</u>				7	<u>Acute Business Only</u>	제		
Outpatient Purchase Price			\$ 39,496,669		Acute Purchase Price	e Price		•
Outpatient IRK Outpatient IRR, including Lab Mult. of Yr 1 EBITDA Mult. of Yr 1 EBITA Mult. of Yr 1 EBIT			3.5% 4.4% 10.3x 11.4x 12.8x		Length of Contract Revenue Per Acute Tx Required iRR Yr 3 Cash on Cash Return	ute Tx ute Tx ish Return		
Mult. of Yr 1 EBITDA - Recur. Oupt. Capex Mult. of Yr 1 Net Income (1) Yr 3 Cash on Cash Return (2) Purchase Price Sensitivity	t. Capex		10.6x 14.5x 8.9%		Finance adjustments? MSP Extension? Likelihood of Extension Months of Extension Year Extension Begins	ments? ? xtension nsion Begins	Yes No 80.0% 6 Months 2	
				Required IRR	d IRR			
Outpatient Business	12% \$ 39,496,669	13% \$ 39,496,669	14% \$ 39,496,669	15% \$ 39,496,669	16% \$ 39,496,669	17% \$ 39,496,669	18% \$ 39,496,669	19% \$ 39,496,669
Acute Contract Total Purchase Price	\$ \$ 39,496,669	\$ \$ 39,496,669	\$ 39,496,669	\$ 39,496,669	\$ 39,496,669	\$ 39,496,669	\$ \$ 39,496,669	\$ \$ 39,496,669
Year 1 & 2 Non-Recurring Capex	\$ 120,000	\$ 120,000	\$ 120,000	\$ 120,000	\$ 120,000	\$ 120,000	\$ 120,000	\$ 120,000
Mult. of DVA Yr 1 EBITDA	10.3x	10.3x	10.3x	10.3x	10.3x	10.3x	10.3x	10.3x
Summary Financials								
Avg. Patients	2004	2005 230	Base Year 230	Year 1 235	Modeled Projections Year 2 Yea 244	ojections Year 3 254	Year 4 264	Year 5 274
Treatments Tx Growth	•	33,126	33,126	33,789 2.0%	35,140 4.0%	36,546 4. <i>0</i> %	38,007 4.0%	39,528 4.0%
Net Revenue Per Tx	' ↔	\$ 4,887,202 \$ 147.53	\$ 10,443,853 \$ 315.28	\$ 10,652,730 \$ 315.28	\$ 11,189,627 \$ 318.43	\$ 11,753,585 \$ 321.61	\$ 12,223,728 \$ 321.61	\$ 12.712,677 \$ 321.61
EBITDA Per Tx % of Revenue	ج	\$ 1,549,047 \$ 46.76 31.7%	\$ 3,817,503 \$ 115.24 36.6%	\$ 3,823,176 \$ 113.15 35.9%	\$ 4,024,118 \$ 114.52 36.0%	\$ 4,223,103 \$ 115.56 35.9%	\$ 4,311,389 \$ 113,44 35,3%	\$ 4,397,692 \$ 111.26 34.6%
Pre-Tax Income				\$ 3,077,336	\$ 3,266,705	\$ 3,349,976	\$ 3,426,691	\$ 3,501,423
Taxes				\$ 1,243,244	\$ 1,319,749	\$ 1,353,390	\$ 1,384,383	\$ 1,414,575
Book Net Income				\$ 1,834,092	\$ 1,946,956	\$ 1,996,586	\$ 2,042,308	\$ 2,086,848
EPS Fully Diluted Shares Outstanding				\$ 0.017 107.2 MM	\$ 0.018 107.2 MM	\$ 0.019 107.2 MM	\$ 0.019 107.2 MM	\$ 0.019 107.2 MM
Capex				\$ 201,000	\$ 81,000	\$ A10.000	\$ 81000	\$ 81 000

 Purchase Price/(Net income + Tax Affected interest Expense)
 After-tax C/F to Capital divided by Total Capital Expended (yrs 1-3). Model created by: NAME

Exhibit 9

Denver Transaction Summary

Component	Valuation	Centers	Valuation per Center	EBITDA (1)	EBITDA Multiple	Patients	Price per Patient
Acquired Centers (2) Divested Centers (3)	\$ 38,571,400 \$ 3,865,000	3 6	\$ 12,857,133 \$ 644,167	\$ 2,423,878 \$ 3,598,929	15.9x 1.1x		\$ 171,428 \$ 6,951

(1) Twelve month period 6/1/2008-5/31/2009.

(2) Valuation figure represents 100% of value. Amount attributable to the 49% ownership interest which DaVita purchased from Denver Nephrology was \$18,899,986.

(3) Valuation figure represents 100% of value. Amount attributable to the 49% ownership interest which DaVita sold to Denver Nephrology was \$1,893,850.

Exhibit 10

REDACTED

and the second second

From: Chet Mehta

Sent: Tuesday, May 19, 2009 11:44 PM

To: Richard Whitney; Bob Badal; Tom Usilton; David Finn

Cc: Javier Rodriguez; Doug Saqui; Theresa Benson; Susan Dynes

Subject: RE: Acquisition Revenue Build Up Assumptions

Wow. Mike Staffieri, Bryan Parker, Dave Barbetta and I have been talking about the exact same issue on Number 3 (Hipper Compression). Mike/Bryan/I have been talking about an idea to retain Hipper compression but much different way than in current model. And then David Barbetta refined it to be something very similar to what Rich/Bob are talking about. I will be talking to Cassie to see what the right threshold for compression is to produce aggregate results comparable to Total SNIPER hit. A bunch of people on this email have been invited to a 7am call (Pacific) on THursday. Please try to participate if you can. (Rich/Tom/Bob mandatory or we will have to reschedule the call.....again)

From: Richard Whitney
Sent: Tue 5/19/2009 9:43 PM
To: Bob Badal; Tom Usilton; David Finn
Cc: Javier Rodriguez; Doug Saqui; Chet Mehta; Theresa Benson; Susan Dynes
Subject: Re: Acquisition Revenue Build Up Assumptions

1. Assumption should be the contracted increases.

2. Uhc. I think using the 2x rate penalty (ie 2/3 of what they owe us contractually) is appropriate for now. This should be consistent w what is in system rev (double check pls).

3. If all of our private pay compresses to 750 without increases in the lower rate biz or mcare...we are out of business. In other words this is not a realistic assumption. I would say for sure you shouldn't lower the rate for plans where we have long term contracts. Then instead of just assuming all of the high rate biz comes down we instead may want to assume a certain % reduction in avg non gov rate or assume avg non gov rate drops to something like 750 (if the acq asset has avg non gov rates above 750)

4. Depending on how we end up on 3 above this may not be relevant bc you just have an overall assumption for non gov whether contracted or not. If we don't go that way then we should consider having rates decline to 70% of charges over time.

Thx for bringing this up. We need to get these assumptions closer to our best (conservative) cut rather than something that is so conservative that it loses its usefulness.

From: Bob Badal
To: Tom Usilton; David Finn
Cc: Javier Rodriguez; Doug Saqui; Richard Whitney; Chet Mehta; Theresa Benson; Susan Dynes; Bob Badal
Sent: Tue May 19 21:07:16 2009
Subject: Acquisition Revenue Build Up Assumptions

TU,

Not sure if you are aware, but I have a standing call every week (sometimes 2x per week) with Theresa Benson, Doug Saqui, and Susan Dynes to discuss current acquisition revenue build up models. During these calls, we review all private payor revenue data for deals in play...both pre due diligence and post due diligence assumptions.

For pre due diligence, it is rare to have complete and accurate private payor data (contracts, rates, cash,

contract terms, etc) from sellers. As such, we make educated decisions on what rates would be appropriate to include in the model. These rate build up assumptions, at the payor level, can be set at 1) sellers rates, 2) DVA's contracted rates with that payor, 3) DVA's non-k rates, 4) % of DVA's billed charge, 5) Medicare...or some combination thereof.

For post due diligence (after DVA has been selected as a finalist), we typically receive more complete and accurate data from the seller re: private payor rates/contract information. During these post due diligence calls, the team evaluates any changes that are necessary to the pre due diligence rate assumptions.

The purpose of this email is to highlight a couple of the revenue assumption practices that we are using in these models, and, where appropriate, recommend changes to those assumptions. Here are a few questions that I would like your input on:

- Currently, the model assumes flat 1% increases on contracts instead of actual contract set increases we
 propose that this change to more accurately reflect contract increases; this will add some extra work to the
 process however.
- For United Healthcare we are assuming booked revenue this includes penalty amounts that were effective 1/1/09; these penalty increases have not yet been realized and will be tied up in legal arbitration for a while; should we continue to include these penalties in our rate build up for acquisitions
- For all contracted and noncontracted payors, the model compresses revenue to \$750 all in for years 3 and beyond. Does this rate compression policy still hold true, given the success (though limited) that we have had in fighting ONR? Also, the logic of compressing contracted revenue that is currently above \$750 RPT is overly conservative for select payors like Multiplan, BCBS IL, Med Mutual of Ohio, etc payors whose current \$750+ contracted RPT is not expected to drop anytime soon.
- Should we consider establishing a general rule that when there is noncontracted payment history in excess of 70% of billed charges, that we cap the revenue at 70% of billed charges in the model (ie., if we are currently getting paid at 90% of billed charge, it seems a bit bold to assume that we will continue to get that much...so should we discount it to a more conservative 70% figure)

Please provide your thoughts to the above 4 items. Thanks

Bob

Case 1:09-cv-02175-WJM Document 35-1 Filed 12/23/11 USDC Colorado Page 75 of 97

Wauseon Valuation Summary

Projection		Year 1	Year 2	Year 3	Year 4	Year 5
With HIPPER Compression Net Cash Flow Minimum Fair Market Value	\$ \$	14,590 1,744,814	\$ 890,240	\$ 280,015	\$ 184,598	\$ 1,743,717
Without HIPPER Compression Net Cash Flow Minimum Fair Market Value	\$ \$	14,590 3,940,163	\$ 890,240	\$ 529,306	\$ 585,480	\$ 5,697,874

HIPPER Compression artifically depressed the supposed fair market value of this center by more than 50%.

Confidental and Proprietary Draft

Atlanta Dialysis Center, LLC

Staffing Projections

∢	
ശ	
÷	
ta	
Ē	
<u></u>	
7	

Atlanta, GA		ts.		e n Assist	13	Overtime Overtime Ptx	Transition Buffer Transition Buffer Alkocation	Total SWC SWC Ptx	Profit Sharing Profit Shanng Ptx	Total SWB SWB Ptx	Annu PD Patients Hemo Equivatent Treatments	CC RN FCT FCT RPCT Reuse Admin Assist Dietician	d Tre Me Ptx	Transition Buffer Transition Buffer Allocation	Total SWC SWC Plx	Profit Sharing Profit Sharing Ptx	Total SWB SWB Pix
35% 3%	3% 5% 10% Annual Yr 1	Salary	73,000 56,150 41,600	30,500 28,120 23,766	56,160 56,160 37,440]	Annual Yr 1 Satary]
	Proje	G.1 54 1,864	888	4 0 0 8 8 8				11.25			Q1						
	ted Year 1 He	02 54 1,947	888	4-0 9-0-0 9-0-0	0.76 0.75 0.40			11.25			ted Year 1 Hee Q.2						
	Projected Year 1 Headcount per Querter	0.3 54 1,983	899		075 27.0			11.25			Projected Year 1 Headcount per Quarter Q2 Q3						
	uarter	9.4 54 1,993	888	0.65 0.65 0.65	0.75			11.25			uarter Q.4						
		Yr 1 54 7,788	1 2 8					11.25		;							
		8,096	1.25 1.25 1.25 1.25					0.01			Pr Yr 2				•		
	roiected Header	Yr 3 58 8,423	404 150 150 100 100	2.36 0.65 0.90	0.75 0.75 0.40			9.31			Projected Headcoun	,					
	turi	~ ۲	4 0% 1 1 00 1 2 0 1 2 0	2.80 0.65 0.90	0.75 0.75 0.40			9.85			ount Yr 4	, , , , , , , , ,					
		Yr 5 63 9,110		3.46 0.65 0.90	0.75 0.75 0.40			10.41			Yr 5 -						
		5	\$ 18,250 \$ 14,040 \$ 10,400		\$ 10,530 \$ 10,530 \$ 3,744	\$ 8,563 5 4.59	\$ 24,549 50%	\$ 147,292 \$ 79.02	•••	\$ 100,252 \$ 102.07	a			\$ - 50%	, WN \$, WN \$, ¥2
	We t swy	02			\$ 10,530 \$ 10,530 \$ 3,744	\$ 8,563 \$ 4.40	\$ 14,729 30%	\$ 137,472 \$ 70.59	ч ••••	\$ 180,432 \$ 92.65	Year 1 SWBs per 9	•••••••••		\$ 30%	. WN	, WN \$. WN
	Ramer Churder	ð	69 V9 V9	69 69 69		\$ 8,563 \$ 4.32	\$ 9,819.44 20%	\$ 132,562 \$ 66.85	\$ 5,302 \$ 2.67	\$ 180,625 \$ 91.19	3s per Quarter Q.3	••••••••••••	чэ Ил Ил И	\$ 20%	. WN S	. www.	• NN
		44	69 69 69	69 1 69 169	\$ 10,530 \$ 10,530 \$ 3,744	\$ 8,563 \$ 4.30	\$ •	\$ 122,743 \$ 61.58	\$ 4,910 \$ 2.46	\$ 170,613 \$ 85.60	70			ۍ مرو	• ^W Z	• • •	, <u>MN</u>
-	_	λι.1	\$ 73 \$ 56 \$1	s 54 54 18 54 54 54 54 54 54 54 54 54 54 54 54 54	 \$ 42,120 \$ 42,120 \$ 14,976 	\$ 34,254 \$ 4,40	\$ 49,097	5 69.35	\$ 10,212 \$ 1.31	\$ 722,122 \$ 92.73	¥11			, ,,	, <u>W</u>	• WZ	. W
		Yr 2	\$ 75 \$ 72 \$ 42	\$ \$ \$ \$2 22 22	\$ 43 15 15	4 \$ 30,488 0 \$ 30,488	-	9 \$ 436,908 5 \$ 53,96	2 5 17,480 1 5 2.16	2 5 6 07,427 3 5 75 00					•	•	•
	and the set of the	Yr 3	59 59 59	~~~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	384 S 44, 384 S 44, 384 S 15, 44, 5	v i 64		•••		ي د د	SWBs per Year	~~~~~~~			\$ 	• •	• • •
		E E	446 \$ 370 \$	445 \$ 081 \$ 720 \$	685 5 685 5 888 5	32,659 \$ 3.88 \$		468,112 \$ 5 55.58 \$	18,724 \$ 2,22 \$	650,675 \$ 6 77.25 \$	<u>11 (041)</u>				* wn	* WN	\$
		(14			46,026 5 46,026 5 16,365 5	34,985 \$ 3.99 \$		501,457 \$ 57.24 \$	20,058 \$ 2.29 \$	667,025 \$ 79.57 \$	1	· · · · · · · · ·			• • WN	• . WN	• • •
		Yr 5			47,406 47,406 16,856	37,473 4.11		537,114 58.96	21,485 2.36	746,589 81,85	Yr 5		• • •		. ¥	. WN	- WN

(1) Fer HR department, profil sharing experiees are delayed 12 months after beginning the program (2) Assumed SWB1K of 375, which is consistent with that of DVA comps. growing at 3% annually thereafter

Confidential and Proprietary Draft

Dr. Dahhan Location

Consolidated Income Statement Outpatient Business Only

TREATMENTS: 5/31/2004 FERTX In Center 102 94% From Center 102 96% Acue 1/1,114 1000 % REVENUES: 1/1,114 1000 % REVENUES: 2,986.225 115.54 Picenser, Revenue 2,986.225 115.54 Picenser, Acute 2,986.225 115.64 Promovine 2,986.225 115.64 Promovine 2,1613 2,1164 Promovine 2,386.225 115.64 Promovine 2,360.3 260.3 Acute 20,522 46.95 For Acute 2,425.41.38 2,60.3 Acute 4,256.41.38 2,60.3 Contractual Allowand 4,256.41.38 2,60.3 Net Revenue 2,435.0 2,733.2 Total Other Income 2,435.0 2,733.8 Net Revenue 2,435.0 3,348 SW& - Contractual 2,435.0 3,348 SW& - Chronic 1,426.30 833.96	\$3112004 11.412 780 12.192 12.192 2.240.068 \$ 2.240.068 \$ 129,433 414,745 \$ (44,245) \$ (44,245	PERIX 93.6% 6.4% 6.4% 6.4% 7.000% 5.833 36.933 36.933 36.933 36.933 36.933 36.933 36.933 36.933 36.933 36.933 36.933 5.933 5.935 5.935 5.833 5.833 5.935 5.855 5.8555 5.8555 5.8555 5.8555 5.85555 5.855555 5.855555555		PERTX 100.0% 0.0% 100.0% 100.0% 55.33 55.33 27.78	0.1 10.627	0.2 0.3 10.485 0.3	03	5	YEAR 1	YEAR 2	YEAR 3	YEAR 4	YEAR 5	
17,012 99.4% 102 102 102 102 102 105 17,114 100.0% 17,114 100.0% 17,114 100.0% 13,115 21,155 14,116 21,155 14,116 21,155 14,116 21,155 14,116 21,155 14,116 21,155 14,116 21,155 14,128 243,55 14,128 243,55 14,128 243,55 14,128 243,55 14,128 243,55 14,128 243,55 14,128 2,33,95 14,140 2,33,35 1,100 1,000 1,100 2,33,35 1,100 2,33,35 1,100 2,33,35 1,100 2,33,35 1,100 2,33,35 1,100 2,33,35 1,100 2,33,35 1,100 2,33,36 </th <th>11,412 700 12,192 12,192 152,144 719,433 414,796 414,796 2536,432 (44,245) (44,245) 2536,432 256,53 87,55 87,55 87,55 87,55 87,55 10,373 11,657,049 11,0373 148,012 16,802</th> <th>92.6% 6.4% 6.4% 100.0% 5.88 359.83 359.83 359.83 359.83 359.83 359.83 359.83 359.83 2.80.06 (3.63) 2.80.06 2.83 2.83 13.30 13.30 13.30 13.30 13.30 13.30 13.30 13.30 13.50 13.50 13.50 13.50 13.50 13.50 13.50 14.</th> <th></th> <th></th> <th>10.627</th> <th>10.485</th> <th>000 01</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	11,412 700 12,192 12,192 152,144 719,433 414,796 414,796 2536,432 (44,245) (44,245) 2536,432 256,53 87,55 87,55 87,55 87,55 87,55 10,373 11,657,049 11,0373 148,012 16,802	92.6% 6.4% 6.4% 100.0% 5.88 359.83 359.83 359.83 359.83 359.83 359.83 359.83 359.83 2.80.06 (3.63) 2.80.06 2.83 2.83 13.30 13.30 13.30 13.30 13.30 13.30 13.30 13.30 13.50 13.50 13.50 13.50 13.50 13.50 13.50 14.			10.627	10.485	000 01							
s 17.114 100.0% venue 5 2.966.225 5 175.54 2.166 205 1613 2.1169 0ther 2.1613 2.1169 0.01 46.56 103.522 46.56 26.03 445.833 26.03 445.833 26.03 445.833 26.03 445.833 26.03 445.833 26.03 46.95 0.000 1.1,428.630 5 83.36 5 23.36 1.1,428.630 5 83.36 001 2.1,428.630 5 83.36 002 1.1,428.630 5 83.36 003 64.5400 10.00 003 64.5400 10.00 003 5.5400 10.00 000 5.5400 10.000 5.5400 10.000 5.5400 10.000 5.5400 10.000 5.5400 10.000000000000000000000000000000000	12.192 12.10068 152.134 729.435 729.435 414.796 3.530.432 (44.245) 3.530.432 135.049 1.057,049 1.057,049 1.0373 148.012 148.012 148.012 148.012	100.0% 196.28 196.02 196.02 36.35 36.35 36.35 36.35 36.35 36.35 26.00 26.33 26.43 11.30 27.63 286.43 11.30 11.30 27.63 286.43 27.63 286.43 27.63 286.43 27.63 286.43 27.63 28.53 28.63 28.53 28.					10.89U	11.025	43.026	45,983	48.016	51.368	54.977	
venue \$ 2,966,225 \$ 175,54 each 21,613 \$ 2175,54 Cither 803,522 \$ 46,55 Cither 803,522 \$ 46,55 at Allowanc \$ 003,842 \$ 5,26 at Allowanc \$ 003,842 \$ 35,26 at Allowanc \$ 003,842 \$ 35	2,240,058 152,146 729,433 414,796 3,536,432 (44,245) (44,245) 2,96,43 87,55 10,373 11,057,049 1,057,049 1,037,049 1,047,049 1,	166 28 156 028 56 88 56 88 56 88 36			10,627	10.485	, 10.890	11,025	, 43.026	45.983	, 48.016	51.368	54.977	
8 21613 21169 Other 235,523 46,65 Other 442,836 26,03 Jai Allowand 5 42,816 26,03 Arradual 603,642 5,524 26,03 Arradual 603,642 5,524 26,03 Arradual 603,642 5,524 26,00 Arradual 603,642 5,524 26,000 Arradual 603,642 5,524 26,000 Arradual 603,642 5,524 26,000 Arradual 1,000 2,000 0,000 Arradual 8 43,850,040 5,93,86 6 Arradual 8 83,459 0,000 1,000 Arradua 7,1,428,630 8,83,98 6 1,040 Arradua 27,1836 1,030 1,040 1,030 Arradua 21,049 1,030 1,030 1,030 Arradua 21,049 1,030 1,030 1,030 Arradua </td <td>152,144 152,144 159,439 1414,7965 141,7965 159,432 159,432 169,7049 1,057,049 1</td> <td>156.02 36.98 36.98 36.98 36.98 36.58 (3.63) (3.63) (3.63) (3.63) (3.63) 13.20 266.43 13.30 13.30 13.30 13.30 13.30 5.65 12.55 5.65 12.56 5.65 12.56 5.65 12.56 5.65 12.56 5.65 12.56 5.65 12.56 5.56 12.56 5.56 12.56 5.56 5.56 5.56 5.56 5.56 5.56 5.56</td> <td></td> <td>55.33 27.78</td> <td>\$ 1.916.908</td> <td>\$ 1.891.517</td> <td>\$ 1 964 646</td> <td>\$ 1989.226</td> <td>3.0% \$ 7.62.297</td> <td>6.9% \$ 8.415.977</td> <td>00 44</td> <td>7.0% • 9519656</td> <td>7.0% * 10.277 RM</td> <td></td>	152,144 152,144 159,439 1414,7965 141,7965 159,432 159,432 169,7049 1,057,049 1	156.02 36.98 36.98 36.98 36.98 36.58 (3.63) (3.63) (3.63) (3.63) (3.63) 13.20 266.43 13.30 13.30 13.30 13.30 13.30 5.65 12.55 5.65 12.56 5.65 12.56 5.65 12.56 5.65 12.56 5.65 12.56 5.65 12.56 5.56 12.56 5.56 12.56 5.56 5.56 5.56 5.56 5.56 5.56 5.56		55.33 27.78	\$ 1.916.908	\$ 1.891.517	\$ 1 964 646	\$ 1989.226	3.0% \$ 7.62.297	6.9% \$ 8.415.977	00 44	7.0% • 9519656	7.0% * 10.277 RM	
Other 442,838 26,00 ue 2,42,64,199 2,243,59 ue 4,254,199 2,243,59 ue 4,254,199 2,243,59 ue 1,428,040 2,243,58 ue 1,428,040 2,243,58 onic 1,428,630 2,83,38 ei 1,428,630 2,83,38 onic 2,1436 10,30 ei 2,1436 10,30 ei 1,428,630 2,83,38 ei 2,1436 10,30 ei 1,304 ei 1,30	414,796 3.530,432 3.530,432 (44,245) (44,245) 3.530,432 186,432 87,55 11,057,049 11,057,049 11,0373 148,012 148,012 148,012 148,012	36.35 280.06 (3.63) 92.63 13.30 13.30 13.30 12.55 13.30 12.55 13.30 13.30 12.55 13.30		27.78		-	•	-						
Nue 5 4.254.128 5 248.56 ati Allowanc 5 0.33.842 5 35.28 arradual er income - - 0.0 0.000 mue - - 0.0 0.000 5 283.66 nue - - - 0.0 0.000 5 3.0 0.000 nue - - 4.858.040 5 283.86 5 283.86 5 3.0 0.000	3536452 (44.245) (44.245) 3492.186 286.43 87.55 10.373 11.867.049 10.373 148.012 461.822	290.06 (3.63) 286.43 286.43 113.30 113.30 112.97 112.97 587.53			295,193	291,177	302,325	305,996	1,194,691	1,285,569	1,324,626	1,425,084	3,002,994 1,533,842	
at Allowanc 5 603,842 5 35.28 tradual er Innorme 5 43.580.040 5 283.86 s 4.558.040 5 283.86 s 83.48 s 83.48 and 1,428.630 5 83.36 er 1,428.630 5 83.36 er 1,428.630 5 83.36 er 1,304 er 1,058 er 1,	(44.245) (44.245) 286.43 286.43 87.55 87.55 1.057,049 10.373 148.012 45.802	(3.63) (3.63) 0.00 286.43 13.30 13.30 13.30 13.30 13.30 13.30 13.30 13.30 13.30 13.30 13.30 13.53 14.53 15.55 15.55		263.49	\$ 2.800.170	\$ 2762 991	\$ 2,869.724	\$ 2.905.537	\$ 11.338.421	\$ 12.261.545	\$ 12.780.067	\$ 13.779.658	5 14.864.437	
s 283.86 83.48 83.48 83.48 83.48 83.48 83.38 1,428.630 \$ 83.98 1,428.630 \$ 83.98 1,428.630 \$ 83.98 1,428.630 \$ 83.98 1,24 1,058 10 10 37 1,058 10 1,058 10 1	286.43 87.55 1,057,049 10,373 10,373 148,012 45,832	·····		263.49	2.800.170	<u> 2.762.991</u>	2.869.724	s 2.905.537	<u>\$ 11.338.421</u>	<u>5 12 261 545</u>	<u>\$ 12.780.067</u>	<u>s 13.779.658</u>	5 14.864.437	
Chronic \$ 1,428 630 \$ 83 38 PD Acute \$ 1,428 630 \$ 83 38 Acute 221 836 13 04 Jupiles Priving 221 836 13 04 Jupiles Acute	1,057,049 10,373 148,012 45,832		263.49 82.84	3	\$ 263.50 \$ 88.36	\$ 263.52 \$ 84.93	\$ 263.53 \$ 81.78	\$ 263.54 \$ 76.38	\$ 263.52 \$ 82.79	\$ 266.65 \$ 76.84	\$ 266.16 \$ 77.90	\$ 268.26 \$ 76.68	\$ 27037 \$ 7547	Rev/tx Total SWB/Tx
221,836 1,058 #D	- 148,012 45,832	- 12.97 58 75	3,459,368	8.78 18	\$ 938,982 -	\$ 890,518 -	\$ 890,518 -	\$ 842,054	\$ 3,562,072	\$ 3,533,225	\$ 3.740,447	\$ 3,939,061	\$ 4,148,895	Vanes Variae
[G #	45,652		466,929	11.18	- 112,093	112,261	- 125,881	131,251	- 481,486	- 563,297	- 588,191	- 629,252	673,470	2.0% per ta stable per tx
	•						, 1							stable per b stable per b
	, ,	10//ND#	078'0trS	8.19 •	86,849	80, 151 -	52,279 -	40,243	259,523	114,959 -	120,039	128,419 -	137,443 -	stable per tx stable per tx
696,995	498,185	40.86	1,757,750	42.09	447,297	- 441,336	458,361	464,058	1,811,052	1,969,392	2.092,414	2,277,659	2,480,369	stable per ty 18% to myrs 2-
Ces 01181 2/18/182 08:502	73,134 23,355	1.92	739,866	0.50	188,275 5,313	185,766 5,243	192,932 5,445	186,330 5,512	762,302 21,513	814,693 22,992	850,697 24,008	910,084 25,684	974,035 27,489	0.0% per tx stable per tx
49,155	71,876 66,394	5.90 5.82	220,070	5.27 2.58	56,003 27,410	55,260 27,046	57,394 28.091	58,111 28,443	226,768	245,231 118.964	255,601 125,279	275,593 134 445	297,289 144 358	2.0% 0.0% net h
ne 75,362 36,954	55,835 24,658	4.89	194,656 83,520	4.66 2.00	50,124 21.891	50,12 4 21,599	50,124 22 433	50,124	200,496 88,634	206,511	212,706	219,087	225.660	3.0%
Taxes and Licenses 27,426 1.60 Office & Other Sup 26.56 1.55	6,533 20 680	0.54	41,760	8.4	10,649	10,649	10,649	10,649	42,595	43,447	44,316	45,202	46,106	2.0%
87,715	86,329	2.08	208,800	5.00 (2)	62,802	57,777	17,825 55,537	16.047	70,430	75,270 239,206	78,597 254,773	84,084 278,009	89,992 303,496	0.0% perto 2.0% perto
es 1,130 120,000	1, 145 65, 000	0.09 5.33	3,340	0.08 8,14	835 85,000	835 85,000	835 · 85,000	835 85,000	3,340 340,000	3,507 340,000	3,682 340,000	3,866 340,000	4,059 340,000	5.0%
Macri. Uper. Lease	80,366 391,641	6.59 32.12	500,325 563.760	11.98 13.50	128,834 143,461	128,834 141,549	- 128.834 147.009	128,834 148,836	- 515.335 580.856	- 530,795 620,776	546.719 648.710	- 563,120 693 462	580,014 742-191	0.0% 3.0% \$13.50 per tv
Total Expenses \$ 4,107,089 \$ 239.98 \$	2,726,706 \$	223.64 \$	9.118,013 \$	5	\$ 2,383,212	\$ 2,311,110	\$ 2,329,148	\$ 2,286,265	\$ 9,309,734	\$ 9,539,831	\$ 10,030,614	\$ 10,662,656	\$ 11.342,334	
EBITDAT \$ 750,951 \$ 43.88 \$ EBITDATx \$ 43.88 \$ EBITDATx \$ 43.88 \$ EBITDAMargin 15.5%	765,481 \$ 62.78 21.9%	62.78 \$ \$	1,885,497 \$ 45.15 17.1%	45.15	\$ 416,958 \$ 39.24 14.9%	\$ 451,081 \$ 451,081 \$ 43.10 16.4%	\$ 540,576 \$ 540,576 \$ 49.64 18.8%	5 619,272 5 619,272 5 56.17 21.3%	5 2,028,687 5 2,028,687 5 47.15 17.9%	5 2,721,714 5 2,721,714 5 59.19 22,2%	5 2,749,453 5 2,749,453 5 7,26 21,5%	\$ 207 58 \$ 3,117,002 \$ 60.68 22 6%	5 206 31 5 3,522,103 5 64.06 23 7%	
Depreciation \$ 155,634 \$ 9.09 \$ Amortization -	43,560 \$	3.57	172,864 \$	4.14 4.08	43,216 42,633	43,216 42,633	43,216 42,633	43,216 42,633	172,864 170,530	255,444 170,530	271.515 170,530	287,586 170,530	303,658 170,530	-
BIT <u>\$ 595.317</u> <u>\$ 34.79</u> <u>\$</u> EBIT/T _X <u>\$ 34.79</u> <u>\$</u>	721.921 \$ 59.21	59.21 \$	1.542.103 5 36.93	36.93	<u>\$ 331.109</u> \$ 31.16	\$ 366.033 \$ 34.91	<u>\$ 454.727</u> \$ 41.76	<u>\$ 533.424</u> \$ 48.38	<u>\$ 1685.293</u> \$ 39.17	\$ 2.295.740 \$ 49.93	<u>\$ 2.307.408</u> \$ 48.06	<u>\$ 2,658,885</u> \$ 51.76	<u>\$ 3047.915</u>	

(1) SWBBs include all benefits, payroli axes, profit sharing (defended for six months in Year 1), and bonuses. SWB projections in Year 1 includes a 10% buffer, 50% of which is allocated to Q1, 30% in Q2 and 20% in Q3 (2) Includes RO Supplies. T&E. Other Purchase Services, Freight/Postage Equipment Rental, Laurdry & Linen, and Misc. & Other expenses in year 1, includes taken buffer of \$0, 300%, allocated 2/3 in Q1 and 1/3 in Q2.

y Centers		
Regional Kidney Centers NW Arkansas	Acquisition Metrics	

Transaction Summary

Feb-08

	\$ 3,790,000	
I otal IRR	16.6%	
Total IRR, Including Lab	19.5%	
Mult. of Yr 1 EBITDA	20	
Mult. of Yr 1 EBITA		
Mult. of Yr 1 EBIT		
Mult. of Yr 1 EBITDA - Recur. Outot. Capex		7.0
Mult. of Yr 1 Net Income (1)	X4.0- X1.0-	
Yr 3 Cash on Cash Return (2)	14.8%	

걸
δ
8
g
1
õ
뉟
읰
a
뙭
OI

	Acute Purchase Price	Length of Contract	Revenue Per Acate Tx	Reduired IRR	Vr3 Cash on Cash Batim		Finance adjustments?	MSP Extension?	Likelihood of Extension	Months of Extension	Year Extension Begins
	3./30,000	19.5%	X0.9-	-5.8x	-5 4x	-8.4x	x6.11-	14.8%			
Outnatiant Purchase Drice	Outpatient IRR	Outpatient IRR, Including Lab	Mult. of Yr 1 EBITDA	Mult. of Yr 1 EBITA	Mult. of Yr 1 EBIT	Mult. of Yr 1 EBITDA - Recur, Outpt. Capex	Mult. of Yr 1 Net Income (1)	Yr 3 Cash on Cash Return (2)			Purchase Price Sensitivity

\$\$\$\$

Acute Business Only

Yes Yes 80.0% 6 Months 2

Purchase Price Sensitivity

L

					Required IRR	d IRR			
	12%	13%	14	*	15%	16%	17%	18%	19%
Outpatient Business Acute Contract	\$ 3,790,000 \$	\$ 3,790,000 \$	\$ 3,7 \$	3,790,000	\$ 3,790,000 \$	\$ 3,790,000 \$	\$ 3,790,000 \$	\$ 3,790,000	\$ 3,790,000
Total Purchase Price	\$ 3,790,000	\$ 3,790,000	\$ 3,7	90,000	\$ 3,790,000	\$ 3,790,000	\$ 3,790,000	\$ 3,790,000	\$ 3,790,000
Year 1 & 2 Non-Recurring Capex	\$ 818,124	\$ 818,124	80 84	818,124	\$ 818,124	\$ 818,124	\$ 818,124	\$ 818,124	\$ 818,124
Mult. of DVA Yr 1 EBITDA	X0.6-	X0.9-		-9.0x	-9.0x	X0.9-	X0.6-	X0.9-	X0.9-
Summary Financials						Modeled Projections	jections		
Avg. Patients	2004	2005	Base	Base Year 110	Year 1 118	Year 2 137	Year 3 153	Year 4 170	Year 5 188

Summary Financials															
	2004	2005		Pase Veer		1		Modeled Projections) ect	Suc	ľ	,			
Avg. Patients	-	-		110		118		137		153		170 170		Year 5 188	
Treatments Tx Growth	•	ı		15,840		17,032 7.5%		19,693 15.6%		21,987 11.7%		24,421 11.1%		27,036 10.7%	
Net Revenue Per Tx	\$ 4,457,575	\$ 3,725,963	6 69	4,012,963 253.34	***	4,314,820 253.34	\$	5,912,172 300.22	ŝ	\$ 6,576,565 \$ 299.11	\$	7,304,537 299.11	6 69	8,086,556 299.11	
EBITDA Per Tx % of Revenue	\$ (558,818) -12.5%	\$ (595,634) -16.0%	\$ \$	(425,218) (26.84) -10.6%	69 69	(423,233) (24.85) -9.8%	\$	807,796 41.02 13.7%	69 69	\$ 1,082,260 \$ 49.22 16.5%	\$ \$	\$ 1,381,531 \$ 56.57 18.9%	\$ \$	1,501,631 55.5 4 18.6%	
Pre-Tax Income					ŝ	(697,379)	ŝ	525,793	•>	790,218	\$	\$ 1,081,631	69	\$ 1,193,874	
Taxes					\$	(281,741)	*	212,420	\$	319,248	65	436,979	\$	482,325	
Book Net Income					•>	(415,638)	•>	313,373	••	470,970	\$	644,652	\$	711,549	
EPS Fully Diluted Shares Outstanding					\$	(0.004) 107.2 MM	\$	0.003 107.2 MM	••	0.004 107.2 MM	\$	0.006 107.2 MM	\$	0.007 107.2 MM	
Capex					ŝ	845,624	\$	55,000	•>	70,276	••	55,000	\$	55,000	

Purchase Price/(Net Income + Tax Affected Interest Expense)
 Affectas C/F to Capital divided by Total Capital Expended (yrs 1-3). Model created by Jaff Young

Lellexa, Nalisas								
Acquisition Metrics					Forecasted Closing Date:	sing Date:		Jun-08
Total Purchase Price			\$ 18,750,000					
Total IRR, Including Lab			15.1%					
Mult. of Yr 1 EBITDA Mult. of Yr 1 EBITA			6.5x 7.3x					
- Recur	Outof Canex		7.8x 6.5v					
Mult. of Yr 1 Net Income (7 Yr 3 Cash on Cash Return (7	(1) (2)		13.2x 12.3%					
Outpatient Business Only				7	<u>Acute Business Only</u>	지미		
Outpatient Purchase Price			\$ 18,750,000		Acute Purchase Price	e Price		\$
Outpatient IRR, Including Lab Mult. of Yr 1 EBITDA			14.1% 15.1% 6.5x		Length of Contract Revenue Per Acute Tx	act tute Tx		A A Z Z
0 0	to Construction		7.3x 7.8x		Required IRR Yr 3 Cash on Cash Return	tsh Return		A N A N
	Outpt. Capex		6.5x 10.0x		Finance adjustments?	ments?	Yes	
	2		12.3%		MSF Extension? Likelihood of Extension Months of Extension Year Extension Begins	r xtension Begins	No 80.0% 6 Months 2	
				Required IRR	d IRR			
Outpatient Business	12% \$ 18,775,000	13% \$18,775,000	14% \$ 18,775,000	15% \$ 18,775,000	16% \$18,775,000	17% \$18,775,000	18% \$ 18,775,000	19% \$ 18,775,000
Acute Contract Total Purchase Price	\$ 18,775,000	\$ 18,775,000	\$ 18,775,000	\$ 18,775,000	\$ \$18,775,000	\$ \$18,775,000	\$ \$18,775,000	\$ \$ 18,775,000
Year 1 & 2 Non-Recurring Capex	\$ 1,842,927	\$ 1,842,927	\$ 1,842,927	\$ 1,842,927	\$ 1,842,927	\$ 1,842,927	\$ 1,842,927	\$ 1,842,927
Mutt. of DVA Yr 1 EBITDA	6.5x	6.5x	6.5x	6.5x	6.5x	6.5x	6.5x	6.5x
Summary Financials						-		
Avg. Patients	2006	2007 189	Base Year 189	Year 1 192	Year 2 Yes 198	ojections Year 3 204	Year 4 210	Year 5 216
Treatments Tx Growth		27,266	27,216	27,624 1.5%	28,453 3.0%	29,307 3.0%	30,186 3. <i>0%</i>	31,091 3. <i>0</i> %
Net Revenue Per Tx	' 0	\$ 7,656,848 \$ 280.82	\$ 8,454,667 \$ 310.65	\$ 9,668,484 \$ 350.00	\$ 9,958,539 \$ 350.00	\$ 10,257,295 \$ 350.00	\$ 10,565,014 \$ 350.00	\$ 10,881,964 \$ 350.00
EBITDA Per Tx % of Revenue	,	\$ 1,459,712 \$ 53.54 19.1%	<pre>\$ 1,934,663 \$ 71.09 22.9%</pre>	<pre>\$ 2,887,596 \$ 104.53 29.9%</pre>	\$ 3,463,764 \$ 121.74 34.8%	\$ 3,532,848 \$ 120.55 34.4%	\$ 3,622,631 \$ 120.01 34.3%	\$ 3,682,594 \$ 118.44 33.8%
Pre-Tax Income				\$ 2,388,909	\$ 2,962,220	\$ 3,028,448	\$ 3,115,373	\$ 3,172,480
Taxes				\$ 965,119	\$ 1,196,737	\$ 1,223,493	\$ 1,258,611	\$ 1,281,682
Book Net Income				\$ 1,423,790	\$ 1,765,483	\$ 1,804,955	\$ 1,856,762	\$ 1,890,798
EPS Fully Diluted Shares Outstanding				\$ 0.013 107.2 MM	\$ 0.016 107.2 MM	\$ 0.017 107.2 MM	\$ 0.017 107.2 MM	\$ 0.018 107.2 MM
Capex				\$ 1,862,927	\$ 20,000	\$ 20,000	\$ 20,000	\$ 20,000


Ъ

Sun

					Modeled Projections	oiections		
	2006	2007	Base Year	Year 1	Year 2	Year 3	Year 4	Year 5
Avg. Patients		189	189	192	198	204	210	21
Treatments Tx Growth	•	27,266	27,216	27,624 1.5%	28,453 3.0%	29,307 3. <i>0%</i>	30,186 3. <i>0%</i>	31,09 3.05
Net Revenue Per Tx	' ج	\$ 7,656,848 \$ 280.82	\$ 8,454,667 \$ 310.65	<pre>\$ 9,668,484 \$ 350.00</pre>	\$ 9,958,539 \$ 350.00	\$ 10,257,295 \$ 350.00	\$ 10,565,014 \$ 350.00	\$ 10,881,96 \$ 350.0
EBITDA Per Tx % of Revenue	, \$	\$ 1,459,712 \$ 53.54 19.1%	<pre>\$ 1,934,663 \$ 71.09 22.9%</pre>	\$ 2,887,596 \$ 104.53 29.9%	<pre>\$ 3,463,764 \$ 121.74 \$ 34.8%</pre>	\$ 3,532,848 \$ 120.55 34.4%	<pre>\$ 3,622,631 \$ 120.01 34.3%</pre>	\$ 3,682,59 \$ 118,4 33.8
Pre-Tax Income				\$ 2,388,909	\$ 2,962,220	\$ 3,028,448	\$ 3,115,373	\$ 3,172,48
Taxes				\$ 965,119	\$ 1,196,737	\$ 1,223,493	\$ 1,258,611	\$ 1,281,68
Book Net Income				\$ 1,423,790	\$ 1,765,483	\$ 1,804,955	\$ 1,856,762	\$ 1,890,79
EPS Fully Diluted Shares Outstanding				\$ 0.013 107.2 MM	\$ 0.016 107.2 MM	\$ 0.017 107.2 MM	\$ 0.017 107.2 MM	\$ 0.011 107.2 MI
Capex				\$ 1,862,927	\$ 20,000	\$ 20,000	\$ 20,000	\$ 20,000
(1) Purchase Price/(Net Income + Tax Affected Interest Expense)	x Affected Interest	Expense)						

Page 1

(1) Purchase Price/(Net income + Tax Affected Interest Expense) (2) After-tax C/F to Capital divided by Total Capital Expended (yrs 1-3). Model created by: SHEILA D. BRUCH



REDACTED

TER 2. A TER TRANSM. WE AND TRANSPORTED STREETS AND STREETS TO THE MARKET AND AND AND AND AND AND AND AND AND A

From: Bryan Parker

Sent: Friday, July 24, 2009 8:51 PM

To: Chet Mehta; David Barbetta

Cc: Queenie Nguyen; Steve Williams (Team Genesis); Bruce Ware; Mike Staffieri

Subject: RE: DeNovo Model

I do. Thanks Chet.

Bryan R. Parker Vice President Special Projects

Casa DaVita 601 Hawaii Street El Segundo, CA 90245 Tel: 650.696.8970 Fax: 866.319.2440 Cell: 650.714.7494 Email: <u>brvan.parker@davita.com</u>

Our Mission: To be the Provider, Partner and Employer of Choice

Our Core Values: Service Excellence, Integrity, Team, Continuous Improvement, Accountability, Fulfillment, Fun

From: Chet Mehta

Sent: Friday, July 24, 2009 8:50 PM To: Bryan Parker; David Barbetta Cc: Queenie Nguyen; Steve Williams (Team Genesis); Bruce Ware; Mike Staffieri Subject: Re: DeNovo Model

Bryan - you mean "gaming" the model, right? Chet Mehta VP, Finance DaVita Inc. 601 Hawaii St. El Segundo, CA 90245 Phone: 310-536-2634 Email: chet.mehta@davita.com

From: Bryan Parker
To: David Barbetta
Cc: Queenie Nguyen; Steve Williams (Team Genesis); Chet Mehta; Bruce Ware; Mike Staffieri
Sent: Fri Jul 24 20:45:17 2009
Subject: DeNovo Model

David

Sorry to hear you are leaving us, but do wish you the best.

I was hopeful before you leave you, or you and Queenie, can give us a list of the most common things

one could do within the model to make sure it passes the COC and IRR hurdles. As we redesign the model I would like to be mindful of these.

Best,

Bryan R. Parker Vice President Special Projects

Casa DaVita 601 Hawaii Street El Segundo, CA 90245 Tel: 650.696.8970 Fax: 866.319.2440 Cell: 650.714.7494 Email: <u>bryan.parker@davita.com</u>

Our Mission: To be the Provider, Partner and Employer of Choice

Our Core Values: Service Excellence, Integrity, Team, Continuous Improvement, Accountability, Fulfillment, Fun

REDACTED

From: Mik e Staffieri

Sent: Friday, July 25, 2008 11:24 AM

To: John Walcher; John Westover

Cc: Marsha Dodd; David Barbetta

Subject: RE: Klamath Falls MDA Question

John --

I am less concerned about whether or not RCC sells its centers to us or not. The important thing is that they sign a 10-year MDA with a 25 mile non-compete around Klamath Falls. If they will not sign that agreement, then we are wasting our time and money. All the patients in Klamath Falls are theirs. Without the agreement and non-compete, they will simply build a DeNovo and move their referrals to the center and we will be left with nothing.

Call me if you want to discuss. I will not approve closing without RCC signing an MDA.

Michael Staffieri Division Vice President North Star Division 2615 SW Trenton Street Seattle, WA 98126-3745 206-935-5423(o) 949-233-4310(c) 866-309-3548(f)

From: John Walcher Sent: Friday, July 25, 2008 10:12 AM To: Mike Staffieri; John Westover Cc: Marsha Dodd; David Barbetta Subject: Klamath Falls MDA Question Importance: High

Mike & John,

We're strategizing on the MDA and need to clarify a key issue.

One possible scenario is:

- DVA buys Sky Lakes;
- DVA hires RCC to be medical director (with a 15-20 mile non-compete radius); and
- RCC sells its centers to FMC.

Another possible scenario is:

- DVA buys Sky Lakes;
- DVA hires our Grant's Pass doctor to be medical director (with a 15-20 mile non-compete radius); and
- RCC sells its centers to FMC.

Do you want us to proceed with the acquisition in the event RCC sells their centers to FMC or some other competitor (whether or not RCC is the Sky Lakes medical director)?

Our concern is being able to close the Sky Lakes acquisition prior to knowing if RCC will sell to us or FMC. If you two are comfortable closing the Sky Lakes acquisition as long as RCC is the medical director (and is bound by a reasonable non-compete clause), we will push both Sky Lakes and RCC for a quick resolution to this issue. If we aren't willing to close Sky Lakes until we know whether or not we're buying

RCC's centers, we'll need to delay the Sky Lakes close (thereby potentially putting the deal in jeopardy) until we have closure on RCC.

Thanks in advance for your input.

John

John Walcher Transaction Director Mergers & Acquisitions / Corporate Development DaVita, Inc. 15253 Bake Pkwy Irvine, CA 92618 Direct: 949,930.4424 eFax: 866.442.3585

Our Mission: To be the Provider, Partner and Employer of Choice.

CONFIDENTIALITY NOTICE

The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer.

•

From: Sent: To: Subject: David Finn Tuesday, May 05, 2009 11:18 AM David Barbetta RE: RCC sensitivity

how abt 70/30, with klamath save and without?

From: David Barbetta Sent: Tue 5/5/2009 11:16 AM To: David Finn Subject: RE: RCC sensitivity

Fixed it. Here are the tables for wholly owned & JV:

Sensitivity -- IRR with Lab -- 100% acquisition

		Purcha se Price			
		\$18M	\$19M	\$20 M	\$21 M
Klamath CF Saved	20%	7.5%	6.0%	4.7%	3.5%
	30%	8.2%	6.8%	5.4%	4.1%
	40 %	9.0%	7.5%	6.1 %	4.7%
	50 %	9.9%	8.3%	6.8%	5.4%

Sensitivity -- IRR with Lab -- 60/40 JV

		Purcha se Price			
		\$18M	\$19M	\$20 M	\$21M
Klamath CF Saved	20%	9.7%	8.4%	7.2%	6.1%
	30 %	10.4%	9.1%	7.8%	6.6%
	40%	11.2%	9.8%	8.5%	7.2%
	50%	11.8%	10.3%	9.0%	7.7%

Klamath Cash Flow

Cash flow decline	Decline in PV*
20%	<pre>\$ (1,D17,442)</pre>
30%	(1,526,508)
40%	(2,D37,966)
50%	(2,546,925)

* at 12% discount rate

From: David Finn Sent: Tuesday, May 05, 2009 10:52 AM To: David Barbetta Subject: RE: RCC sensitivity definitely not right...

From: David Barbetta Sent: Tue 5/5/2009 10:45 AM To: David Finn Subject: RCC sensitivity

David,

,

Here is the new table based on changes to the model that Ben made this morning. This is for 100% owned again. I'd send the 60% JV scenario too but the returns are lower than wholly-owned, which doesn't seem right. I'm waiting for Ben to review.

Sensitivity -- IR R with Lab

		Purcha se Price			
		\$18M	\$19M	\$20 M	\$21 M
ith CF /ed	20%	7.5%	6.0%	4.7%	3.5%
	30%	8.2%	6.8%	5.4%	4.1%
8°3	40%	9.0%	7.5%	6.1%	4.7%
Klamath Save(50 %	9.9%	8.3%	6.8%	5.4%

REDACTED

REDACTED

From: D avid Finn

Sent: Wednesday, October 08, 2008 6:25 AM

To: Jo hn Walcher

Cc: D avid Barbetta

Subject: klamath falls

assuming we get joinders from all docs in the med dir group (4?), you can go up to 3.5mm

thx